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Abstract 
Fragile X Syndrome (FXS) is an inherited developmental disorder characterized by 
disturbances in emotional and social behavior.  Our studies have revealed suppressed 
hippocampal PKCε expression in Fmr1 knockout (KO) mice, the leading model of FXS. To 
compensate for this deficiency, we stimulated PKCε in neonatal KO mice by administering a 
selective PKCε activator, dicyclopropyl-linoleic acid (DCP-LA), and studied its effect on ventral 
hippocampal neurons and a proximal target of the ventral hippocampus, the hypothalamus, 
which regulates social and emotional behavior.  We observed that at postnatal day 18 (P18), 
vehicle-treated KO mice displayed increased surface localization of the 3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor subunit GluR2 in the ventral CA1 region, indicative of 
increased neuronal excitability.  Since the hippocampus is known to exert an inhibitory influence 
on the hypothalamus, we tested if this possible CA1 stimulation was associated with a 
suppression of oxytocin synthesis in the hypothalamus.  Intriguingly, the number of oxytocin+ 
cells in the hypothalamic paraventricular nucleus (PVN) of P20 KO mice was sharply 
suppressed.  However, both the increased surface localization of GluR2 and the suppression of 
PVN oxytocin+ cells in the KO mice were rescued by DCP-LA treatment from P6-14, to levels 
comparable to that in the wild-type controls.  Moreover, this neonatal treatment regimen was 
able to fully rescue hyper-anxiety and social behavior deficits in adult (>P60) KO mice. Thus, 
we present a novel strategy to circumvent aberrant brain development in FXS and accompanying 
behavioral deficits, by activating PKCε signaling during neonatal development. 
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I. Background and Significance  
 
1.1. Fragile X Syndrome  
1.1.1. Foreword 
Fragile X Syndrome, I have found, is surprisingly a relatively little-known disorder 
among the general public. Indeed, while most people in recent years have at least heard of autism 
spectrum disorder, if not directly knowing a person affected by it, Fragile X Syndrome has 
received considerably less attention. As a case in point, whenever the topic of my work comes up 
in conversation with strangers, I have learned to preface myself with the question, "Have you 
heard of Fragile X Syndrome?" This disparity is largely due to the explosive surge in autism 
awareness that has taken place over the past few decades. However, despite its lack of notoriety 
compared to autism, Fragile X Syndrome is, in fact, the most common known monogenic cause 
of autism, as well as the most common cause of intellectual disability.1 In spite of this, no single 
effective treatment for Fragile X Syndrome exists, and current treatments suffer from serious 
limitations and drawbacks. Many of these disadvantages stem from the fact that although Fragile 
X Syndrome is a disorder of brain development, current pharmaceutical treatment strategies tend 
to address symptoms only after they have already become permanent. In our studies, we address 
the possibility of early intervention during the neonatal period as a means to improve prognosis 
for Fragile X Syndrome in a permanent manner. In the process, we have identified a novel 
PKCε-dependent signaling pathway that appears to be disrupted in Fragile X Syndrome; and 
along these lines, demonstrate that pharmacologically targeting this pathway during early brain 
wiring is capable of significantly improving behavioral outcomes in a Fragile X mouse model.  
 
 
 
 
2 
	  
	  
	  
	  
1.1.2. What is Fragile X Syndrome? 
 In essence, Fragile X Syndrome (FXS) is a complex neurodevelopmental disorder that is 
marked by deficits in cognitive, sensory, emotional, motor, and peripheral functioning.1 FXS is 
estimated to occur in approximately 1 in 3,600 to 4,000 men, and 1 in 4,000 to 6,000 women. As 
a matter of greater concern, however, genetic carriers of the disease are estimated to be among 
approximately 1 in 151 women (or about 1 million women in the United States); and 1 in 468 
men (about 320,000 men in the United States). While carriers of the disorder do not necessarily 
have FXS, per se, they are at risk of developing symptoms associated with the disorder, and 
passing it on to their children.  
First described in 1943 by James Purdon 
Martin and Julia Bell, FXS is fundamentally caused 
by a heritable mutation of the fragile X mental 
retardation 1 (Fmr1) gene on the X chromosome.2 
Fragile X Syndrome is in fact named based on the 
physical appearance of X chromosomes bearing the 
mutation: presence of the mutation causes the ends 
of the long (q) arms of the chromosome, where the 
mutation is located, to appear fractured under the 
microscope (Figure 1). This part of the chromosome is called the “fragile site” because when 
studied in the laboratory, the chromosome has the tendency to fracture at that location. Because 
of this characteristic appearance, an affected X chromosome is easily detectable by karyotyping.  
Individuals of all ethnic and racial backgrounds can be affected by FXS, as well as both 
sexes. However, it is important to note that the disorder is twice as prevalent in men as it is in 
Normal X 
Chromosome 
Fragile X 
Chromosome 
Figure 1. Representative karyotypes of a 
normal X chromosome (left) versus a FXS 
mutation-bearing X chromosome (right). 
Arrow indicates the fragile site. Image 
credit: McGill University, University of 
Edinburgh.  
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women. Moreover, females typically experience milder symptoms than men. This is primarily 
attributed to the fact that all males affected by the disease are homozygous, whereas the vast 
majority of affected females are heterozygous. Additionally, variability in random X-inactivation 
on the affected X chromosome can further reduce the severity of the symptoms in female 
patients.  
Although FXS can significantly affect quality of life, carriers are often unaware that they 
harbor the mutation, since many carriers are either asymptomatic or display milder, associated 
symptoms (discussed in Section 1.1.3). Because of this, unless a family history of FXS is known, 
a carrier may not be aware they are at risk of having an affected child. Further complicating 
matters, infants born with FXS typically appear perfectly normal at birth and symptoms are not 
easily apparent during the first few years of life.3  Parents usually begin to notice cause for 
concern at around 12 months of age in boys, and 16 months of age in girls. The most common 
signs that prompt a visit to the doctor are delayed attainment of developmental milestones, such 
as the onset of walking or first words, or failure to reach such milestones altogether. However, 
because many of the symptoms of FXS are behavioral and can be confused with those of other 
developmental disorders, a correct diagnosis typically does not occur until ~35-37 months in 
boys, and ~42 months in girls.4 The disorder is typically diagnosed via polymerase chain reaction 
(PCR) or Southern blot analysis, both of which are sensitive to the primary mutation responsible 
for FXS (described in Section 1.1.3).  
As it is a spectrum disorder, the symptoms of FXS vary widely in type and severity from 
patient to patient.1 As the individual grows older, many physical abnormalities typically begin to 
emerge, including a narrowed face with an enlarged forehead and ears (Figure 2) flexible joints 
and fingers, macro-orchidism in males, heart defects, and/or reproductive issues in both males 
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and females.1-3, 5-7 These abnormalities aside, FXS patients are 
usually otherwise physically healthy and generally have a 
normal life expectancy. Much more pressing than the physical 
features of FXS, however, are its behavioral and neurological 
symptoms.1, 8-10 As the foremost cause of inherited cognitive 
impairment, FXS patients often have a lower than average IQ 
and may suffer from impairments in short-term and working 
memory, visuo-spatial abilities, and executive functioning. Also 
associated with FXS are numerous behavioral issues, including 
anxiety disorders, problems with speech and language, impairments in communication and social 
interaction, attention deficits, hyperactivity, perseverative behavior, and repetitive, stereotyped 
behaviors, such as self-injury, twirling, hand flapping, and rocking. Other neurological features 
of FXS include hypersensitivity to sensory stimuli, motor disturbances, epilepsy, and sleep 
disorders. Importantly, out of all of these symptoms, clinical anxiety ranks among the most 
common, present in 70% of male and 56% of female children with FXS,8 and generally 
persisting throughout the lifespan.11 At the neuronal level, the hallmark of FXS is the presence of 
abnormal dendritic spines with immature morphological characteristics.12, 13 This in turn 
interferes with normal communication between neurons, leading to expansive, global alterations 
in brain functioning that are ultimately responsible for the neurological and behavioral symptoms 
associated with the disorder. 
Though great efforts have been made to shed light on the complex neurological processes 
underlying FXS, no direct cure for the disorder exists. Current treatment approaches generally 
involve a combination of behavioral therapy, as well as lifelong medication regimens aimed at 
	  
Figure 2. Crano-facial features 
of a child with FXS. Image 
credit: Fengler et. al, 2002.  
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individual symptoms,6 as further discussed in Section 1.6.1. However, the need for effective 
treatments for FXS remains imperative, not only due to its substantial impact on the quality of 
life for the patient, but also due to its great socioeconomic impact. Highlighting this point, a 
1992 survey estimated that the average lifetime cost for the care of a single FXS patient could 
total to roughly $2 million USD (at the time of the study).14 In 2002, this was calculated to 
translate to an out-of-pocket medical cost to families of $17,016 annually, when costs of 
hospitalizations, therapies, physician visits, and medications were taken into consideration. 
Compounding the problem, the majority of caregivers for FXS patients report experiencing 
employment problems due to the demands of caring for someone with the disability.15 Perhaps 
most disheartening of all, only 9% of men and 44% of women with FXS are able to reach a high 
level of independence in adulthood, with the majority of patients requiring daily assistance for 
life.8  When all of these difficulties are taken together, therefore, it is perhaps unsurprising that 
mothers of children with FXS have drastically elevated rates of mood disorders (43%) compared 
to mothers in the general population (13%).16 Thus, although FXS lacks the attention received by 
many other neurological disorders, its tremendous impact on patients, families, and wider society 
cannot be denied, and the need for therapeutic advancements is high. 
1.1.3. The Fragile X Mutation	   
At its core, FXS is characterized by a pervasive central synaptopathy, in turn manifesting 
as the broad range of neurological and behavioral symptoms overviewed in Section 1.1.2. In over 
99% of cases, FXS is caused by a CGG repeat expansion mutation in the Fmr1 gene on the X 
chromosome.17 The number of CGG repeats determines whether an individual is classified as 
unaffected, a premutation carrier, or a full-mutation carrier. In unaffected individuals, the Fmr1 
gene contains 5-44 repeats of the CGG codon, located in the 5' untranslated region of the gene 
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(Figure 3). Here, the Fmr1 alleles are stable upon transmission and are not methylated (and 
hereby silenced), except when located on an inactive X chromosome in females. When 55-200 
CGG repeats are present, however, the allele is considered to be in the premutation form. Like 
normal alleles, FXS premutation alleles are not methylated and silenced, unless they are located 
on an inactive X chromosome. However, when transmitted maternally, the CGG repeat carries 
the risk of expanding in future generations, eventually becoming the FXS-causing full mutation.  
While a person carrying the premutation allele does not typically present the full range of 
symptoms of FXS, they have a heightened risk for associated disorders such as Fragile X-
Associated Tremor/Ataxia syndrome and/or Primary Ovarian Insufficiency.1  Lastly, individuals 
with over ~200 repeats are considered to possess the full mutation. While the mechanism is still 
not fully understood, this high number of CGG repeats leads to hyper- methylation of the repeats 
CH3 
	  
	  
Normal Premutation Full mutation 
FMRP FMRP FMRP x 
CH3 
	  
Figure 3. Schematic of variations in the Fmr1 gene. Left: In unaffected individuals, the Fmr1 gene contains 
5-44 repeats of the CGG codon, located in the 5' untranslated region of the gene. Here, the Fmr1 alleles are 
stable upon transmission and are not methylated. Middle: When 55-200 CGG repeats are present, the allele 
is considered to be in the premutation form. Like the normal allele, the premutation is not methylated; 
however, it can expand upon maternal transmission. Right: Individuals with over 200 repeats are considered 
to possess the full mutation. This leads to extensive hyper-methylation of the CGG repeat, causing silencing 
of the gene. Image adapted from FRAXA.org. 
5-44  
CGG 
55-200 
CGG 
200+ 
CGG 
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and upstream CpG islands, resulting in silencing of the gene and loss of its product, Fragile X 
Mental Retardation Protein (FMRP).18 FMRP is a neuronal RNA-binding protein believed to be 
involved in post-transcriptional regulation of gene expression. Downstream consequences of the 
loss of FMRP and its regulatory activities are generally accepted to underlie the pathophysiology 
of FXS. Bolstering this hypothesis, while the CGG expansion mutation accounts for the 
overwhelming majority of FXS cases, one case has been reported where a missense mutation 
was instead discovered  in one of FMRP's RNA binding domains  (the KH2 complex),19 which 
has been found to be critical for stabilizing FMRP-RNA interactions.20  
Significant efforts towards unraveling the mechanisms underlying Fmr1 methylation and 
silencing have been made in recent years. To begin, we have learned that typically, in mammals, 
FMRP is most abundantly expressed in the central nervous system, as well as within the testes.21, 
22 In the mouse brain, expression levels of FMRP peak at around 1 - 2 weeks postnatally, before 
gradually declining.23, 24 This period is believed to correspond to the infancy stage in humans. 
Methylation and silencing of the expanded Fmr1 CGG repeat is a dynamic process that begins 
early in development. Studies of chorionic villi samples from human fetuses harboring the full 
mutation have revealed that the expanded repeat is methylated to an increasing degree as 
development progresses.25 Southern blotting and MALDI-TOF studies have advanced as far as to 
pinpoint the main methylation site that is linked to blockade of FMRP expression: the FREE2 
sequence, located within intron 1 of the gene.26 Interestingly, mosaicism of CGG repeat length 
(and consequently, methylation status), is a well-described phenomenon in full-mutation 
carriers.27-32 In most patients, variations in repeat length are apparent in all tissues. This 
phenomenon is especially pronounced in ~15% of patients, which are conveniently termed 
"mosaics.” This mosaicism is believed to account for the wide variability in symptoms and 
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severity of the syndrome from one patient to the next. Moreover, interestingly, a subset of high-
functioning patients have been found to express un-methylated premutation bands,33 which 
presumably yield functional FMRP. However, these patients still express deficient levels of the 
protein overall compared to their neurotypical counterparts, resulting in the symptoms associated 
with FXS. 
1.1.4. FMRP: Structure and Function 
Elucidating the precise mechanisms of FMRP’s function is undoubtedly key to 
deciphering its role in more complex processes at the level of synapses, circuits, and behavior.  
Correspondingly, the precise function of FMRP has been a subject of extensive study over recent 
decades. To begin, it has been found that within the central nervous system, FMRP is 
predominantly expressed in neurons, less so in glial cells.21, 24, 34, 35 Within these neurons, FMRP 
is primarily localized within the cell body, dendrites, and synaptic compartments. While the 
latter especially points to a role in neuronal signaling, what exactly is FMRP’s function? 
The current hypothesis proposes a major role for FMRP in translational control. What 
evidence supports this idea? First, the majority of the protein (~85%) has been found to associate 
with actively-translating polyribosomes.36 Second, FMRP contains three domains that mediate 
interactions with mRNA: two tandem K-homology (KH) domains, and one C-terminal RGG 
box.37 While the KH2 domains of FMRP have been shown to bind to mRNA kissing complex 
motifs, the RGG box instead binds to G-quartet motifs. Additionally, it has been found that the 
RGG box of FMRP also binds to a novel motif found within Superoxide Dismutase 1 (Sod1) 
mRNA, referred to as SoSLIP.38 (This particular motif consists of an arrangement of three 
independent, successive stem-loop structures, separated by short, single-stranded regions.) Taken 
together, these findings point to a role of FMRP in the translational regulation of a wide variety 
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of mRNAs, and that FMRP-mRNA recognition appears to depend largely on mRNA secondary 
and tertiary structure rather than nucleotide sequence alone.  
The precise role of FMRP in translational regulation appears to be a fascinatingly 
complex one. Unfortunately, as a result, many of the molecular mechanisms behind FMRP’s 
function still remain unclear.  One prominent early theory of FMRP function was that FMRP 
shuttles newly-transcribed mRNAs from the nucleus to post-synaptic sites in the cell, 
presumably to facilitate translation. Supporting this hypothesis, FMRP has been found to not 
only contain a nuclear export signal (NES) and a Rev-like export signal,39 but has also been 
demonstrated to be capable of shuttling between the nucleus and cytoplasm.40 
FMRP also appears to be involved in mRNA trafficking along dendrites and axons. 
Within cells, mRNAs are co-transported with ribosomal subunits, translation factors, and other 
translation machinery within motile compartments called RNA granules. Studies have 
demonstrated that FMRP is found within such RNA granules, where it serves as a “molecular 
adaptor” between these granules and kinesin-II motor complexes, which transport the granules to 
their final destination in the cell.41, 42  
Perhaps of greatest impact, however, recent ground-breaking work has suggested that 
FMRP may in fact be involved in translational inhibition as well (Figure 4). Specifically, it has 
been found that FMRP is capable of hampering mRNA translation by binding to polyribosomes, 
and consequently, blocking the elongation step of translation.43 In this process, FMRP appears to 
interrupt ribosomal translocation - the synchronized movement of tRNA and its associated 
mRNA through the ribosome, thereby advancing the translational reading frame - by complexing 
with target mRNAs and the ribosomes associated with them. Thus, FMRP may, among other 
roles, function as a general repressor of translation. However, this role might be restricted to 
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specific mRNAs, and it has been suggested that FMRP may have opposing effects on translation 
depending on the mRNA target.  
Nevertheless, many of the finer details regarding how FMRP regulates the translation of 
its target mRNAs have yet to be clarified.  However, some important clues have been uncovered 
in recent years. It has been found that KH binding with mRNA kissing complexes, in addition to 
RGG binding with G-quartets, are generally associated with translational suppression,20, 44-46 
whereas RGG binding with SoSLIP is associated with translational enhancement.38 Moreover,  
FMRP is subject to post-translational modifications that may influence the direction of 
translational regulation – phosphorylated FMRP is associated with stalled ribosomal 
translocation and inhibition of translation, whereas de-phosphorylation of FMRP is instead 
associated with the upregulation of translation.47 FMRP phosphorylation, in turn, has been 
shown to be bi-directionally regulated in response to synaptic activity.48, 49 Thus, the role of 
Figure 4. Schematic depicting mechanisms by which FMRP may regulate neuronal translation. (A) For some 
mRNA targets, FMRP may facilitate nuclear export to enhance translation. (B) For other mRNA targets, FMRP 
appears to interrupt ribosomal translocation complexing with its target mRNAs and associated ribosomes. Image 
credit: adapted from Fridell et. al, 1996; Darnell and Klann, 2015. 
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FMRP in translational regulation appears to be rather multi-faceted.  
Regardless of this, due to the extensive evidence pointing to a regulatory role of FMRP in 
neuronal gene expression, a great deal of effort has been devoted to identifying the protein’s 
specific mRNA binding partners. Invaluable immunoprecipitation studies have revealed that 
FMRP binds to the coding region of a diverse host of transcripts, encoding roughly 1,000 
different proteins, many of which are pre- and post-synaptic (for a complete list, see Darnell et. 
al, 2011).43 For instance, several of FMRP’s target transcripts are associated with pathways 
involved in synaptic long term potentiation (LTP) and long term depression (LTD), through both 
glutamate and GABA receptor signaling. Further complicating the molecular mechanisms 
underlying FXS, signaling pathways associated with FMRP’s targets are also involved in gene 
expression, regulation of the cell cycle, and programmed cell death – including, but not limited 
to CREB, calcium, PKA, PKC, G-protein coupled receptor (GPCR), RhoA, cAMP, and 
P13K/Akt signaling. 
As one might imagine, given the broad range of proteins that are translationally regulated 
by FMRP, loss of FMRP can undoubtedly create cascading effects on larger neural networks, 
ultimately impacting cognition and behavior. The currently known mRNA binding partners of 
FMRP code for a multitude of intracellular signaling molecules that interact in elaborate and 
intricate ways that are still only beginning to be understood. Thus, despite being a single-gene 
disorder, the molecular underpinnings of FXS are extremely complex.  
1.2. FXS is a Disorder of Brain Development 
1.2.1. Synaptic Changes Associated with FXS 
What exactly are the consequences of the FXS mutation and therefore, FMRP deficiency, 
in the brain? It is a simple question, but one that researchers have spent decades attempting to 
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answer. However, it has long been found that the major underlying cause of aberrant brain 
function in FXS is a pervasive central synaptopathy, marked by an overabundance of immature 
dendritic spines and aberrant synaptic transmission.12, 13 
The dendritic spine is widely regarded as the cardinal anatomical substrate of synaptic 
plasticity, or the ability of synapses to modify their strength in response to changes in their 
activity.50-53 Dendritic spines themselves are small (0.01 – 0.8 cu µm), membranous protrusions 
located on the dendrites of post-synaptic neurons. Nearly all dendritic spines possess a general 
“door-knob” like structure consisting of two compartments, termed the head and the neck. The 
head refers to the tip of the spine, upon which an incoming axon can terminate to form a synaptic 
contact. Localized within the head of the spine is the post-synaptic density: a complex 
membrane-associated structure containing neurotransmitter receptors, channels, and signaling 
proteins. The neck, in contrast, connects the head of the spine to the parental dendrite, extending 
up a few micrometers in length. Dendritic spines can be further classified by their shape as one 
of five conventional types: thin, stubby, mushroom, cup-shaped, or filopodia, which are widely 
believed to be spine precursors (Figure 5).54 
However, the prevailing theory is that 
dendritic spines actually exist as part of a 
continuum of these four types. Because the 
head of the spine is separated from the 
parent dendrite by the neck, each spine can 
form a local, synapse-specific compartment 
that is capable of segregating postsynaptic 
chemical responses, such as calcium 
Figure 5. Dendritic spine classification. Dendritic 
spines are generally classified by their shape as one of 
five conventional types: thin, stubby, mushroom, cup-
shaped, or filopodia (spine precursors). Image credit: 
Hering and Sheng, 2001.52 
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waves.54-58 This isolation from the parent dendrite allows for input-specific synaptic plasticity 
restricted to independent, individual spine heads. Thus, dendritic spines act as functional 
integrative units within synapses, where synaptic inputs from each spine head can be integrated 
to collectively modulate the entire postsynaptic neuron's response to incoming signals. It has 
long been thought that through changes in their morphology, density, and distribution on a post-
synaptic neuron, dendritic spines act as important modulators of neuronal responses to incoming 
stimuli.  
Importantly, a spine’s morphology is tightly linked to the functional properties of its 
synapse. Correspondingly, the postnatal maturation of the brain involves a dramatic shift in spine 
morphology profiles from immature to mature, as the brain adapts to its surroundings. However, 
these morphological profiles appear to vary greatly depending on the brain region. For example, 
the maturation of the cortex entails a shift in the distribution of spines from predominantly long 
and thin, to short and stubby.59-62  In pyramidal neurons of the hippocampus, however, the 
opposite appears to hold true - young animals have an abundance of stubby and mushroom-
shaped spines, whereas adults seem to predominantly display long, thin ones.63  
FMRP appears to play an essential role in modulating dendritic spine architecture, and 
therefore, synaptic function and plasticity. First, FMRP is normally enriched within dendritic 
spines.35 Secondly, FMRP appears to regulate the translation of a multitude of post-synaptic 
proteins, including receptors, channels, scaffolding proteins, and synaptic adhesion proteins, as 
well as a variety of intracellular signaling proteins.43 Lastly, FMRP itself is dynamically 
regulated by synaptic activity – FMRP itself is translated, degraded, and post-translationally 
modified in response to synaptic inputs.35 FMRP and associated mRNAs are also co-transported 
into dendrites both under basal conditions, as well as in response to synaptic activity.64-66 
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Moreover, FMRP’s synthesis coincides with the time-scale of the induction of stable synaptic 
plasticity (10 – 30 minutes).67  
Dendritic spine dysmorphogenesis is considered the hallmark neuroanatomical feature of 
FXS.13 Most intriguingly, dendritic spine aberrations observed in FXS patients are reminiscent of 
the developing brain. For instance, post-mortem analyses of human tissue from FXS patients 
have revealed an increased density of cortical dendritic spines compared to neurotypical 
controls.68 This observation is reminiscent of the early postnatal brain, prior to synaptic pruning. 
Moreover, an elevated proportion of these spines assume the long, thin morphology that is 
associated with spine immaturity within the 
cortex (Figure 6),68-70 and these findings 
have been paralleled in Fmr1 knockout 
mice71, 72 Similar observations have also 
been made within the hippocampus – Fmr1 
KO pyramidal neurons display a heightened 
proportion of immature spines; however, 
here the total spine density is unchanged.73  
Based on these findings, the general 
consensus is that FXS results from the 
uncontrolled expression of dosage-sensitive 
genes that are required for normal dendritic spine development, remodeling, and transmission. 
Concisely put, in patients with the full-blown Fmr1 mutation, FMRP is under-expressed, and as 
a result, mRNA translation of proteins essential for normal synaptic plasticity becomes 
dysregulated. As a result, the net global effect appears to be one where proteins required for 
Figure 6. Representative photo-micrographs of 
cortical dendritic spines obtained from (A) human 
FXS patient compared to neurotypical control; (B) 
Fmr1 knockout mouse (KO) versus wild-type 
control (WT). Irwin et. al, 2000,10 Hayashi, 2007.261 
FXS WT KO Control 
A B 
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normal synaptic function may be under-expressed, whereas other proteins may be overexpressed 
when they are not required. 
What, then, are the functional consequences of FMRP deficiency within synapses?   
Dendritic spine morphology is exceptionally plastic, and closely associated with a spine’s 
functional properties. Plastic changes in dendritic spines are thought to adjust synapse function 
and strength, subsequently governing information storage and processing in the brain.50-54, 60 As 
touched on in the previous section, one major identified consequence of FMRP silencing is that it 
perturbs the processes of long-term potentiation and long-term depression,74 two major 
mechanisms of synaptic plasticity that are widely believed to be the molecular correlates of 
cognition and emotion. Long-term potentiation (LTP) refers to a persisting increase in synaptic 
strength that occurs with repeated, high frequency stimulation, capable of lasting for hours or 
longer. In contrast, long-term depression (LTD) is recognized as the weakening of synaptic 
connections, typically in response to low frequency stimulation. Together, LTP and LTD work in 
concert to permit bimodal, activity-dependent adjustments in synaptic strength. Accordingly, 
memories are believed to be encoded by modifications in synaptic strength through the 
coordination of both LTP and LTD.75 In essence, LTP is thought to provide a mechanism 
through which new memory traces can be formed and retained in the brain. On the other hand, 
LTD appears to selectively weaken synapses so that cells can make practical use of LTP - if all 
synapses were permitted to continue increasing in strength, they would eventually reach a ceiling 
level of efficiency, which would prevent the encoding of new information. At the molecular 
level, LTP is believed to result in part from the activation of calcium-sensitive kinases that 
phosphorylate various protein targets to ultimately increase sensitivity of the post-synaptic site to 
incoming excitatory signals (for example, CAMKII). Oppositely, LTD is thought to arise from 
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the activation of calcium-sensitive phosphatases that may instead dephosphorylate these 
targets.76  
Widespread changes in LTP and LTD have been associated with FXS. In Fmr1 KO mice, 
marked deficits of LTP have been reported in the cortex, including the prefrontal, 
somatosensory, and visual cortices.77-81 Decreases in LTP magnitude have also been reported in 
the hippocampus.82, 83 On the other hand, metabotropic glutamate receptor-dependent LTD 
(mGluR-LTD) has been found to be enhanced in the hippocampus and cerebellum in the absence 
of FMRP84-86. The latter phenomenon in particular has gained a great deal of attention in recent 
years due to the potential of group I mGluR antagonists as a therapeutic strategy for FXS. 
Unfortunately, however, this strategy has not yet demonstrated meaningful improvements in the 
human patients, compared to placebos.87 Nevertheless, en masse, these observations suggest that 
FMRP plays an essential role in dendritic spine maturation, stabilization, and plasticity; and 
absence of FMRP results in stunted spine maturation and altered synaptic signaling.  
1.2.2. FXS Arises From Changes in Synaptic Function During Brain Wiring 
Considering that FMRP expression peaks during the early postnatal period, one of its 
most important functions is presumably to direct the development and function of young 
synapses as they undergo dynamic changes during postnatal brain maturation. Importantly, 
alterations in synaptic plasticity and transmission during early life may have an especially 
deleterious effect on the brain. Synaptic function must be tightly controlled to ensure appropriate 
levels of neuronal signaling during the early stages of brain wiring.. Subsequently, FXS is 
believed to stem from disturbances in normal brain maturation, due to inherent changes in 
synaptic functioning. However, while the anatomical and functional abnormalities of synapses in 
FXS are well described, less is known about circuit-level alterations that ultimately lead to the 
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behavioral symptoms of FXS. As of yet, it is still unclear how FXS-related changes in LTP and 
LTD may alter the activity of larger neuronal networks. However, it is known that the activity of 
a circuit is influenced by the balance of net excitatory and inhibitory synaptic activity within that 
circuit. This balance of excitation and inhibition is a delicate one, and is crucial for precise 
nervous system development and functioning.  
Importantly in the context of FXS, the functions of neuronal circuits are greatly shaped 
by their activity during critical, or sensitive, periods during development. Critical periods are 
restricted time windows in which a brain region or circuit is most receptive for a developmental 
stage to occur, often in response to a stimulus - for instance, an environmental influence. The 
presence of the stimulus triggers the brain region or circuit to undergo the developmental 
changes, and thus become altered in a profound and often permanent way. However, the absence 
of the stimulus during this period of time leads to aberrant development, or even a lack of 
development altogether. Moreover, after the window closes, the developmental stage is usually 
no longer able to occur. A very well-studied example is the development of the visual cortex, 
first described in the ground-breaking work of Wiesel and Hubel in 1963.88 In their studies, 
Wiesel and Hubel discovered that neurons in the cat visual cortex were most responsive to visual 
inputs at an early age, and that this responsiveness disappeared after the cat reached maturity. 
They further demonstrated that if cats had one eye deprived of light from birth to three months 
old, they only developed vision in their un-deprived eye. After the three months had elapsed, the 
cats were no longer able to see from the deprived eye at all.  
In the case of FXS, it is believed that synaptic plasticity is altered during critical periods 
of brain wiring in regions that contribute to cognition, behavior, and sensory processing; such as 
connections within and between the cortex, hippocampus, amygdala, and hypothalamus. In this 
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scenario, stimuli needed to trigger developmental changes in the brain may not necessarily be 
missing, but the synaptic machinery required to respond to such stimuli are impaired, or may 
respond inappropriately to a stimulus. Importantly, once a few of such improper connections 
have formed, they may lead to further inappropriate connections during early learning, thereby 
amplifying the defect. Moreover, these effects on the initial wiring of the brain may be to a large 
extent irreversible upon reaching adulthood, highlighting the need for early intervention 
strategies that target the root of the malady as opposed to the symptoms.   
1.2.3. Circuit-Level Hyper-Excitability is Associated with FXS 
As described, FXS is marked by the over-abundance of immature synapses across 
multiple brain regions. As a result, the FXS brain is considered reminiscent of the developing 
brain. Importantly, a wealth of studies have shown that the immature brain is much more 
excitable than the mature brain; with much of this work focusing on the hippocampus and cortex 
as model systems.89, 90 However, whether this increase in excitability involves mainly excitatory 
or inhibitory neurons or synapses, remains unclear. In the first few days of life in rodents, the 
neurotransmitter GABA exerts an excitatory effect due to high intracellular chloride levels 
established by the Na-K-Cl cotransporter NKCC.91 However, studies in which fast GABAergic 
transmission is blocked have demonstrated an important role of glutamatergic AMPA receptors 
in this hyper-excitability, as opposed to GABA receptors alone.92 Supporting this hypothesis, 
during the first few weeks of life, there is an over-abundance of AMPA receptors in the brain.93, 
94 The resulting increase in circuit-level excitability in the immature brain, relative to the mature 
brain, is believed to be the reason why the early postnatal brain is far more susceptible to 
seizures than the adult brain.95, 96  
 This observation is especially interesting in the context of FXS because increasing 
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evidence has pointed to the possibility of circuit hyper-excitability in the Fragile X brain.  At 
first glance, many of the disorder's symptoms, such as hyperactivity, sensory hypersensitivity, 
hyperarousal, and enhanced seizure susceptibility, appear to reflect elevated excitability of 
different brain regions. Interestingly, studies on the Fmr1 knockout (KO) mouse model of FXS 
have provided evidence that this notion is indeed the case. For one, Fmr1 KO mice demonstrate  
higher synchrony of cortical network activity, as determined by calcium imaging studies,97 and 
higher hippocampal excitability, as determined by electrophysiological studies.85 Secondly, 
Fmr1 KO mice exhibit longer spontaneously-evoked Up states, brief periods of local network 
activity marked by tonic, synchronous firing between groups of neighboring neurons.98 Third, 
Fmr1 KO cortical neurons demonstrate higher firing rates  during these Up states.97, 99 
Unfortunately, human studies in this area are still few and far between. However, a recent 
EEG study has reported that FXS patients exhibited greater power in the cortical gamma 
frequency band,100	   indicating heightened neuronal activity.101 Interestingly, this phenomenon 
was shown to correlate with difficulties in sensory and social processing in the patients. This data 
is consistent with mouse studies reporting reduced excitatory drive to inputs to fast-spiking 
inhibitory interneurons which normally synchronize and regulate gamma band neural activity.102, 
103  Additionally, FXS patients have also been shown to demonstrate heightened theta 
rhythms,104, 105 which have been associated with working memory,106 and might explain 
information processing deficits in these individuals.107  
 The hyper-excitable state of the Fragile X brain unquestionably has consequences on 
brain function, but these consequences are still only beginning to be understood. The most clear 
manifestation of this phenomenon is the high occurrence of seizures in FXS patients. Seizures 
are thought to arise from excessive electrical activity in the brain, and it is estimated that at least 
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20% of FXS patients experience them.108, 109 Interestingly, the majority of FXS patients with a 
seizure disorder display an EEG pattern characterized by centro-temporal spikes, in a similar 
manner to those observed in Benign Rolandic Epilepsy of Childhood (BREC).110, 111 However, 
while nearly all children with BREC outgrow the disorder, FXS patients often do not, supporting 
the idea that the FXS brain remains in an immature state throughout the lifespan. 
 Another likely consequence of circuit hyper-excitability in FXS is sensory hyper-
sensitivity. Specifically, this feature of FXS is believed to result from abnormally increased 
cortical responses to sensory stimuli. For instance, a host of studies have found that FXS patients 
display abnormally heightened EEG responses to sound	  (see Rotschafer and Razak, 2014 for a 
review).112 Consistent with human data, Fmr1 KO mice reliably demonstrated enhanced auditory 
startle responses,113-115 paired-pulse-inhibition,116, 117 and a heightened propensity for audiogenic 
seizures.113, 118  
Lastly, the concept of hyper-excitability in the FXS brain is an interesting one because it 
may also potentially contribute to the exaggerated anxiety levels associated with the syndrome. 
In this scenario, one likely culprit may be hippocampal over-excitation. As will be described in 
the upcoming sections of this literature review, the hippocampus is an important regulator of the 
stress response and anxiety levels through its inputs to the hypothalamus. While this regulation is 
quite multifaceted, it has been shown that the hippocampus sends inhibitory projections to the 
parvocellular subdivision of the paraventricular nucleus (PVN), which contains centrally 
projecting, oxytocin producing neurons.119, 120, 164 Therefore, if activity of the hippocampus were 
increased in FXS, this could result in excess inhibition of these PVN neurons, and consequently, 
suppression of oxytocin production. Given the importance of oxytocin in social behavior and 
anxiety (discussed further in Section 1.5.2), hyper-activity of the hippocampus could potentially 
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result in abnormalities in both of these behavioral domains in FXS. Moreover, as will be 
described in the next few sections, many other symptoms of FXS are attributed to excess anxiety, 
and this is feature of FXS differentiates its behavioral phenotype from that idiopathic autism. 
Thus, targeting hippocampal hyper-excitability may prove effective in rescuing a significant 
portion of the FXS behavioral phenotype.  
1.3. FXS vs. Idiopathic Autism 
Before continuing, at this point it is important to address the connection between FXS 
and idiopathic autism. Most intriguingly, approximately 46% of male and 15% of female FXS 
patients are co-diagnosed with an autism spectrum disorder (ASD).1 Moreover, FXS is the most 
common monogenic cause of ASD. As a result, FXS has attracted considerable interest for its 
potential value in uncovering some of the neurobiological underpinnings of idiopathic autism. 
On the surface, FXS and idiopathic autism appear to share many similarities. Numerous 
symptoms of FXS seem to overlap with the symptoms of idiopathic autism, including the core 
deficits in sociability, communication, and the presence of stereotyped behaviors.1, 8 A 
considerable overlap also exists between the secondary symptoms, including anxiety, hyper-
activity, sleep disorders, and seizure susceptibility. However, a growing body of evidence 
suggests that FXS and idiopathic autism may not be as comparable as they first seem.  
To begin, the first and foremost difference between FXS and idiopathic autism lies in the 
etiology of the two disorders. At present, idiopathic autism is believed to be due to multiple, 
varied causes – some genetic, some environmental, and others unknown – that lead to similar 
changes in behavioral outcomes.121, 122 Thus, ASD relies primarily on a behavioral diagnosis 
based on observations by parents, caretakers and clinicians. On the other hand, FXS relies on a 
medical diagnosis as all cases stem from a single, identifiable cause – mutation of the Fmr1 
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gene.  
Nevertheless, the behavioral symptoms of FXS and idiopathic autism may appear 
identical at first glance. Could this mean that mutations in ASD-associated genes lead to similar 
outcomes as the FXS mutation? While further study is still needed to answer this question, 
growing evidence seems to suggest that the behavioral symptoms of the two disorders may, for a 
large portion of the patients, actually originate from rather distinct biopsychosocial pathways. 
For example, let us consider the shared core deficit in social interaction. Classically, individuals 
with autism are described to live in their own world, unaware of or indifferent to the social 
situations surrounding them, and hence may rarely seek out social interaction.121-123 Of course, 
this is certainly not the case for all individuals with ASD, especially high-functioning patients. 
Nevertheless, this phenomenon is considered the general underlying cause for the social deficits 
associated with ASD. On the other hand, many patients with FXS are generally not only socially 
alert, but in fact often yearn for interaction with others.124, 125 Despite this, however, FXS patients 
are often so plagued by severe social anxiety that they tend to avoid social situations altogether.1  
Gaze avoidance is yet another shared feature of both disorders that may stem from 
distinct origins. Many patients with idiopathic ASD exhibit deficits in eye contact because they 
are indifferent to social cues,121-123 while others may find eye-contact to be over-stimulating and 
therefore, aversive. On the other hand, patients with FXS typically avoid eye contact as a direct 
result of their social anxiety.1 A major study illustrating this difference examined eye movements 
in patients with either FXS or idiopathic ASD.126 It was found that when the ASD patients were 
presented with images of human faces, their gaze path was for the most part, random. On the 
other hand, when FXS patients were presented with the same images, they would initially glance 
at the eyes of the faces, but then quickly look away – a strong indicator of social anxiety.  
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Along these lines, patients with autism often have deficits in theory of mind – the ability 
to infer what another person is thinking or feeling, in order to see things from their point of 
view.121-123, 127 However, this is usually not the case for patients with FXS. Highlighting this 
point, in the aforementioned gaze-tracking study, FXS and ASD patients displayed striking 
differences in brain activation when presented with images of emotional faces. Interestingly, it 
was revealed that the FXS group, compared to the ASD group, displayed elevated activity within 
the hippocampus, superior temporal gyrus, insula, and post-central gyrus, all areas associated 
with social and/or emotional processing.  
Lastly, let us consider the shared core symptom of repetitive and stereotyped movements, 
such as rocking or hand-flapping. Because these actions are self-stimulating, engagement in 
these behaviors are colloquially referred to as “stimming.” For patients with idiopathic autism, 
stimming behavior can be attributed to multiple, varied reasons.128 One theory is that such 
behaviors promote the release of beta endorphins within the nervous system, producing a 
calming effect. Another explanation is that for some patients, stimming may instead help to 
regulate sensory input. For example, stimming may provide sensory stimulation for patients who 
feel under-stimulated, or alternatively, can soothe patients who feel over-stimulated. In other 
cases, stimming can also take on the form of self-injurious behavior. This form of stimming may, 
at times, be communicative in nature. For instance, a patient may engage in head-banging or 
other forms of self -injury because they are frustrated and unable to express what they are 
thinking or feeling.  In individuals with FXS, on the other hand, stereotypic behaviors are almost 
always provoked by anxiety, hyper-arousal, or hyper-sensitivity to sensory stimuli.1 In these 
cases, stimming helps to calm the patient and/or reduce sensory overload. For example, a FXS 
patient may stim because he/she perceives their environment to be too loud or too crowded, or 
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may feel overwhelmed by a stressful social encounter. 
Taken together, these findings suggest that while, on the surface, individuals with FXS 
and ASD may display similar behavioral profiles, on closer inspection, it is apparent that these 
behaviors stem from substantially different psycho-emotional and motivational factors. Again, 
let it be noted that this is not the case for all individuals with FXS or ASD: as a counter-point, 
one study reported that 33% of children with FXS between the ages of 21 to 48 months were 
indistinguishable from children of the same age with idiopathic autism.129 However, at this 
young age, it may be difficult to discern the underlying causes of behavioral issues such as gaze 
aversion or stereotypies.  
The extent of the overlap between FXS and idiopathic ASD, at the neurobiological level, 
still remain unclear. Studies comparing FXS and ASD are uncommon, and therefore, results 
must be interpreted cautiously. However, it is known that a few key differences generally exist 
between FXS and ASD brains, both in structure and function. Structurally, children with FXS 
display greater volumes of white matter in the temporal lobe, grey matter in the cerebellum and 
caudate nucleus, and reduced volume in the amygdala, compared to neurotypical controls.130 On 
the other hand, children with ASD instead display cortical enlargement compared to controls. 
Functionally, it has been found through EEG studies that ASD patients have reduced long-range 
activity between the frontal lobe and the rest of the cortex131,132 as well as potentially reduced 
local connectivity within the cortex.133 In a different vein, FXS patients display increased long 
and short ranged connectivity.104  
Thus, FXS and idiopathic ASD are not entirely discrete, nor are they entirely 
disconnected. Many genes that are regulated by FMRP may overlap with genes altered in ASD.43 
Additionally, FMRP may regulate proteins with similar regulatory functions as those affected in 
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ASD. Thus, different neurological etiologies may result in a similar developmental course for 
some patients. Conversely, patients may have different behavioral outcomes depending on the 
genes and pathways affected, as well as the individual’s environmental experiences. 
Nevertheless, the general consensus is that most behavioral symptoms associated with FXS are 
traceable to excessive anxiety and hyper-arousal, whereas the pathology of ASD is much more 
varied and multi-faceted. Consequently, such distinctions are important to bear in mind while 
developing therapeutic approaches geared specifically toward either disorder.  
1.4. Anxiety, a Prominent Feature of FXS 
1.4.1. What is Anxiety? 
One of the most prominent features of FXS is the presence of excessive anxiety. It is 
estimated that anxiety disorders occur in 70% of male FXS patients and 56% of female patients.1 
Moreover, in many cases, numerous behavioral symptoms of FXS – such as social deficits, gaze 
aversion, and stereotypies, for instance – are believed to be, at their core, anxiety-driven.  
 Anxiety is a general term for the emotional state characterized by feelings of persistent 
worry, tension, and unease.134 Like most emotions, these feelings may range from mild to severe 
in their intensity. For healthy individuals, anxiety is a normal reaction to stimuli that may prove 
threatening or dangerous. Thus, anxiety is useful from an evolutionary standpoint in that it serves 
a protective function, motivating an organism to escape or address the source of the anxiety. 
Importantly, a distinction must be made between anxiety and stress. Stress generally refers to the 
emotional and physiological response to the presence of a stress-causing factor (“stressor”). 
While stress typically disappears after the stressful situation is over, anxiety is a sustained state 
that can persist even long after the stressor is gone.  
No single person is free from anxiety, yet how it affects an individual is relative. Anxiety 
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is considered pathological when it is persistent, disproportionate to the cause, and/or disruptive 
to the extent where it may interfere with daily functioning (such as performance at work, or 
interpersonal relationships). In many cases, anxiety may manifest even in the absence of an 
identifiable threat. These conditions are collectively termed anxiety disorders, and altogether, are 
the most common mental illnesses in the United States, with 40 million Americans affected.135 
Among the most prevalent anxiety disorders are generalized anxiety disorder and social anxiety 
disorder. Generalized anxiety disorder is characterized by persistent, excessive, and exaggerated 
worry that may not necessarily be specific to one particular event or issue.136 On the other hand, 
social anxiety disorder refers to the specific, pervasive fear of social situations.137 For instance, a 
person with social anxiety disorder may feel highly anxious about being embarrassed, judged, or 
rejected by others; and as a result,, tend to avoid social situations whenever possible, even if 
doing so negatively impacts the person’s ability to lead a normal life. Both generalized and social 
anxiety are frequently associated with FXS.1  
1.4.2. Anxiety Detection in Rodents 
Recent years have witnessed an explosion of interest in anxiety disorders and their 
neurological correlates. Many of the resulting studies have employed the use of rodent models to 
identify anxiety’s molecular underpinnings. One would be correct in thinking that anxiety 
detection in rodents would likely be a challenging task – how can one truly peer into the mind of 
a mouse? In truth, it is impossible to know what a rodent is thinking without either being one, or 
being able to communicate with one. However, the manipulation of specific circuit components 
in model organisms is necessary to gain a mechanistic understanding of the neurobiological 
underpinnings of anxiety. As a result, quantitative measurements of rodent behaviors that meet 
the criteria for validity – namely face, predictive, and construct validity – have been historically 
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well-used and accepted in the study of anxiety disorders.138 
In general, anxiety assays for rodents are based on approach-avoidance conflict tasks.138 
These tasks capitalize on the conflicting drives of rodents to explore novel environments, yet at 
the same time, avoid open spaces where they may be more vulnerable to danger (for example, 
predation). The gold standard for the detection of anxiety phenotypes in rodents is the elevated 
plus maze (Figure 7).139, 140 This test employs the use of a plus-shaped apparatus, consisting of 
two oppositely-positioned, precipice-like open arms, and two closed (walled) arms, elevated 
several feet above the floor. From the center of the maze, the rodent has access to all four arms 
of the maze. During the test, the rodent is placed within the center and allowed to explore the 
maze over a set interval of time, usually five to ten minutes. Time spent in and entries to the 
Figure 7. Common behavioral assays of anxiety in mice. (A) Elevated Plus Maze, (B) Light-Dark Box, 
(C) Open Field, (D)Three-Chambered Social Interaction Test, in which reduced sociability may be an 
indicator social anxiety, under careful interpretation. 
A B 
C D 
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open arms are then calculated. Rodents predisposed to anxiety will spend more time huddled 
within the safety of the closed arms, as opposed to venturing out into the open arms, where there 
is a risk of falling. This test is especially attractive to behaviorists because of its high degree of 
face validity, as patients with anxiety disorders tend to avoid situations deemed hazardous or 
risky (such as skydiving). Performance in the elevated plus maze is also sensitive to 
pharmacological manipulation, indicating a high degree of predictive validity. For instance, time 
spent in the open arms is improved by many anxiolytic drugs, such as benzodiazepine141; while it 
is reduced by anxiogenic drugs, such as caffeine,142 phenylethylamine, and amphetamine.143 
Lastly, plasma corticosterone, a biological marker of stress, is elevated with open arm 
exposure.144 
Other commonly used assays of anxiety in rodents are the open field and light-dark 
box.138 Both of these tests are similar to the elevated plus maze in that they, too, capitalize on 
approach-avoidance conflicts. In the open field test, the rodent is allowed to explore a large, 
brightly-lit, enclosed arena. In such a scenario, anxious animals will spend more time against the 
walls of the apparatus compared to the center, where they would be more exposed to danger 
(such as a potential predator).145 The light-dark box is similar in concept in that it is based on 
intrinsic motivation to escape a brightly illuminated environment, in which the rodent may be 
vulnerable or exposed, into a dark compartment.146 Here, the rodent is placed into a smaller 
apparatus that consists of a brightly lit chamber and a pitch black chamber, separated by a 
window. The rodent is allowed to move freely between the two chambers, and time spent in 
either chamber is recorded. In this particular assay, anxiety-like behavior is measured by time 
spent in the dark chamber, where the rodent is better hidden from predators (or pesky human 
experimenters). Like the elevated plus maze, both the open field and light dark test have a high 
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degree of face and predictive validity. However, an important caveat of all these tests is that they  
are all dependent on normal locomotor functioning. Therefore, animal models predisposed to 
motor deficits or hyper-activity, cannot be accurately assessed for anxiety-like behaviors in these 
tests. In these cases, alternative measures of anxiety that depend less heavily on movement may 
be used, such as assays of neophagia (fear of novel objects or foods), or novelty-suppressed 
feeding, in which exposure to a new environment suppresses food consumption.	   
Lastly to be considered are measures of social anxiety. Unfortunately, distinguishing 
between autistic-like impairments in social cognition (i.e. indifference or failure to recognize 
social cues) versus social anxiety in rodents remains a difficult challenge. Caution must be taken 
to avoid jumping to the conclusion of socially-provoked anxiety in rodents without a strong 
basis. However, reduced sociability could potentially reflect socially-evoked anxiety in models 
that already demonstrate hyper-anxiety in non-social tasks. The three-chambered social 
interaction test is considered the gold-standard for assessing sociability in rodents.147 In this test, 
the subject is placed within an apparatus divided into three accessible compartments: left, right, 
and center. On one far end of the apparatus, an empty wire cage is placed (“novel object”); 
whereas on the opposite end, a wire cage holding captive an unfamiliar mouse (“novel mouse”) 
is placed. The subject is allowed to freely roam the apparatus, and time spent investigating either 
the novel object or the novel mouse is recorded. Social preference can then be assessed by 
calculating the ratio of time spent with the novel mouse versus the novel object. Avoidance of 
the novel mouse may be considered an indicator of social anxiety, although additional measures 
may be helpful supporting this claim, such as whether this avoidance disappears after repeated 
exposure to the novel mouse. 
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1.4.3. Neurological Basis of Anxiety 
A host of studies, human and animal alike, have identified several key brain regions in 
the regulation of anxiety (Figure 8).148 While our knowledge of these circuits is still limited, the 
advent of optogenetic techniques will likely vastly improve our understanding of anxiety 
disorders and their neurobiological underpinnings within the near future. Based on the current 
knowledge, it has been postulated that anxiety arises from complex interactions between the 
amygdala, bed nucleus of the stria terminalis (BNST), medial prefrontal cortex (mPFC), and 
ventral hippocampus.148-151 These structures all highly interconnected, and together, register 
emotionally salient stimuli and coordinate both physiological and behavioral responses to them 
through several downstream effectors. Remarkably, these circuits are highly conserved between 
rodents and humans.   
The basolateral amygdala (BLA) is considered the master orchestrator of the anxiety 
response.152 Primarily, the BLA is believed to be involved in ‘threat assessment’ and the 
subsequent initiation of appropriate behavioral responses.148 First, sensory inputs from the 
thalamus and sensory association areas are received by the BLA and processed to determine their 
relative level of threat. Here, these incoming sensory cues are associated, via Hebbian 
mechanisms, with predicted outcomes of either a negative or positive emotional weight. In this 
way, the stimulus is appraised as threatening or rewarding, thereby determining whether fear or 
reward pathways should be subsequently recruited. This information is then relayed to a number 
of different downstream pathways to direct the anxiety response, when appropriate. Threat 
assessment within the BLA is further refined through the BLA’s dense reciprocal connections  
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Figure 8. Major circuits involved in anxiety generation. BLA: basolateral amygdala, BNST: bed 
nucleus of the stria terminals, BS: brainstem, CeA: central amygdala, Hyp: hypothalamus, mPFC: 
medial prefrontal cortex, PAG: periaqueductal grey, vHPC: ventral hippocampus. (Image credit: 
Calhoon and Tye, 2015.) 
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with both the mPFC and ventral hippocampus. The ventral hippocampus further aids in this 
process via its own efferents to the mPFC. 
In the event that a stimulus is deemed sufficiently threatening, the BLA orchestrates the 
anxiety response through the recruitment of several brain regions. The first of these is the local 
central nucleus of the amygdala, the amygdala’s major output site. The central amygdala is 
associated with two major downstream effector pathways. First, the central amygdala projects to 
the brainstem to orchestrate the autonomic responses associated with anxiety, such as changes in 
respiration, heart rate, blood pressure, and respiration. Second, the central amygdala is 
speculated to be involved in conscious perception of anxiety via the ventral amygdalofugal 
pathway to the anterior cingulate, orbitofrontal, and prefrontal cortices. The other major efferent 
target of the BLA is the BNST. This area instead acts as a relay site to the hypothalamic-
pituitary-adrenal (HPA) axis, which governs the body’s neuroendocrine responses to stress.153 
Activation of the HPA axis ultimately leads to release of cortisol into the bloodstream, which 
prepares the body for energy expenditure and physical activity by inundating the circulation with 
glucose, thereby supplying an immediate energy source to the muscles needed for flight (or to 
fight). Importantly, the activity of the BLA is shaped not only by sensory inputs, but also through 
afferents from the mPFC and ventral hippocampus.148 Projections from the mPFC are believed to 
influence the likelihood of a threat appraisal through fear-memory retrieval. On the other hand, 
projections from the ventral hippocampus appear to target fear-encoding neurons in the BLA to 
provoke fear renewal after extinction has taken place.154 
Lastly, the BLA itself promotes anxiety-associated responses through direct activation of 
the ventral hippocampus. Specifically, excitatory projections emanating from the BLA have been 
found to activate pyramidal neurons in the CA1 region of the ventral hippocampus;155 and 
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activation of these neurons has been shown to produce anxiety-like behavior in rodents in both 
elevated plus maze and open field tests.155, 156 Similarly, lesions to the ventral, but not dorsal, 
hippocampus produce an anxiolytic effect.157, 158  
1.5. The Paraventricular Nucleus is an Important Modulator of 
Anxiety and Social Behavior  
1.5.1. The Paraventricular Nucleus of the Hypothalamus 
What are the downstream effectors that drive these behavioral responses? One major 
player is the paraventricular nucleus (PVN) of the hypothalamus. Among other roles, the PVN is 
a vital component of the HPA axis that initiates the endocrine and autonomic responses to 
stress,153 and thus may be of particular relevance to the pathology of FXS. Consisting of a 
butterfly-shaped pair of nuclei that flank either side of the third ventricle, the PVN has been 
recognized in recent years as one of the most important autonomic control centers of the central 
nervous system.159  
The PVN is densely innervated by glutamatergic inputs from the amygdala (Figure 9).160 
In response to incoming stress signals, the medial parvocellular division of the PVN synthesizes 
and secretes corticotropin releasing hormone (CRH) into the median eminence, the anatomical 
link between the hypothalamus and the anterior pituitary gland. In response, the anterior pituitary 
gland secretes adrenocorticotropic hormone (ACTH) into the bloodstream, which ultimately 
stimulates the secretion of glucocorticoid steroid hormones from the adrenal gland. Among their 
many physiological roles, the glucocorticoids are the primary mediators of the body’s peripheral 
and central responses to stress. Peripherally, glucocorticoids prepare the body for stress by 
mobilizing glucose to the bloodstream, increasing muscle tone, and delaying parasympathetic 
processes that are non-essential during a crisis, such as feeding and digestion. Centrally, 
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glucocorticoids act on the hippocampus, amygdala, and frontal lobe in the short-term to enhance 
the formation of emotional memories. However, the long-term effects of chronic glucocorticoid 
exposure appear to exact the opposite effect, leading to the atrophy of hippocampal synapses and 
ultimately, hippocampal neurons themselves, reducing cognitive function.161 
Concomitantly, the PVN also putatively serves to eventually blunt the anxiety response 
after exposure to a stressor. In mammals, the PVN is the body’s main supplier of the peptide 
hormone oxytocin, which, among other roles, functions centrally as regulator of anxiety 
(discussed in greater detail in the following section). In brief, anxiogenic and stressful stimuli 
significantly boost oxytocin synthesis within the PVN and stimulate central oxytocin release.162-
166 In turn, centrally-released oxytocin has widely been shown to generate an over-arching 
anxiolytic effect (discussed further in Section 1.5.2). Taken together, these findings suggest that 
PVN-derived oxytocin may be especially important in tempering anxiety after activation of the 
stress response. 
Importantly, PVN activity is highly regulated by the hippocampus. Primarily, stimulation 
of the hippocampus produces a net inhibitory effect on the parvocellular division of the PVN.119, 
120, 167 Explaining this, projections from the ventral portion of the subiculum (a major source of 
hippocampal efferents to the hypothalamus) contact GABA-ergic neurons in the BNST, medial 
pre-optic area, and hypothalamic nuclei, which in turn project directly to the PVN.168 It has been 
hypothesized that the ventral hippocampus may serve to inhibit HPA axis activity following 
exposure to a stressor.169 Significantly, the parvocellular division of the PVN is not only 
responsible for synthesizing CRH to initiate the HPA axis, but also produces and releases 
oxytocin centrally.  Therefore, it is possible that over-activation of the ventral hippocampus 
could additionally lead to an inhibitory effect on the central oxytocin system.  
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Figure 9. Schematic of the HPA axis. Image credit: Papadopoulos and Cleare, 2012. 
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1.5.2. Oxytocin Mediates Sociability and Tempers Anxiety 
 What are the potential consequences of 
suppressed oxytocin synthesis on behavior? 
Oxytocin is a mammalian peptide hormone 
that is associated with diverse peripheral and 
central effects.170-176 The mature, active form 
of oxytocin consists of nine amino acids with 
an amidated C-terminus (cysteine-tyrosine-
isoleucine-glutamine-asparagine-cysteine-
proline-arginine-glycine-amide), and a disulfide bridge formed between the two cysteines at 
positions 1 and 6 (Figure 10). Oxytocin’s structure is remarkably similar to that of arginine 
vasopressin, which is also a nonapeptide containing a sulfur bridge. However, the two differ at 
residues 3 and 8. Oxytocin is colloquially referred to as the "love" hormone, and indeed, appears 
to play a significant role in a number of pro-social behaviors, in addition to anxiety- and stress-
coping.171-174, 177  
Endogenous oxytocin primarily originates from the paraventricular nucleus (PVN) of the 
hypothalamus.174  Additionally, it is produced in the adjacent supra-optic nucleus (SON) and 
medial preoptic area (MPA). Oxytocin-expressing neurons in the SON project mainly to the 
posterior pituitary and are responsible for oxytocin release into the peripheral bloodstream.177  
Oxytocin produced within the MPA, on the other hand, is predominantly associated with male 
and female sexual behavior.178, 179 
Two classes of neurons within the PVN synthesize and secrete oxytocin: magnocellular 
and parvocellular. Magnocellular oxytocin-producing neurons project to the posterior pituitary, 
Figure 10. Structure of oxytocin. Oxytocin is a 
nonapeptide hormone and neurotransmitter 
involved in a wide range of physiological and 
behavioral functions. 
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where oxytocin is released into the bloodstream to exert peripheral effects.177 However, oxytocin 
also possesses several important functions centrally as a neurotransmitter.174, 176 For this purpose, 
oxytocin is instead synthesized within parvocellular neurons of the PVN that project to the 
amygdala, BNST, nucleus accumbens, prelimbic cortex, and other regions of the brain to 
mediate a wide variety of behavioral effects. 
Due to its diverse peripheral and central actions, oxytocin synthesis has been well 
characterized.174 Oxytocin is encoded by the OXT gene and synthesized from an inactive 
precursor protein that is enzymatically hydrolyzed into smaller fragments to yield the mature 
peptide. Additionally, the OXT gene encodes an additional oxytocin carrier protein, neurophysin 
I, which is co-synthesized with oxytocin. Upon synthesis, oxytocin is stored within Herring 
bodies and transported to axon terminals for release.180 In magnocellular neurons, these axons 
project to the posterior pituitary gland and secrete oxytocin into the blood of the 
neurohypophysis to exert peripheral (hormonal) effects.174, 177 On the other hand, the 
parvocellular subset of neurons within the PVN are responsible for producing centrally-acting 
oxytocin.174 Central targets of the PVN are known to include the brainstem, spinal cord, and 
structures of the hypothalamus and limbic system. 
Oxytocin is associated with a single receptor, conveniently referred to as the oxytocin 
receptor or OXTR.181, 182 The OXTR belongs to the G-protein coupled-receptor (GPCR) 
superfamily, and is specifically associated with the G-protein Gq, which activates the canonical 
phosphatidylinositol-calcium second messenger system to exert a variety of intracellular effects. 
The OXTR is widely expressed throughout the body, including the male and female reproductive 
tracts (uterus, ovaries, testes, and prostate gland), mammary glands, kidneys, and brain. 
Peripherally, oxytocin and its receptor are well studied for their roles in lactation and parturition. 
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Several reports have also pointed to a role for oxytocin in the estrous cycle, male reproductive 
system function, and bone formation.  
Within the brain, oxytocin acts as a neurotransmitter and is known to mediate a wide 
spectrum of behavioral functions,170-177 as well as processes related to energy homeostasis, 
including thermoregulation and food intake.183-185 More pertinent to FXS, however, oxytocin is 
strongly linked to a variety of pro-social behaviors186 in both males and females.171, 173, 174, 177 
These behaviors include, but are not limited to social attachment, affiliative behaviors, pair-
bonding, sexual receptivity, parental care, social preference, social recognition, and social 
memory.187 
The circuits through which oxytocin mediates social behavior are still a subject of much 
research. However, it has been found that the extended amygdala is receptive to socio-sexual 
stimuli, and in response, elicits release of both oxytocin and arginine vasopressin from the 
PVN.188 In turn, the PVN is known to radiate oxytocinergic projections to the nucleus accumbens 
of the ventral striatum, a key component of the brain’s reward circuitry. Here, OXTR activation 
and D2-like dopamine receptor co-activation are thought to be involved in assigning 
motivational value to social stimuli.189  
Given its crucial role in social behavior, the oxytocinergic system has attracted great 
interest as a potential target in the treatment of ASD. For instance, recent work has demonstrated 
that both exogenous and evoked oxytocin can ameliorate social deficits in the Cntnap2 knockout 
mouse, a widely used model of autism.190 Importantly, these studies are not limited to mouse 
models - for instance, oxytocin delivery via intranasal spray has shown some success in 
improving face processing,191 emotion recognition,192 social interaction,193 and repetitive 
behaviors194 in autistic individuals. On the other hand, like most drugs, exogenous oxytocin is 
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not without unintended side effects, and has been linked to hyperactivity and aggression in some 
patients.195 Since most side effects are due to non-specific actions of therapeutics, correcting 
abnormalities within the endogenous oxytocinergic system may prove to be a better therapeutic 
strategy than exogenous administration, as shall be discussed in more detail in the next section.  
 In addition to its facilitative effects on social behavior, oxytocin is also believed to be 
important regulator of anxiety and stress coping.173, 196, 197 In rodents, both peripheral and central 
administrations of oxytocin have been shown to exert anxiolytic effects.198-201 This phenomenon 
has also been observed in humans administered oxytocin via intranasal spray.202-204 Endogenous 
oxytocin has also been found to have anxiolytic actions during the post-partum period205, 206 and 
in males post-mating.207 Moreover, oxytocin-deficient female mice display enhanced anxiety-
related behavior, and this is reversed by central administration of oxytocin.208  
How does oxytocin serve to temper anxiety? One current model proposes a role for 
oxytocin in the modulation of serotonin release. It has long been recognized that the 
neurotransmitter serotonin plays important roles in the regulation of emotional behavior.209 
Centrally, serotonin is primarily synthesized in the raphe nuclei of the midbrain, pons, and 
medulla.210 Importantly, about half of serotonergic neurons within the raphe nuclei have been 
found to express the oxytocin receptor, and local oxytocin infusion enhances serotonin release 
within the median raphe nucleus (MRN),211 which supplies serotonin to brain areas relevant to 
anxiety, including the cortex, septal region, hippocampus, and amygdala. Furthermore, this local 
infusion of oxytocin to the MRN has been shown to reduce anxiety-associated behaviors in the 
open field in mice in 5-HT2A/2C receptor dependent manner.211 These results may have important 
implications for FXS, as serotonin dysregulation is speculated to occur in FXS patients.212  
Oxytocin may also mediate anxiety behaviors through actions in the medial prefrontal 
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cortex (mPFC). Supporting this hypothesis, the pre-limbic region of the mPFC both expresses 
oxytocin receptors213, and receives axonal projections from oxytocin-producing neurons in the 
hypothalamus.214, 215 Furthermore, it has been found that oxytocin infusion to the mPFC reduces 
anxiety-like behavior in rodents independent of sex.216  However, the mechanisms by which 
endogenous oxytocin may regulate anxiety in the mPFC remain unclear. Infusion of an oxytocin 
receptor antagonist was found to produce no effect on anxiety-behavior in the aforementioned 
study, yet oxytocin receptor antagonists have been shown to block the anxiolytic properties of 
oxytocin in other studies in contexts where endogenous oxytocin is elevated.207, 217 As such, 
further studies are needed to address this discrepancy.  
1.5.3. Early Organizational Effects of Oxytocin 
Lastly, some work has demonstrated that early postnatal oxytocin plays a fundamental 
role in shaping later life behavior. While this is still a new and exciting area of research, 
manipulation of the oxytocinergic system in rodents has provided some insight into how 
oxytocin may be especially important in establishing adult social behavior. In one study, it was 
found that female mice treated with an oxytocin receptor antagonist on postnatal day zero make a 
reduced number of social approaches in a three-chambered social interaction apparatus as 
adults.218 Interestingly, oxytocin-treated male mice in this study did not differ significantly from 
controls. However, another group found that male rats given oxytocin treatments during the 
adolescent period, they were more socially interactive during adulthood.219 Taken together, these 
studies indicate that oxytocin appears to perform some kind of organization role during the 
development of circuits mediating social behavior in both males and females, although the 
timing of its effects appears to be sex-dependent. Based on these studies, it is possible that in 
male mice, oxytocin might be more influential in establishing social behavior during later stages 
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of development; whereas in female mice, oxytocin appears to exert its effects earlier on.  
Interestingly, the effects of oxytocin during brain maturation are not limited to the 
development of social behavior. A growing body of work suggests that at a young age, oxytocin 
also appears to be involved in establishing adult responses to stress. For instance, rats 
administered daily oxytocin injections in the pubertal period were shown to be more exploratory 
in a novel open field environment, which was interpreted as an anxiolytic effect.219 Supporting 
this case, it was found in a separate study that female prairie voles administered oxytocin on 
postnatal day 1 have lower baseline levels of plasma corticosterone by postnatal day 8.220  
How does oxytocin impact the development of these behaviors, mechanistically? 
Unfortunately, this is also a relatively new and untouched area of research. On the other hand, 
some existing work has shown that oxytocin also seems to direct the organization of the 
serotonergic system. In one study, it was shown that male prairie voles treated with oxytocin 
daily displayed greater serotonin innervation in the hypothalamus and cortical amygdala at 
P21.221 Given the importance of serotonin in anxiety and mood, any disruption to the early 
oxytocinergic system would potentially have a huge impact on later-life emotional functioning. 
Alternatively, it is also possible that early oxytocin levels help direct the development of the 
oxytocinergic system itself. In this case, disturbances to the oxytocin system during early life 
would impact both social and emotional behavior. Moreover, it is possible that during the 
postnatal period, oxytocin may regulate the development of circuits or brain regions that are less 
or non-responsive to oxytocin later in life, if expression of the OXTR in those regions is 
transient. Since both social behavior and anxiety are affected in FXS, it is likely that early 
defects in the oxytocin system could contribute to long-term changes in socio-emotional 
functioning.  
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As described in Section 1.5.1,  stimulation of the hippocampus produces a net inhibitory 
effect on the parvocellular division of the PVN, where centrally-released oxytocin is primarily 
synthesized.119, 120 This inhibition has been attributed to the ventral hippocampus, which 
activates inhibitory interneurons within the BNST which project to the PVN.168, 222 Based on this 
knowledge, it is possible that over-excitation of the ventral hippocampus in FXS may lead to 
exaggerated suppression of PVN oxytocin synthesis. Given the likely role of oxytocin in 
establishing later life emotional and social behavior, we speculate that this reduction in oxytocin 
levels during early circuit formation may be a key culprit in anomalies in these behaviors in 
FXS.	  
1.6. Significance and Objectives of the Current Study 
1.6.1. Shortcomings of Current Approaches in Treating FXS 
Taken together, the aforementioned findings provide compelling evidence that oxytocin 
is essential for normal social functioning and anxiety levels. Considering that social deficits and 
hyper-anxiety are hallmark characteristics of FXS, it is highly likely that the oxytocinergic 
system may be compromised in the disorder, particularly during brain development. If this is 
indeed the case, then targeting the oxytocinergic system and its upstream/downstream effectors 
may prove a useful strategy in correcting many FXS-associated symptoms. However, to our 
knowledge, studies investigating the integrity of oxytocinergic system in FXS or taking 
advantage of this promising avenue of treatment are astonishingly lacking. 
Presently, treatments that directly counteract the effects of the FXS mutation remain 
elusive, and those currently in use are aimed at secondary symptoms of the disorder. As a result, 
many patients with FXS take must take multiple medications simultaneously in order to manage 
their symptoms. These may include anti-convulsants, anti-anxiety medications, drugs to manage 
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irritability, attention problems, and/or hyper-activity. It is not unheard of for a patient to have as 
many as four prescriptions at once. This is disadvantageous not only because of the potential for 
side effects and the risk of drug interactions, but also because not enough is known about how 
long-term exposure to such psychiatric medications may affect developing brains when treating 
children. As of yet, there is no one single treatment approach for FXS. Recently, it was reported 
that although group 1 metabotropic glutamate receptor antagonists demonstrated promise in early 
stages of research, they ultimately failed to improve symptoms in double-blinded clinical trials 
beyond placebos,87 a major setback for FXS research. Exogenous administration of oxytocin has 
shown some promise in patients with autism,191-193, 195 but to our knowledge, however, only one 
study has examined its effects on FXS patients.223 Here, it was reported that intranasally-applied 
oxytocin improved eye-gaze frequency and reduced salivary levels of cortisol in the short-term 
(20 minutes post-administration). However, unfortunately, these are rather indirect measures of 
an individual’s emotional state, and more salient effects were not reported.  
1.6.2. Exogenous Oxytocin Administration is Not an Ideal Therapeutic Strategy for FXS 
While exogenous oxytocin administration may therefore hold some promise for FXS 
patients, based on data from studies on ASD patients, it is certainly not without its shortcomings. 
In humans, oxytocin is generally administered via one of two main routes: intravenously and 
intranasally. Intravenous administration is primarily utilized to achieve peripheral effects, such 
as the stimulation of uterine contractions during labor. In contrast, intranasal administration is 
primarily utilized to achieve behavioral effects.  
The first problem with exogenous oxytocin administration to achieve behavioral effects is 
that the half-life of oxytocin is quite short. Human studies have estimated a half-life of 
approximately 3-8 minutes in the plasma in rodents224 and humans225 although it is longer-lasting 
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in the cerebrospinal fluid: approximately ~19 minutes in rats.226 Oxytocin is believed to be 
cleared from the cerebrospinal fluid (CSF) via two mechanisms: (1) pooling into the 
subarachnoid space, where it is ultimately absorbed into the venous blood through the arachnoid 
villi;227 and (2) active transportation into the blood by peptide transport system 1.228 
The second problem regarding exogenous oxytocin administration is its efficiency. 
Oxytocin administered intravenously does not cross the blood brain barrier in meaningful 
amounts; therefore, intranasal administration must be employed to achieve central effects.229 
There has been much controversy regarding the efficacy of oxytocin penetration into the brain 
following intranasal administration. Based on human and animal studies, it has been estimated 
that only 0.002-0.005% of intranasally administered oxytocin reaches the CSF within 1 hour, 
even when doses greatly exceeding the pituitary content are administered.229  
However, one might argue that CSF concentration is an indirect measure that does not 
necessarily reflect availability in brain tissue. Circumventing this issue, one recent study 
explored intranasal oxytocin penetration via arterial spin labeling, a non-invasive 
pharmacodynamic technique that quantitatively measures regional cerebral blood flow (rCBF). 
In this study, 40 IU of oxytocin was administered to healthy male subjects, and this dose was 
found to be sufficient to increase rCBF in areas part of the social brain network within 78 min.230 
It is prudent to note that this dose greatly exceeds human pituitary oxytocin content, which has 
been estimated via bioassay to be approximately 14 IU (28 ug).231 In the aforementioned study 
on FXS patients, moreover, doses of 24 and 48 IU were necessary to improve eye-gaze 
frequency and reduce salivary cortisol, respectively.  
Therefore, on account of oxytocin’s poor brain penetrance and rapid clearance, relatively 
high doses of the peptide are required to achieve appreciable effects on behavior. Moreover, it is 
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likely that larger amounts of exogenous oxytocin are required to produce behavioral effects, 
compared to peripheral effects. This is because the oxytocin receptor (OXTR), like most G-
protein coupled receptors, is de-sensitized upon stimulation.232 Since basal concentrations of 
oxytocin are higher in the brain than in the plasma (~1-10 pg/mL),233 higher doses are therefore 
likely needed to elicit meaningful effects on behavior. However, the usage of supra-physiological 
doses of oxytocin to achieve central effects is problematic for many reasons. First, intranasal 
application has been found to achieve higher concentrations of the peptide in plasma than in the 
CSF. It is estimated that 1% of intranasally-administered oxytocin enters the systemic 
circulation.234 This is precarious because much lower amounts of oxytocin are required to 
produce peripheral effects than central ones. Basal concentrations of oxytocin are much lower in 
the plasma than in the brain, and thus, peripheral OXTRs are normally exposed to far lower 
concentrations of oxytocin than central OXTRs. Because of this, peripheral OXTRs are much 
more sensitive to stimulation and it likely that they would be inadvertently affected by intranasal 
oxytocin administration. Moreover, peripheral targets of oxytocin are widespread. These include, 
among others, the kidneys, where oxytocin is involved in water homeostasis; the pancreas, where 
oxytocin increases glucagon and insulin secretion; and the heart, where oxytocin has been found 
to raise heart rate variability.235  
Furthermore, the usage of supra-normal doses to achieve central effects is problematic for 
economic reasons. The production of synthetic oxytocin relies on solid-state synthesis with 
modifications for disulfide bond formation and amidation of oxytocin’s C-terminus. This is a 
multi-step process that is relatively expensive and time-consuming compared to the synthesis of 
many non-peptide drugs. Moreover, since oxytocin penetration is thought to be relatively poor, 
and its clearance from the body is relatively swift, the majority of the oxytocin administered is 
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wasted. 
It is also important to consider the practicality of the treatment from a clinical standpoint. 
The effects of exogenously-administered oxytocin are fleeting, lasting only about 45 minutes 
post-administration in humans.236 Therefore, repeated administration over the long term would 
be required to achieve normal functioning in many patients. However, human data on outcomes 
following chronic treatment are still lacking. In fact, there is some evidence that extended 
treatment with oxytocin may be counter-productive. In male prairie voles, long-term 
administration, beginning in youth through adulthood, in fact was discovered to lead to deficits 
in social bond formation.237  
Last, but not least, exogenous oxytocin has also been reported to carry the potential for 
undesirable behavioral side effects. For instance, intranasal oxytocin has been found to cause  
hyperactivity and aggression in a subset of ASD males.195 On the other hand, some reports have 
found that oxytocin has no effect at all in some patients. For instance, one study detected no 
benefits of oxytocin in autistic youths that were given 12 or 24 IU intranasal oxytocin once daily 
for four consecutive days.238 Thus, intranasal administration of oxytocin, though better than other 
methods of delivery, may not be an ideal solution for a significant proportion of patients. 
1.6.3. Targeting Defects in Brain Development: A New Angle for Approaching FXS 
 Current approaches in treating FXS are limited and are fraught with many disadvantages. 
In light of these shortcomings, we propose that identifying and correcting FXS-associated 
changes within the endogenous oxytocinergic system may be a worthwhile new direction to 
pursue. In the current study, we have honed in on FXS-associated changes in the ventral 
hippocampus, as a major upstream regulator of the hypothalamus. The ventral hippocampus is 
potentially among the most relevant brain structures to the pathogenesis of FXS, as it modulates 
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the activity of the cortex, amygdala and hypothalamus to coordinate emotional and social 
behavior.148, 155, 239, 240 Hence, the hippocampus is likely to play a central role in the socio-
emotional make-up of a human being.  
When envisaging such strategies, however, it is once again important to remember that 
FXS is a developmental disorder – that is to say, FXS arises from intrinsic changes in the normal 
trajectory of brain development, leading to lifelong consequences; as opposed to a condition that 
can be caused by intrinsic or extrinsic factors at any age, which may or may not be life-long. 
Given the role of the ventral hippocampus in social and emotional behavior, we postulate that 
any insult to its development during early life may potentially leave a profound impact on the 
behavior of an individual, as clearly appears to be the case in FXS. Since FMRP functions as a 
widespread neuronal translational regulator, FXS is considered to result from global, 
uncontrolled expression of dosage-sensitive genes that are required for normal dendritic spine 
development, remodeling, and function. Such alterations in synaptic plasticity during early stages 
of developmental wiring may in turn lead to defects in the formation of many cognitively and 
behaviorally relevant neurological circuits, such as connections within and between the 
hippocampus, hypothalamus, and amygdala.  Moreover, these effects on the initial wiring of the 
brain may be to a large extent irreversible upon reaching adulthood, highlighting the need for 
early intervention strategies that target the root of the malady, as opposed to the symptoms. 
Importantly, even a few aberrant connections made during brain development may be capable of 
resulting in developmental disorders: once a few of such improper connections are formed, it is 
likely that they may lead to further inappropriate connections during early circuit formation, 
thereby amplifying the defect into a syndrome that the affected individual would have to live 
with their entire life.  
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Despite this point, most therapeutic strategies to ameliorate FXS-associated dysfunctions 
have avoided treatment during brain development. In contrast, in our efforts toward a therapeutic 
strategy, we have focused on the early stages of postnatal brain development in FXS. Thus, 
unlike the majority of studies conducted in this area, we have adopted a novel strategy of early 
intervention to prevent or reduce the onset of the socio-emotional symptoms associated with 
FXS. In other words, instead of treating symptoms after they have already developed, our 
strategy aims to guide brain developmental back onto the correct trajectory before the symptoms 
become permanent.   
 Of course, we recognize that it is desirable in the clinic to avoid therapy during the early 
stages of life. However, most clinical scientists agree that aberrant brain connections formed 
during the early brain development are likely to be causal to the FXS-associated behavioral 
deficits. The impression that mouse studies do not translate to human therapy is often based on 
treatments that are offered beyond the point critical development, when the brain can still be 
nudged to form the right connections. Therefore, it is highly important to conduct preclinical 
studies during early brain development. Such studies would have a greater likelihood of 
eventually translating into successful human clinical trials.  
1.6.4. Objectives of the Current Study 
 For a number of years, our team has been interested in elucidating hippocampal serotonin 
1A receptor- mediated signaling pathways linked to anxiety and depression. Our mechanistic 
studies have identified protein kinase C epsilon (PKCε) as an important signaling molecule 
during neonatal brain development, with an integral role in early hippocampal neurogenesis.241 
These findings have inspired us to study the role of PKCε in other disorders of brain 
development, such as FXS. However, because of the fact that PKCε signaling appears to be key 
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to proper brain development, we speculate that targeting PKCε during adulthood may prove far 
less effective in treating the symptoms of FXS. Thus, the objectives of the current study were 
two-fold. First, we sought to examine the integrity of early postnatal PKCε signaling in FXS. 
Second, we investigated whether early intervention, by stimulating PKCε signaling during early 
postnatal development, could permanently, yet safely, prevent or reduce the onset of FXS-
associated socio-emotional disturbances. 
In this thesis, we report that PKCε expression is stunted in the developing Fmr1 KO 
mouse brain, and that this is linked to heightened GluR2-containing AMPA receptor expression 
in hippocampal glutamatergic synapses. This may provide a mechanism by which hippocampal 
excitability may become exaggerated in the syndrome. The ventral hippocampus is a major 
regulator of the HPA axis and stress response through its inhibitory projections to the 
paraventricular nucleus of the hypothalamus (PVN). Accordingly, over-activity of the ventral 
hippocampus might lead to inappropriate inhibition of neuroendocrine cells within the PVN. We 
have found that during the early postnatal stage, the Fmr1 KO PVN displays a reduction in the 
number of oxytocin positive cells. This is an important finding not only because of the role of 
oxytocin in pro-social behavior, but because oxytocin itself may help to organize the 
development of neuronal circuits relevant to behaviors altered in FXS, including social 
interaction and anxiety. Based on these findings, we questioned whether targeting PKCε 
signaling in the neonatal Fmr1 KO hippocampus might serve to correct oxytocin levels in the 
downstream PVN at this age. By targeting this pathway early in life, we speculated it might be 
possible to mitigate the effects of the Fmr1 mutation on later-life social behavior and anxiety.  
True to our hypothesis, we report that neonatal administration of a PKCε-specific activator is 
sufficient to normalize changes in GluR2- AMPA receptor density in neonatal ventral 
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hippocampal synapses, oxytocin levels in the PVN, and significantly reduce the severity of FXS-
associated changes in social and anxiety-like behavior in Fmr1 KO mice during adulthood. Thus, 
in the current study we (1) have uncovered a previously-unidentified signaling pathway 
implicated in FXS; and (2) present a novel strategy to circumvent aberrant brain development in 
FXS and accompanying socio-emotional disturbances, by augmenting PKCε signaling during 
neonatal development.  
1.6.5. PKCε  is an Important Signaling Molecule in Postnatal Brain Development 
Before moving forward, it may be prudent to review the current knowledge of the role of 
PKCε in brain development. Protein Kinase C (PKC) is a family of serine and threonine protein 
kinases which play important roles in numerous signal transduction cascades within and outside 
of the nervous system.242 PKCs are categorized into three subfamilies based on sequence 
homology and activator requirements: conventional (α, β and γ), novel (δ, ε, ζ, µ, and ε), and 
atypical (λ and δ). Conventional PKCs require calcium, diacylglycerol (DAG), and a 
phospholipid such as phosphatidylserine to be activated. On the other hand, novel PKCs, such as 
PKCε, require DAG, but not calcium. Thus, they both are activated through similar signal 
transduction pathways, such as phospholipase C (PLC). Lastly, atypical PKCs require neither 
calcium nor DAG.  
Protein kinase C epsilon (PKCε) is a novel PKC isotype.243 While calcium independent, it 
is phorbol ester and DAG sensitive. The responsiveness of PKCε to second messengers requires 
phosphorylation at three conserved sites: Thr-556 in the activation loop, Ser-729 in the C-
terminal hydrophobic site, and Thr-710 at an autophosphorylation site. Neuronal PKCε is 
activated by a variety of different second messengers, though primarily DAG and 
phosphatidylinositol 3,4,5,-triphosphate (PIP3). Importantly, PKCs are known for their long-term 
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activation: they remain catalytically active in the cell after the original activation signal and/or 
calcium wave has subsided. The intracellular localization of PKCε, following its activation, is 
dependent on which second messenger is bound to its C1 domain. For instance, PKCε is 
translocated to the plasma membrane and/or cytoskeleton in response to DAG, whereas it instead 
translocates to Golgi-networks in response to arachidonic acids and linoleic acids. Enhancing the 
spatial and temporal organization of PKCε are adaptor proteins, collectively called RACKS 
(receptors for activated C kinase), which anchor PKC near its substrates to optimize the speed 
and precision of the response.  One such adaptor protein responsible for PKCε translocation that 
has been identified is RACK2, a Golgi membrane protein associated with vesicular release.244  
Though it is expressed throughout the entire body, PKCε is predominantly localized in 
the brain.245, 246 Highest levels of expression are found in the hippocampus, islands of Cajella, 
and olfactory tubercule; but moderate expression also occurs in the frontal cortex, striatum, 
nucleus accumbens, lateral septal nuclei, and caudate putamen. The known actions of PKCε 
within neurons are numerous and diverse. In vitro, activation of PKCε has been demonstrated to 
promote the outgrowth of neurites during neuronal differentiation via stabilization of actin 
filaments.247 When bound to actin, PKCε becomes anchored to the cytoskeletal matrix and 
remains catalytically active. One important functional consequence of this in the nerve terminal 
appears to be the facilitation of glutamate release, and thus, may participate in regulating 
excitatory neurotransmission and plasticity.  
We have previously reported that the PKC isoform epsilon (PKCε) is highly enriched in 
the mouse hippocampus at postnatal day 6 (P6), the onset of postnatal hippocampal development 
(Figure 11).248 During this time, PKCε orchestrates neurogenesis within the dentate gyrus 
downstream of the serotonin 1a receptor (5-HT1A-R) (Figure 12). Moreover, PKCε’s 
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upregulation further increases up to the event of eye-opening at P15,248 suggesting that it may be 
essential in guiding early postnatal hippocampal synaptogenesis in response to incoming visual 
stimuli.  
Most intriguingly, Darnell and colleagues have recently demonstrated that PKCε mRNA is one 
of the many targets of FMRP-mediated translational regulation, raising the possibility that its 
expression may be dysregulated in FXS.43  Supporting this hypothesis, recent work by Sun and 
colleagues  demonstrate  that  juvenile  administration  of   bryostatin-1,   a   non-selective  PKCε 
activator, is able to rescue hippocampal synaptic structural abnormalities in FXS knockout (KO)  
mice, as well as deficits in spatial memory.249  Thus, it is very likely that PKCε-mediated 
signaling may guide some of the processes underlying synaptic maturation that are impaired in 
FXS. As discussed in Section 1.6.3, insults to synaptic transmission during hippocampal 
development may have dire consequences on the formation of downstream circuits involved  in 
cognition, mood, and behavior. We have obtained data that demonstrates hippocampal PKCε 
signaling may be an especially important early mediator of these functions.  
In a set of studies conducted prior to this thesis, we have found that neonatal 
intraperitoneal injection of 3 mg/Kg DCP-LA (i.p.) is able to permanently rescue elevated 
anxiety-like behavior in adult serotonin 1a receptor knockout mice, a frequently-used model of 
mood and anxiety disorders (Figure 13).  This occurs in conjunction with a partial rescue of 
hippocampal neuroblast proliferation at P6 in these mice (Figure 14).  
 
 
 
 
53 
	  
	  
	  
	  
Figure 11. PKCε is highly expressed in the hippocampus during neonatal development, its levels steadily 
increasing from P6 through P15. Solid black arrows: cell bodies, thin black arrows: stratum radiatum. (Purkayastha 
et. al, 2009). 
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Figure 12. PKCε directs early postnatal hippocampal neurogenesis downstream of the serotonin 1a receptor (5-
HT1A-R) .C57/BL6 mice, aged P6, were injected with BrdU 2h before intra-hippocampal infusion of 8-OH-
DPAT in the presence and absence of agonists and inhibitors.  Immunolabeling of newly divided cells with 
BrdU (red), mature neurons labeled with NeuN (green) and neuronal progenitor cells marked with doublecortin 
(DCX, blue) was performed. D= 8-OH-DPAT, WAY = WAY100635, M = Myr-εV1/2, U = U1026. Data 
presented as mean ± S.E.M. (Samaddar et. al,2013.)  
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Taken together, these findings suggest that PKCε-mediated signaling may contribute to 
the establishment of normal anxiety behavior during adulthood, one possible mechanism being 
regulation of early postnatal hippocampal neurogenesis. Indeed, mounting evidence has 
suggested that activation of the upstream serotonin 1a receptor by serotonin, agonists of the 
receptor, and mechanisms elicited by antidepressant drugs can augment the production of 
newborn granule cells in the hippocampus, and that a fine balance of this process is necessary to 
maintain normal mood and anxiety levels.250, 251  During early development, this process is 
furthermore putatively involved in the normal establishment of hippocampal mossy fibers, and 
likely the downstream hippocampal circuitry. However, the extent to which these processes are 
impacted during early brain development in FXS remains unknown. A fine balance of these 
processes during the postnatal period is likely necessary for the precise formation of fundamental 
circuits involved in learning, memory, and emotion, and disruption of this balance could 
presumably lead to profound effects on the FXS brain, manifesting as behavioral deficits in these 
areas. 
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Figure 13. Peripheral administration of PKCε  activator DCP-LA (3 mg/kg, i.p.) at P6, P10, and P14 rescues 
anxiety-like behavior in female 5-HT1A-R knockout (KO) mice the light-dark test (LD, A and B) and elevated 
plus maze (EPM, C and D). Compared to wild-type mice (WT), the knock-out mice (KO) displayed significantly 
decreased number of entries (A) and time spent (B) in the lit chamber, indicating heightened anxiety. Similarly, 
KO mice spent less time in, and made fewer entries to the open arms of the EPM. All of these anxiety-like 
behaviors were fully corrected in KO females that were neonatally treated with DCP-LA. No significant 
difference was observed among WT and KO mice in locomotion in the open field test (OF, E, F) indicating that 
the results in the LD test were not influenced by differences in motor capability. In our studies, male KO mice 
did not demonstrate anxiety-like behavior (data not shown).  
0 
10 
20 
30 
40 
WT(F)	   KO(F)	  Untreated	   KO(F)	  +	  DCPLA	  systemic	  
LD
: N
um
be
r o
f E
nt
rie
s 
 
to
 L
it 
C
ha
m
be
r 
0 
20 
40 
60 
80 
O
F:
 D
is
ta
nc
e 
Tr
av
el
ed
 (m
) p=0.3 
E 
0 
200 
400 
600 
O
F:
 T
im
e 
 
M
ob
ile
 (s
) 
p=0.27 
F 
0 
50 
100 
150 
200 
250 
WT(F)	   KO(F)	  Untreated	   KO(F)	  +	  DCPLA	  systemic	  
LD
: T
im
e 
in
 L
it 
 
C
ha
m
be
r (
s)
 
p=3x10
-4
 p=0.0095 
p=0.54 
 W
T+
Ve
hic
le 
 K
O+
Ve
hic
le 
 K
O+
DC
P-
LA
 
	   
	   	   
A p=0.47 
p=3x10
-4
 p=0.007 
	   
	   	   
B 
 W
T+
Ve
hic
le 
 K
O+
Ve
hic
le 
 K
O+
DC
P-
LA
 
0 
1 
2 
3 
4 
5 
6 
1	   2	   3	  
E
P
M
: %
 T
im
e 
in
 
O
pe
n 
A
rm
s 
C 
p=0.02 p=0.05 
p=0.35 
60
50
40
30
20  
10
 
	   
	   	   
 W
T+
Ve
hic
le 
 K
O+
Ve
hic
le 
 K
O+
DC
P-
LA
 0 
10 
20 
30 
40 
50 
60 
1	   2	   3	  E
P
M
: %
 E
nt
rie
s 
to
  
O
pe
n 
A
rm
s 
D p=0.56 
p=0.033 p=0.034 
	   
	   	   
 W
T+
Ve
hic
le 
 K
O+
Ve
hic
le 
 K
O+
DC
P-
LA
 
 
 
 
 
57 
	  
	  
	  
	  
  
W
T+
Ve
hi
cl
e 
K
O
+D
C
P-
LA
 
BrdU + NeuN + DCX BrdU + DCX 
K
O
+V
eh
ic
le
 
Figure 14. Stimulation of PKCε boosts neuroproliferation in 5-
HT1A-R KO female mice at P6.  As shown earlier, PKCε mediates 
5-HT1A-R-linked activation of Erk1/2 in the P6 hippocampus to 
regulate neuroblast proliferation (Figure 12). While female 5-
HT1A-R KO mice demonstrate reduced neuroblast proliferation at 
P6 compared to wild-type (WT) controls, this suppression was 
partially corrected following intrahippocampal infusion of DCP-
LA 24 hrs prior. In contrast to the females, no differences were 
observed in male P6 KO pups (data not shown). Green: NeuN, 
Red: BrdU, Blue, doublecortin (DCX). Scale bars=75 µm. Data 
represents mean ± S.E.M. (Samaddar et. al, 2013.)241 
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1.6. 6. The AMPA Receptor – A Potential Target of PKCε-Mediated Signaling 
Although we have discovered that PKCε is an important mediator of early postnatal 
hippocampal neurogenesis and the establishment of normal anxiety behavior (see Section 1.6.4), 
it is prudent to bear in mind that PKCε may also guide hippocampal development through 
additional, independent pathways. Moreover, abnormalities in early postnatal neurogenesis may 
not easily explain deficits in synaptic functioning that persist in FXS throughout the lifespan. In 
our attempts to uncover additional potential PKCε-mediated pathways that may be altered in 
FXS, we have focused on hippocampal AMPA receptors, which largely influence synaptic 
function and plasticity in this region during the early postnatal period.  
The AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor is a 
transmembrane receptor of glutamate, and the most common receptor in the brain.252 An 
ionotropic receptor permeable to cations, 
the AMPA receptor is primarily 
responsible for fast, excitatory synaptic 
transmission within central synapses. The 
AMPA receptor consists of a ligand-
gated ion channel composed of 
combinations of four discrete subunits 
(Figure 15), termed GluR1-4.253 Most 
AMPA receptors are assembled in the 
endoplasmic reticulum as dimers, which 
are later joined together to form 
tetramers. Each subunit contains an 
Figure 15. Structure of the α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptor with an 
antagonist bound to the glutamate binding site. Image 
credit: Curtis Neveu. 
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agonist binding site at the N-terminal. When two of these sites are occupied, the ion channel pore 
opens, with current increasing as more binding sites become occupied. Remarkably, the channel 
can open and close quite quickly, at a speed of 1 ms.254 The AMPA receptor is highly expressed 
in the hippocampus throughout the lifespan, including development.255 Within the hippocampus, 
most AMPA receptors contain both GluR1 and GluR2.256	   
AMPA receptor function is largely dependent on its subunit composition. Much evidence 
has suggested that the GluR2 subunit is particularly important in this regard.257 First, GluR2 is 
responsible for determining the permeability of the channel to specific ions. Primarily, AMPA 
receptors lacking GluR2 are permeable to sodium, potassium, and calcium; whereas receptors 
containing the unit are impermeable to calcium. This is because the GluR2 subunit can be post-
transcriptionally modified so that uncharged glutamine within AMPA-R’s ion channel lining 
(residue 607) is converted into the positively charged arginine, which prevents calcium from 
passing through the pore.258 Almost all GluR2 subunits in mature neurons are edited in this 
fashion.257 In addition to cation permeability, the GluR2 receptor has also been shown to be 
required for normal long-term synaptic strengthening (LTP)259 and long-term synaptic 
weakening (LTD)260 in the hippocampus. Lastly, the GluR2 subunit also appears to be 
responsible for AMPA receptor trafficking. For instance, it has been found that PKC-dependent 
phosphorylation of the intracellular serine 880 (Ser880) residue triggers internalization of the 
receptor from the synapse to dampen the neuron's response to incoming excitatory signals.261, 262 
Specifically, GluR2 is stabilized at the synapse through its interactions with the PDZ proteins 
PICK1 and GRIP; but phosphorylation of Ser880, located within the PDZ-binding domain of 
GluR2, destabilizes this interaction. 
Given its function in mediating fast excitatory synaptic transmission, AMPA receptors 
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are integral to normal synaptic plasticity. Changes in the number and composition of synaptic 
AMPA receptors have been shown to mediate both LTP and LTD.255 Along these lines, changes 
in AMPA receptor dynamics would certainly impact not only hippocampal development, but 
also the foundational wiring of hippocampal-mediated macro-circuits that are involved in 
cognition, behavior, and mood. Since LTP and LTD are both disrupted in FXS,74 we therefore 
sought to identify possible changes in AMPA receptor dynamics during hippocampal 
development that may underlie this phenomenon. Given that PKCε is abundantly expressed in 
the hippocampus during its postnatal development,248 we investigated whether PKCε may 
potentially play a role in AMPA receptor dynamics during this time. 
1.6.7. DCP-LA, A Selective Activator of PKCε 
PKC activators have been widely used in the treatment of various medical conditions.263 
In our attempts to correct altered PKCε signaling in the Fmr1 KO brain, we have employed a 
highly selective PKCε activator, the linoleic acid derivative 8-[2-(2-pentyl-cyclopropylmethyl)-
cyclopropyl]-octanoic acid (dicyclopropyl-linoleic acid, or DCP-LA).264 The derivative is 
structurally identical to linoleic acid, except that it contains cyclopropane rings instead of cis-
double bonds (Figure 16). Importantly, DCP-LA does not occur in nature, but is synthesized 
from linoleic acid.265 In brief, linoleic acid methyl 
esters are cyclopropanated using a modified 
Simmons-Smith reaction265 and purified by column 
chromatography.	   
An essential fatty acid, linoleic acid is 
abundant in nuts, fatty seeds, and vegetable oils, 
including palm and olive oil. Linoleic acid is 
Figure 16. Chemical structure of 8-[2-(2-
pentyl-cyclopropylmethyl)-cyclopropyl]-
octanoic acid (DCP-LA) compared to 
linoleic acid. 
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known to participate in a wide range of biological activities. For instance, it is the major dietary 
precursor of arachidonic acid,266 which is required for the synthesis of prostaglandins and 
thromboxanes; and it is also a regulator of PLC267 and PKC268 signaling. In contrast to linoleic 
acid, however, the biological activity of DCP-LA is much more restricted, acting primarily as a 
selective activator of PKCε. DCP-LA has shown to exhibit >7-fold specificity for activation of 
PKCε versus other PKC isozymes, by binding to PKCε’s phosphatidylserine binding site.264, 269 
This is a significant advantage of DCP-LA as a therapeutic because as a phosphatidylserine-
binding PKC activator, unlike diacylglycerol-binding activators, seeming to produce little or no 
downregulation of PKC.270 Moreover, DCP-LA is quite potent, demonstrating activity at 
concentrations as low as 10nM, but with maximal effects at 100 nm.264  
Since its recent development, DCP-LA has gained growing interest due to the many and 
diverse roles of PKCε in both normal physiology and in disease. The therapeutic potential of 
DCP-LA has been particularly investigated in the context of Alzheimer’s disease (AD). In one 
study, for instance, it was found that treatment with 3 mg/Kg of DCP-LA twice a week for 12 
weeks was able to prevent synaptic loss, accumulation of amyloid plaques, and cognitive deficits 
in the rapidly-progressing 5XFAD transgenic mouse model of AD.271 Similarly, it was 
independently found that acute intra-peritoneal injection of 1 mg/Kg DCP-LA was able to 
improve learning deficits imparted by amyloid-β1−40 peptide, which is linked to synaptic 
disorder and cognitive function; as well as improve deficits imparted by scopolamine, a 
muscarinic ACh receptor inhibitor that is also linked to cognitive impairment.272 Additionally, 
DCP-LA has been shown to improve age-related learning impairments in accelerated-
senescence-prone mice (SAMP8) treated with this same dose.273 Possibly explaining these 
findings, it has been found that DCP-LA promotes the translocation of presynaptic α7 
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acetylcholine (ACh) receptors to the synapse, which in turn leads to enhanced glutamate release 
and long-lasting facilitation of hippocampal synaptic transmission.274  
Interestingly, DCP-LA has also been evaluated as a potential therapeutic in the context of 
depression, albeit to a lesser degree than AD. Intriguingly, it was found that DCP-LA promoted 
translocation of the serotonin 1a receptor to hypothalamic post-synaptic membranes of mice 
subjected to restraint stress.275 This was associated with increased serotonin release and 
inactivation of glycogen synthase kinase 3β (GSK-3β), which has been linked to serotonin-
sensitive anxiety and social behavior.276-278 Remarkably, even oral administration of 1 mg/Kg 
DCP-LA treatment was able to rescue depressive-like behaviors in these mice. 
DCP-LA has several attractive advantages as a therapeutic agent. First, the precursor of 
DCP-LA, linoleic acid, is naturally abundant.  Second, as an unsaturated fatty acid, linoleic acid 
readily crosses the blood brain barrier, most likely by simple diffusion.279 Numerous studies have 
shown that DCP-LA is also capable of crossing the blood brain barrier,271-273, 275 and peripheral 
injection of doses as low as 1/mg kg produce appreciable effects on behavior.272, 273 As 
mentioned above, DCP-LA also appears to produces therapeutic effects on behavior when this 
same dose is administered orally.275 DCP-LA is also superior to many alternatives due to its 
relatively high biovailability: due to the presence of its cyclopropane rings, DCP-LA resists 
metabolism in vivo.280 DCP-LA’s effects are also relatively long-lasting, compared to other PKC 
activators:  it has been found that PKC exposed to DCP-LA remains activated for at least four 
hours.281 Lastly, using appropriate drug delivery methods, DCP-LA can also be targeted to 
specific brain regions, reducing the risk of potential behavioral and peripheral side effects. For 
instance, DCP-LA-containing nanoparticles decorated with antibodies directed towards 
hippocampal-specific proteins could be delivered intranasally, bypassing the blood brain barrier, 
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as well as non-specific brain regions. Although oxytocin could arguably be delivered in a similar 
fashion, one must still contend with its abysmally short half-life. Furthermore, nanoparticles 
which could be used for slow, chronic release of oxytocin (which are usually, polylactide, poly-
glycolide, and or poly-lactide-co-glycolide), are incompatible with antibody-directed targeting, 
since these have no functional groups to graft the antibodies onto, such as hydroxyl, amine, or 
thiol groups. Thus, DCP-LA has the advantage. Additionally, preparation of DCP-LA and an 
appropriate delivery system would likely be more economical than mass-production of oxytocin, 
considering the relative simplicity of the reaction and the abundance of linoleic acid in nature. 
In sum, although many questions regarding the therapeutic potential of DCP-LA still 
remain to be answered, it has shown great promise thus far, and has several advantages as a 
therapeutic agent for FXS. Based on these advantages, the use of DCP-LA and its methyl esters 
have been already been patented for the treatment of neurodegenerative diseases,280, 281 and 
undoubtedly will be the focus of much study in the near future.  
However, it is important to note that DCP-LA has also been reported to demonstrate 
some activity that is possibly independent of PKCε stimulation. In one study, it was found that 
DCP-LA may inhibit protein-phosphatase 1 (PP1),282 a serine/threonine phosphatase involved in 
neuronal signaling, glycogen metabolism, muscle contraction, and protein synthesis, among 
other roles. In the aforementioned study, this effect was found to indirectly augment levels of 
phosphorylated (activated) Ca2+/calmodulin-dependent protein kinase II (CaMKII), a 
downstream target of PP1. Therefore, to confirm whether DCP-LA corrects FXS-associated 
changes via activation of PKCε as opposed to independent pathways, we have conducted a 
subset of our studies using DCP-LA in conjunction with a myristoylated form of the selective 
PKCε peptide inhibitor, εV1/2 (EAVSLKPT). This widely-used PKCε inhibitor specifically 
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exerts its effects by blocking the translocation of the kinase.283, 284 Like DCP-LA, Myr-εV1/2 has 
been used in a variety of applications,283, 285, 286 and, like DCP-LA, appears to be capable of 
crossing the blood brain barrier, due to the presence of the myristoyl moiety. 
1.6.8. The Fmr1 Knockout Mouse Model of FXS 
The use of appropriate models is critical in elucidating the pathogenesis of human 
disorders, and developing treatments for them. The inbred laboratory mouse has been used as a 
model organism to study inherited human conditions over the past century. Much of what is 
known about FXS is thanks to in vivo studies performed on mice. In particular, the Fmr1 
knockout mouse has been an invaluable tool in unraveling the molecular mechanisms underlying 
FXS.287-289 Knock-out (KO) mice are those in which investigators have inactivated ("knocked 
out") a pre-existing gene, typically by either replacing the gene or inserting an artificial piece of 
DNA into the gene’s sequence, thereby disrupting the function of the protein product.290 Briefly, 
such knock outs are generated in vitro in pluripotent stem cell lines via homologous 
recombination, in which process the normal copy of the gene or portion of the gene is exchanged 
for the KO version. Cells containing the KO gene subsequently then cloned and micro-injected 
into a host blastocyst, which are then implanted into pseudo-pregnant recipient females. The 
resulting offspring, which will be chimeras for the KO gene, can then be bred to eventually 
produce a homozygous KO line, in which the gene has been knocked out in all tissues. 
In many cases, the loss of the gene's activity results in phenotypic changes that mimic 
those observed in the human condition. Such is the case for Fmr1 inactivation, as the gene is 
particularly well-conserved from mouse to human: the genomic structure of the mouse and 
human Fmr1 genes share 95% sequence identity, 97% amino acid identity (including a 
conserved serine residue that is believed to tune the activity of FMRP on the translation of the 
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mRNA it is bound to), and lastly, exceptional structural conservation.291 Thus, although the 
Fmr1 KO model does not emulate the mutation found in patients, it is a fitting model for 
analyzing the consequences of the loss of function of FMRP. 
An immeasurable number of studies have established that the Fmr1 KO mouse model 
demonstrates exceptional face validity, or the degree of descriptive similarity between the model 
and human patients (for a review, see Kazdoba et al, 2014).288 In other words, Fmr1 KO mice 
share many molecular, morphological, and behavioral abnormalities with human patients with 
FXS, and respond well to treatments that are effective in humans. For example, some phenotypes 
exhibited by the model that are analogous to human features of FXS include macro-orchidism, 
heightened seizure susceptibility, heightened sensitivity to sensory stimuli, deficits in pre-pulse 
inhibition, perseverative and repetitive behaviors, hyper-anxiety, reduced social interaction, and 
cognitive deficits, although mixed results across laboratories have been obtained for the latter.  
Microscopic analysis of post-mortem brain tissue from both human patients and Fmr1 
KO mice also reveal similarities at the synaptic level. Both the mouse model and human patients 
share the presence of immature dendritic spines in the cortex.71, 292 Moreover, the model 
replicates the elevated cortical spine density that is observed in human patients, corresponding to 
periods of early development prior to synaptic pruning.293, 294 This is especially important 
considering that this synaptopathy is central to the symptoms of FXS. As a result, because of 
these similarities, the Fmr1 KO mouse model is well accepted for its usefulness in studying 
synaptic changes that occur in FXS, and consequently for illuminating the repercussions of these 
changes on early brain development.  
Despite the usefulness of the Fmr1 KO mouse as a tool for studying FXS, it must be 
noted that some strain-dependent phenotypic variability has been reported. Several reports have 
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demonstrated the importance of genetic background on behavioral features of Fmr1 KO mice 
(for a review, see Spencer et al, 2011).295 Two of the most commonly used genetic backgrounds 
for producing Fmr1 mutants are the C57/BL6 (C57) and FVB/NJ (FVB) strains. However, 
numerous behavioral phenotypes appear to be dependent on which of these two strains is used. 
For instance, Fmr1 KO mice appear to demonstrate reduced sociability296 and impaired 
learning297 on the FVB background, but not the C57 background Nonetheless, both strains 
replicate the immature spine phenotype observed in the patients,71, 294, 298 suggesting that the 
variability between strains, and possibly between individuals with FXS, may be due (in part) to 
contributions by background genes, although this area requires further exploration.   
In our preliminary studies, we have used Fmr1 KO mice on the FVB/NJ strain, selected 
for their behavioral similarity to human FXS patients. This model was originally generated via 
insertional mutagenesis of the mouse Fmr1 gene.299 Briefly, exon 5 of the gene was interrupted 
by insertion of the neomycin resistance gene (Neo). This artificial sequence was then introduced, 
via homologous recombination, to embryonic day 14 (E14) stem cells derived from the 129/Ola 
strain. A FVB/N-129 hybrid mouse line carrying the mutation was then bred, and later repeatedly 
backcrossed to the FVB/NJ strain (Jackson labs).300, 301 The resulting Fmr1 KO mice and their 
WT counterparts were generously gifted to us by Drs. Carl Dobkin and Abdeslem El Idrissi. 
Importantly, it must be noted that the FVB/NJ strain has one major drawback: they are 
homozygous for a retinal degeneration-causing mutation in the Pde6b gene (“retinal 
degeneration 1” or “rd1”), which normally encodes the rod CGMP-phosphodiesterase beta-
subunit required for transmission of visual stimuli. As a result, all FVB/NJ mice are near blind 
by the time they are weaned.302 This is arguably a significant confound because many behavioral 
assays in mice rely at least partially on visual perception (the elevated plus maze being a good 
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example). To counter this problem, we have conducted the majority of our studies on transgenic 
FVB/NJ mice (Fmr1 KO and control) that are homozygous for the wild-type Pde6b gene 
(Pde6bWT), and therefore have intact vision.  (Jackson labs).303, 304 Consequently, results obtained 
from behavioral assays performed on this sighted transgenic strain are more reliable than those 
obtained from the original, blind FVB/NJ strain (Pde6brd1).  
1.6.9. Summary 
Fragile X Syndrome (FXS) is an inherited developmental disorder characterized by 
disturbances in emotional and social behavior. FXS primarily arises from a silencing mutation of 
the Fmr1 gene on the X chromosome, and subsequent loss of the neuronal translational regulator 
protein FMRP. Decades of studies have established that FMRP is a prerequisite for normal 
synaptic plasticity and transmission. However, alterations in synaptic plasticity during early 
stages of developmental wiring may in turn lead to defects in the formation of many cognitively 
and behaviorally relevant neurological circuits, such as connections within and between the 
hippocampus, hypothalamus, and amygdala. Moreover, these effects on the initial wiring of the 
brain may be to a large extent irreversible upon reaching adulthood. 
Current treatments for FXS are greatly limited, have many drawbacks, and, despite the 
fact that FXS is a disorder of brain development, avoid intervention while the brain is still 
maturing. Moreover, although FXS is characterized by socio-emotional disturbances, and thus it 
is very likely that the oxytocinergic system is compromised in FXS, the majority of studies have 
surprisingly overlooked this line of research. In our efforts toward a therapeutic strategy, we 
have focused on correcting inherent changes in the oxytocinergic system, during the early stages 
of postnatal brain development. To do this, we have targeted the ventral hippocampus as a major 
regulator of the HPA axis. Recent findings have indicated that the expression of a key signaling 
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molecule during hippocampal development, PKCε, may be dysregulated in FXS. We therefore 
investigated the integrity of PKCε signaling in the Fmr1 KO mouse brain, and potential 
consequences of disrupted PKCε signaling on ventral hippocampal regulation of the 
oxytocinergic system. Lastly, we evaluated whether early postnatal stimulation of PKCε could be 
a viable therapeutic strategy for FXS. To answer this question, we employed the use of a 
selective PKCε activator, dicyclopropyl-linoleic acid (DCP-LA), which has several advantages 
as a therapeutic agent and has already shown promise in the treatment of neurological conditions. 
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…………………………………………… 
II. Materials and Methods 
 
2.1. Subjects 
All mice were housed in the College of Staten Island (CSI) Animal Care Facility and 
handled following a protocol approved by the CSI Institutional Animal Care Committee. All 
mice were housed in a temperature-controlled room (20±2°C) under a standard light-dark cycle 
of 12:12 h, with free access to food and water. All mice were housed with at least one partner, 
and one enrichment object, in the same home cage. Blind (Pde6brd1) FVB/NJ mice used in 
preliminary studies were generously provided by Drs. Carl Dobkin and Abdeslem El Idrissi. 
Sighted (Pde6bWT) FVB/NJ mice were obtained from The Jackson Laboratory (Fmr1 KO: strain 
#004624; WT controls: strain #004828).  Unless otherwise stated, all mice used in the study were 
males, since men are more severely affected by the FXS mutation than women. Female KO mice 
used were homozygous for the Fmr1 mutation.  Fmr1 KO mice were backcrossed after every 
second generation, and no generational differences were detectable in any of the groups. For all 
drug treatments, litter-mates were randomized into experimental or control groups, using at least 
one pup per litter per treatment group, in order to account for potential litter effects.  
2.2. Drug Treatments 
2.2.1. DCP-LA and Vehicle Treatments 
DCP-LA was obtained from R&D systems. Fmr1 KO littermates were injected intra-
peritoneally with 3 mg/Kg DCP-LA or vehicle at P6, P10, and P14. These time points were 
chosen because they coincide with the time-frame of postnatal hippocampal development. In 
particular, P6 and P14 are crucial time-points in this process: P6, because it corresponds to the 
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timing of when GABAergic signaling switches from excitatory to inhibitory;91 and P14, because 
it coincides with eye-opening and an immediately-following peak in synaptogenesis in response 
to visual inputs.305 Moreover, PKCε expression in the hippocampus begins to increase at P6, and 
peaks around P14. In humans, P6 corresponds to the third trimester, and P14 corresponds to 
roughly 2 years old, at which point symptoms have begun to emerge in the patients. 
A 1 mg/ml DCP-LA solution in 95% PBS, 5% DMSO was dissolved in sterile PBS to 
obtain a working solution. The working solution was injected intra-peritoneally (i.p.) into each 
pup to achieve a final concentration of 3 mg/Kg of body weight for DCP-LA, with a final 
systemic DMSO concentration of <1%. WT and KO controls were similarly injected with 
vehicle (sterile PBS containing the same concentration of DMSO) at the same time points. 
Hippocampal infusion via stereotactic injection was avoided since (1) previous studies have 
found that systemic DCP-LA administration is sufficient to correct behavior (see Section 1.6.6.), 
(2)  this technique is highly invasive and likely to damage the structures targeted, as well as 
surrounding tissues, and (3) PKCε is highly expressed in the hippocampus, relative to most other 
central and peripheral tissues.306 
2.2.2. Myr-εV1/2 Treatments 
For studies involving the use of the selective PKCε inhibitor, Myr-εV1/2 (N-Myr-
EAVSLKPT), the peptide was prepared by solid-phase synthesis as previously described.283, 307, 
308 The peptide was then dissolved in the aforementioned DCP-LA working stock solution to 
achieve a final systemic dosage of 50 µg/Kg, in accordance with previously-published studies.309 
The inhibitor was then injected (i.p.) simultaneously with 3 mg/Kg DCP-LA at P6, P10, and P14.  
WT and KO controls were similarly injected with vehicle at the same time points. 
To ensure the inhibitor would enter the brain, we additionally delivered Myr-εV1/2 
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intranasally at the aforementioned time-points. For each time point, we administered an intra-
brain concentration of 1 µM, assuming an efficiency of 10% transfer across the olfactory 
epithelium. Brain volumes at P6, P10, and P14 were estimated, using water-displacement in a 
graduated cylinder, to be ~100, ~150, and ~200 µl, respectively. For these intranasal 
administrations, a 1 mg/ml stock solution of the inhibitor was prepared, then diluted in sterile 
PBS to create a working solution of 4 µl total volume per pup. The pups were anesthetized via 
i.p. injection of ketamine (60 mg/Kg) and xylazine (6 mg/Kg), then placed in the supine position 
on a warm heating pad. For each pup, the 4 µl volume of inhibitor working solution was applied 
to each nostril, alternately, in 0.25 µl aliquots. An interval of 3 minutes was allowed in between 
each application, to avoid suffocating the pups. To allow enough time for the inhibitor to reach 
the hippocampus and take effect, the pups were given the previously-described i.p. injections of 
inhibitor and DCP-LA approximately 30 minutes after the intranasal application of the inhibitor. 
Importantly, for all experiments in which the inhibitor was used, control WT and KO pups were 
also anesthetized as described above and administered an equal volume of sterile PBS 
intranasally. 
2.3. Immunohistochemistry 
2.3.1. Immunolabeling Procedure 
Mice were anesthetized via i.p. injection of ketamine (60 mg/Kg) and xylazine (6 
mg/Kg), then perfused trans-cardially with sterile PBS, followed by 4% paraformaldehyde (PFA) 
in sterile PBS. The brains were fixed by overnight immersion in 4% PFA in PBS, then 
dehydrated overnight in 30% sucrose in PBS. Serial coronal slices of 30 µm thickness were 
obtained by cryosectioning, and blocked overnight in 0.1% Triton X-100 and 10% serum 
obtained from the species used to raise the secondary antibody, in PBS. This was followed by 
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treatment with the primary antibody in the same blocking solution overnight. The slices were 
then washed 3x in PBS (10 minutes each wash) and incubated overnight in blocking solution 
containing secondary antibody covalently linked to ether Alexa Fluor 488 (green), 568 (Red), or 
633 (Far-Red). The slices were then washed again 3x in PBS, then incubated in a solution of 25 
ug/ml of Hoechst33342 in PBS for 25 minutes, and washed again as described. Lastly, the slices 
were mounted onto glass slides using ProLong Gold-Antifade Mountant. To obtain a complete 
representation of the structures along the anterior-posterior axis, every 6th slice was used. For all 
immunohistochemical procedures, control slices were stained omitting primary antibody, to 
confirm specificity of binding. For hippocampal studies, slices were taken exclusively from the 
ventral hippocampus, which has been demonstrated to be involved in the regulation of emotional 
behavior.310, 311 
2.3.2. NeuN Immunolabeling 
For NeuN staining, the following antigen retrieval steps preceded blocking: 2N HCl at 
37°C for 25 min, 1N HCl at 0°C for 10 min, neutralization with 0.1 M boric acid for 10 min, and 
then 3 rinses with 1x PBS buffer (10 min each). Slices were then processed as described in 
Section 2.3.1. 
2.3.3. Surface GluR2 Immunolabeling 
To study surface levels of GluR2, primary antibody targeting the extracellular N-terminus 
was used in conjunction with non-permeabilizing conditions (Triton X-100 and antigen retrieval 
steps omitted). For all studies of surface levels of GluR2, control slices were stained under 
permeabilizing conditions (including Triton X-100), allowing us to analyze total levels of protein 
(cytosolic vs. membrane-bound protein). 
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2.3.4. BrdU Immunolabeling 
For neuroproliferation studies, P6 pups were injected with 100 mg/Kg of 5-bromo-2'-
deoxyuridine (BrdU, Sigma) intra-peritoneally. The pups were sacrificed 24 h later, and 
proliferating neuroblasts were then detected with antibodies against BrdU, and counter-probed 
with antibodies against doublecortin and NeuN. 
2.3.5. Antibodies 
 The following primary antibodies were used: Mouse-anti NeuN, Millipore (1: 500); Goat-
anti GluR2 (N-19), Santa Cruz (1:1,000); Rabbit-anti Oxytocin, Immunostar (1:1,000); Rabbit-
anti PKCε (C-15), Santa Cruz (1:1,000); Mouse-anti BrdU, Sigma (1:250); and Goat-anti DCX, 
Santa Cruz (1:500). Secondary antibodies used were Goat-anti mouse Alexa-Fluor 488, Goat-
anti Rabbit Alexa-Fluor 568, Rabbit-anti Goat Alexa-Fluor 568, and Rabbit-anti Goat Alexa-
Fluor 633, Santa Cruz (1:500). 
2.3.6. Imaging and Analysis 
All images were acquired using a Leica SP2 AOBS confocal microscope at a 1024 x 
1024 pixel resolution. Z-stacks were acquired along the height of each slice at 20x and 63x 
magnification, with an interval of 1 µm between each z-position. Z-stacks were carefully 
examined to ensure even penentration of the antibody throughout the entirety of each slice. For 
each experiment, laser settings were kept constant from group to group and slice to slice. For all 
experiments, at least 3 sections each from at least 3 different animals were studied. Moreover, at 
least 3 such sets of experiments were performed for proper statistical analysis. 
For studies where relative levels of PKCε or GluR2 were compared, the 
immunofluorescence intensity of each channel (red, green, and/or blue) per stack was measured 
with Adobe Photoshop after subtracting background levels of fluorescence present in a 
 
 
 
 
74 
	  
	  
	  
	  
secondary antibody control, although these were minimal. For cell quantification studies, cells 
were counted with IMARIS 7.6. Briefly, three-dimensional volumes of the stacks were rendered 
to view the exact positions of positive cells in the slice.  For these quantification studies, all Z-
stacks used were of the same thickness (30 µm). Cells were then automatically counted using the 
counter tool and double-checked for accuracy by a blind observer. Data obtained from Photoshop 
or IMARIS 7.6 was plotted using Excel to obtain column graphs, and statistical analysis was 
subsequently performed in Statistica 10. All data were presented as mean ± S.E.M. Statistical 
significance was defined as p<0.05. 
2.4. Western Blotting 
2.4.1. Western Blotting Procedure 
Hippocampal and hypothalamic lysate were acutely acquired from mice as follows: mice 
were fully anesthetized via i.p. injection of ketamine (60 mg/Kg) and xylazine (6 mg/Kg), then 
sacrificed by cervical dislocation. Brains were harvested and immediately submerged in 
oxygenated, ice-cold artificial cerebrospinal fluid (ACSF) containing 0.25 M sucrose. The brains 
were then sectioned into 300 µm thick slices using a Leica vibratome and incubated in the above 
solution. A 1.5mm diameter biopsy hole-puncher was used to isolate the DG, CA3, and CA1 
subregions of the ventral hippocampus, and paraventricular region of the hypothalamus. A 
dissection microscope was used in order to fully discern each of these regions. The tissue 
samples were then immediately homogenized in RIPA buffer containing a complete protease 
inhibitor cocktail. 
Protein concentration from each sample was determined using the DC Protein Assay 
(Bio-Rad) in a micro-plate, then scanned using the SoftmaxPro software version 2.6 (Molecular 
Devices).  Aliquots containing 30 ug of total protein were then resolved on a 10% SDS PAGE 
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gel. The proteins were then transferred to a PVDF membrane, blocked in 3% BSA (for 
phosphorylated proteins) or 5% NFDM (for non-phosphorylated proteins) for 2 h at room 
temperature. The blots were then incubated with primary antibodies in the same blocking 
solution overnight at 4°C and washed 3X with 1x TBS containing % Tween (TTBS). Lastly, the 
blots were incubated with secondary antibodies for 2 h at RT, washed 3X with TTBS, and then 
developed using SuperSignal West Pico Chemiluminescent Substrate for non-phosphorylated 
proteins or SuperSignal West Dura Extended Duration Substrate for phosphorylated proteins 
(Thermo Fisher). Lastly, resulting chemiluminescent bands were imaged using an Alpha 
Innotech Fluorochem FC2 version 1307 scanner, using the accompanying Alpha View software.   
2.4.2. Antibodies 
The following primary antibodies were used for western blotting: Rabbit-anti PKCε (C-
15), Santa Cruz (1:1,000); Goat-anti GluR2 (N-19), Santa Cruz (1:1,000); Goat-anti phospho-
GluR2 (Ser 880), Santa Cruz (1:1,000); Rabbit Anti-ERK1/2, Santa Cruz (1:1,000); Mouse anti- 
Phospho-T202, Y204-ERK, Cell Signaling (1:1,000); Rabbit anti GluR1, Immunostar (1:1,000); 
Goat anti phospho-GluR1 (Ser 831), Santa Cruz (1:750); and Mouse-anti β-actin, Sigma 
(1:10,000). Secondary antibodies used were Goat anti-Rabbit IgG-HRP (1:50,000); Rabbit anti-
Goat IgG HRP (1:20,000) and Goat anti-Mouse IgG-HRP (1:50,000), Santa Cruz.  
2.4.3. Analysis 
Densitometric analysis was performed using Image J software. The intensity of each 
protein band was quantified on unadjusted images. To account for potential loading artifacts, all 
protein bands were normalized to the intensity of corresponding β-actin bands, which served as 
internal controls. For all experiments, at least 3 brains were processed per group, and at least 3 
such sets of experiments were performed for proper statistical analysis. Data were presented as 
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mean ± S.E.M. Statistical significance was defined as p<0.05. 
2.5. Co-Immunoprecipitation 
2.5.1. Co-Immunoprecipitation Procedure 
Hippocampal lysate was acutely acquired from P18 mice as described above. A 200-ug 
aliquot of total protein lysate was incubated with 2-ug of primary antibody for 24 hours, and then 
this mixture was incubated with Protein A/G sepharose beads (Santa Cruz) for an additional 24h 
to pull down the antibodies, target protein, and linked protein complexes.  The samples were then 
resolved via SDS-PAGE and subjected to western blotting as described in Section 2.4. For the 
input samples, 25-ug aliquots of total protein lysate that did not undergo co-immunoprecipitation 
were loaded. For all experiments, at least 3 brains were processed per group, and at least 3 such 
sets of experiments were performed for proper statistical analysis. Data were presented as mean 
± S.E.M. Statistical significance was defined as p<0.05. 
2.6. Behavioral Testing 
2.6.1. Subject Handling 
Behavior testing was conducted in age- and sex- matched mice between the ages of P60 – 
P80. All behavior testing was conducted during the light phase. Mice were subjected to only one 
behavior test per day starting at P60, and were tested every other day. Because the mice were 
housed on a standard 12:12 light:dark schedule, on each testing day, the mice were transported to 
a quiet, adjacent anteroom to the behavior testing room and were acclimated in the dark for 1 hr 
prior to testing, allowing sufficient time for the animals to become active and alert. During 
testing, the animals were recorded using an overhead camera. No experimenters remained in the 
room during testing. Additionally, a white noise generator was used to block out any extraneous 
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noises that might cause distraction. After each trial, the apparatus was thoroughly cleaned with 
70% ethanol in order to prevent odor cues left behind by the previous mouse. Importantly, the 
person conducting the test was always the same female. We make this acknowledgement in light 
of recent findings that female experimenters may induce less stress in mice than male 
experiment,312 as well as to address the possibility that mice may react differently to different 
experimenters in general. At all times, the mice were handled very quietly and gently to avoid 
causing undue stress, and were transported to and from the behavioral testing room on a 
comfortable soft platform to which they were acclimated previously.   
2.6.2. Elevated-Plus Maze (EPM) 
The EPM apparatus used consisted of two opposing open arms (36 cm x 7 cm) and two 
closed arms (36 cm x 7 cm), joined at a square central area (5 cm × 5 cm). The apparatus was 
constructed of wood with the maze floor covered with white-painted vinyl, which allowed 
sufficient traction for the mice to explore the maze comfortably while also providing sufficient 
contrast to detect their movements. The entire apparatus was elevated to a height of 50 cm above 
the floor by four supports beneath each arm. The open arms were illuminated at 70 lux and the 
closed arms were illuminated at ~10 lux by a central, overhead light. This was done to avoid the 
potential of a ceiling effect on anxiety measures that could be induced by stressful bright 
lighting. Mice were initially placed in the center of the maze, and the number of entries to and 
time spent in the open arms were subsequently measured over a period of ten minutes.  
2.6.3. Light-Dark Test (LD) 
 Designed based on the innate tendency of mice to hide in a dark chamber, the light-dark 
test was conducted according to published protocols with minor modifications.313 The light-dark 
test apparatus consisted of a plastic box consisting of a 50 cm x 25 cm rectangular arena with 40 
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cm high walls, which was divided into two 25-cm compartments. The dark compartment was 
unlit (<5 lux), painted black with an opaque ceiling and walls, and the light compartment was 
transparent and illuminated by an overhead fluorescent tube (150 lux at cage floor). During the 
test, each mouse was placed in the center of the lit chamber and subsequently monitored for 10 
min as it moved freely between the two chambers. Lastly, the total time spent in each chamber 
was  recorded as an anxiety measure. 
2.6.4. Three-Chambered Social Interaction Test (SI) 
  Testing was conducted based on previously-published protocol.147 Testing took place 
over three sessions within a three-chambered box of standard dimensions,147 with openings 
between the chambers. The apparatus was illuminated to 7 lux as opposed to normal overhead 
lighting to avoid provoking anxiety in the subjects.  After habituation to the empty box for 10 
min, the subject was presented with the choice to investigate an unfamiliar age- and sex-matched 
mouse under one pencil cup (target mouse) on one side of the apparatus, versus an empty pencil 
cup (novel object) on the opposite side of the apparatus, for 10 min. The time spent investigating 
each pencil cup and the number of approaches to each cup was measured. Social approaches 
were defined as instances where the subject mouse sniffed or engaged in active, close contact 
with the novel mouse. Sociability was defined as the subject mouse spending more time 
investigating the novel mouse than in the chamber containing the inanimate novel object. Lastly, 
a social preference index was calculated for each mouse as follows: social preference index = 
time spent with novel mouse / (time spent with novel mouse + time spent with novel object). An 
index above 0.5 indicated that more time was spent investigating the novel mouse versus the 
novel object; an index below 0.5 indicated more time was spent with the novel object versus the 
novel mouse; and an index of 0.5 indicated that the subject spent an equal amount of time with 
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the novel mouse and novel object. Lastly, to avoid any potential biases towards one particular 
chamber, the positions of the target and novel object were alternated between subjects.  
2.6.5. Innate Olfaction Test 
To address the possibility that differences in social interaction could be attributed to 
differences in olfactory perception, we first performed an innate olfaction test prior to conducting 
the social interaction test. Mice were familiarized to a highly palatable treat (Nabisco Teddy 
Grahams) every day for one week, then were food-deprived for 18 hours prior to the test. The 
mice were placed in a clean, empty cage and the latency to detect a Teddy Graham (buried 3 cm 
under the bedding) was scored using a stopwatch. Latency to discover the treat was then 
measured using a stopwatch. Mice were allowed to eat their treat and then returned to the home-
cage. However, no differences were found in olfactory sensitivity between our WT and KO 
mice, in accordance with previous reports.314 
2.6.6. Open Field (OF) 
This test was conducted according to a previously published report with minor 
modifications.145 In this test, each mouse was placed in a large, rectangular arena (92 cm x 62 
cm, illuminated at 400 lux) from which escape was prevented by high (23 cm) surrounding 
walls.  In such a situation, mice generally prefer the periphery of the apparatus to the center of 
the open field, as open spaces correspond to areas where, in the wild, predators may easily spot 
the mice. Animals were individually placed in the center of the arena (covering one-fourth of the 
total area of the arena, i.e. 46 cm x 30 cm), and their movements video recorded for ten minutes 
by an overhead camera positioned above the center of the arena. To characterize spontaneous 
locomotor activity of each mouse, the total distance traveled, time spent mobile, and average 
speed were recorded. Additionally, time spent in and entries to the center of the arena were used 
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to assess anxiety. 
2.6.7. Analysis 
Captured videos were subsequently analyzed using ANY-Maze motion-tracking 
software. For behaviors that could not be detected by ANY-Maze, the videos were scored 
manually while blinded to the treatment groups. Statistical analyses were carried out using 
Statistica 10, using unpaired, two-tailed Student’s t-test or analysis of variance (ANOVA) 
whenever appropriate. Significant main effects or interactions were followed up with Tukey's 
HSD (honestly significant difference) post hoc test. For all experiments, at least 4 mice were 
tested per group, and at least two such sets of experiments were conducted for proper statistical 
analysis.  Data were presented as mean ± S.E.M. Statistical significance was defined as p<0.05.  
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III. Results 
 
3.1. Pharmacological stimulation of PKCε  during the neonatal stage 
rescues  behavioral abnormalities in adult male Fmr1 KO, 
Pde6brd1 mice. 
In our earlier studies, we have found that neonatal administration of a selective PKCε 
activator, dicyclopropyl-linoleic acid (DCP-LA), rescues anxiety-like behavior in 5-HT1A 
receptor KO mice upon adulthood (Figure 13). Since many symptoms of FXS are attributed to 
hyper-anxiety, we sought to investigate whether this treatment regimen could similarly rescue 
anxiety-like behavior in Fmr1 KO mice, the leading model of FXS. In a preliminary study, male 
WT and Fmr1 KO pups on the FVB/NJ, Pde6brd1 (retinal degeneration 1) background were 
administered i.p. injections of 3 mg/Kg DCP-LA or vehicle (PBS containing <1% DMSO) at 
ages P6, P10, and P14, corresponding to the time frame of postnatal hippocampal maturation. 
The pups were then allowed to reach adulthood (P60), at which time they were subjected to 
behavioral testing (Figure 17). In these preliminary experiments, only male mice were studied 
because men are generally more severely affected by the FXS mutation than women. 
 
 
 
 
 
 
Figure 17. Treatment scheme for behavioral studies. 
Vehicle or DCP-LA  
(I.P. Injection) 
Behavioral 
Testing 
Day    0       6     10    14                                        2 months 
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3.1.1. Anxiety-like Behavior 
 In accordance with previous reports, we observed that our Fmr1 KO mice that were 
treated with inert vehicle as pups displayed significantly heightened anxiety-like behavior in the 
elevated plus maze (EPM) at P60, compared to vehicle-treated WT controls. We observed that 
the vehicle-treated KO mice spent approximately 4x less time in the open arms (Figure 18A), 
and made half as many entries as to the open arms (Figure 18B) as their WT counterparts. The 
vehicle-treated KO mice were also less exploratory in the EPM compared to the WT group, as 
measured by a drastically reduced number of head dips, a risk-assessment behavior in which the 
mouse peers over the edge of the open arm towards the floor (p=0.007) (Figure 18C). 
As expected, the hyper-anxiety phenotype displayed by the vehicle-treated KO mice was 
nearly fully reversed in KO mice treated with DCP-LA as pups. DCP-LA treated KO mice were 
statistically comparable to the WT group in both time spent in the open arms and entries to the 
open arms (p=0.30 and 0.79, respectively), and these improvements were on the cusp of 
significance when compared to the vehicle-treated KOs (p=0.051 and 0.052, respectively) 
(Figure 18A and B). The KO+DCP-LA group was also significantly more exploratory in the 
EPM than the vehicle-treated KO group, as measured by the number of head dips (p=0.022), and 
were marginally comparable to controls (p=0.11) (Figure 18C). Nevertheless, taken together, 
these findings suggest that neonatal DCP-LA administration appears to considerably diminish 
anxiety-like behaviors in the EPM during adulthood, in Fmr1 KO mice on the classical FVB/NJ 
background. 
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Figure 18. Neonatal DCP-LA treatment rescues anxiety-like behavior in the elevated plus 
maze (EPM) in male FVB/NJ Fmr1 KO mice. Group n’s: 4-5 per group. 
KO
+D
CP
-LA
 
	  
KO
+D
CP
-LA
 
	  
 
 
 
 
84 
	  
	  
	  
	  
3.1.2. Social Interaction 
Encouraged by the above results, we then investigated whether social behavior was 
altered in the Fmr1 KO mice, and moreover, whether our neonatal DCP-LA treatment regimen 
could correct any apparent social deficits. In accordance with independent studies, we found a 
marked reduction in social investigation in our vehicle-treated KO mice compared to WT 
controls in the three-chambered social interaction test (Figure 19). When given the choice 
between investigating a novel mouse versus a novel inanimate object, we found that the vehicle-
treated KO mice did not display a preference for either stimulus, spending roughly an equivalent 
percentage of time investigating the novel mouse and object (Figure 19A). On the other hand, we 
observed that the WT mice displayed a trend towards a preference for the novel mouse over the 
object (p=0.12). In sharp contrast, DCP-LA-treated KO mice significantly preferred the novel 
mouse to the object (p=8.1x10-5). 
Overall, we observed that vehicle-treated KO mice spent a lower percentage of time 
investigating the novel mouse compared to WT mice, with the difference only slightly missing 
the threshold of statistical significance (p=0.067) (Figure 19B). On the other hand, the DCP-LA 
treated KO mice were roughly comparable to the WT mice in time investigating the novel mouse 
(p=0.19). It is important to note that our observed results that were on the border of significance 
may be attributed to the small group sizes used in these preliminary studies (4-5 mice per group). 
Nevertheless, when we examined the number of social approaches to the novel mouse per group, 
we found that the vehicle-treated KO mice made significantly less approaches than the WT mice, 
despite the small group size tested (p=0.046) (Figure 19C). Consistent with our previous 
findings, this deficit was fully rescued in the DCP-LA treated KO mice when compared to the 
WT controls (p=0.023). Collectively, these results point to a deficit in social interaction in Fmr1 
KO mice on the FVB/NJ strain, which appears to be rescued with neonatal DCP-LA treatment.  
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Figure 19. Social behavior deficits in male FVB/NJ Fmr1 KO mice are corrected by 
neonatal DCP-LA treatment. Group n’s: 4-5 per group. 
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3.1.3. Locomotor Behavior 
To address the possibility that the previously observed differences in the EPM and SI 
tests were influenced by differences in locomotor behavior, we then performed the open field test 
(OF). Although we noted that the vehicle-treated KO mice spent less time mobile and traveled 
less distance at the beginning of the test, they were comparable to their WT counterparts by the 
final two minutes of the test in both measures (Figure 20, panels A and B, respectively). Based 
on this, it is possible that the hypoactivity observed in the vehicle-treated KO mice at the 
beginning of the test could likely have been due to a delay in acclimation to the unfamiliar 
testing environment. In other words, though the KO mice appeared to refrain from exploring the 
apparatus initially, they eventually appear to adjust, behaving similarly to the WT mice by the 
end of the test (Figure 21). Considering that the test was relatively short in duration (10 min), it 
is likely that this observation reflects reactions to novelty rather than motor impairment.  
In addition, we observed distinct hypoactive phenotype in the DCP-LA treated KO males 
throughout the test, as measured by both time mobile and distance traveled (Figure 20 A and B). 
However, this seems unlikely to be due to anxiety, if our results from the EPM test are any 
indication. Based on this observation, is possible that DCP-LA may exert an inhibitory effect on 
locomotor activity in this strain of mice, through currently unknown mechanisms. 
We then examined whether the Fmr1 KO mice demonstrated reduced exploration of the 
center zone of the OF, which can be interpreted as an indicator of anxiety, since anxiolytic drugs 
often increase this measure. However, we detected no differences between vehicle-treated KO 
mice and WT controls in time mobile in the center zone (Figure 22). This is not wholly 
surprising since the open field is considered to be better suited for measuring locomotor behavior 
rather than anxiety-like behavior. On the other hand, we observed robust differences between the  
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Figure 20. FVB/NJ Fmr1 KO mice display hypo-activity in the open field compared to WT 
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vehicle treated WT and KO groups in the EPM, as described in 3.1.1 (Figure 18), which is 
considered the gold standard for assessing anxiety-like behavior.  Thus, the OF may not have 
been anxiogenic enough to produce a discernable effect on exploration in the center zone.  
Lastly, we observed a pattern of reduced exploration of the center zone in the DCP-LA 
treated KO mice (Figure 22). However, this observation may not automatically indicate 
heightened anxiety: these results are in fact consistent with our earlier observations that DCP-
LA-treated KO mice appear hypoactive in the OF (Figure 20). Moreover, our DCP-LA-treated 
mice appear to display reduced anxiety-like behavior in the EPM (Figure 18), which is generally 
accepted to be a better assessment of anxiety phenotypes. 
It is important to note that the mice used in these preliminary studies harbored the retinal 
degeneration 1 mutation in the Pde6b gene (rod cGMP phosphodiesterase), which leads to near 
blindness by weaning age. This may present a significant confound when attempting to interpret 
results obtained from the above behavioral assays. Thus, we transitioned to a sighted variant of 
these mice possessing the wild-type Pde6b gene (FVB/NJ Pde6bWT) for all subsequent studies.  
Nevertheless, these preliminary results collectively indicated that DCP-LA appears to normalize 
anxiety-like behavior and social deficits in FVB/NJ Fmr1 KO mice, at least in the assays we 
performed.  
3.2. PKCε  is under-expressed in the Fmr1 KO ventral hippocampal 
CA1 region during postnatal hippocampal maturation. 
 Inspired by these preliminary findings, we hypothesized that PKCε-mediated signaling 
may potentially be compromised in Fmr1 KO brain, and by extension, in FXS. This would 
provide a likely avenue by which the selective PKCε activator DCP-LA appears to restore 
anxiety levels and social behavior in FVB/NJ Fmr1 KO mice, as we have observed. Further 
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bolstering this hypothesis, Darnell and colleagues have found that FMRP binds to PKCε 
mRNA.43 Thus, expression of PKCε itself may be subject to translational regulation by FMRP, 
and therefore is likely dysregulated in FXS. However, given that FMRP seems to bimodally 
influence translation depending on the mRNA target, the precise consequences of absence of the 
FMRP on PKCε expression remained unknown. If PKCε expression is indeed altered in FXS, is 
the kinase over-expressed or under-expressed? Given our findings that DCP-LA seems to 
normalize anxiety and social behavior in Fmr1 KO mice, we predicted that the drug may 
potentially compensate for a reduction in expression of PKCε.  To address this hypothesis, we 
next investigated the integrity of PKCε expression in the Fmr1 KO brain. 
 PKCε expression may be governed by different regulatory mechanisms depending on 
spatiotemporal factors such as age and brain region. Since PKCε is predominantly expressed in 
the hippocampal formation relative to most other brain regions,306 we therefore honed in on this 
structure in our next set of studies. Particularly, we questioned whether PKCε expression was 
altered in the ventral portion of the hippocampus, which, as discussed, is a hub which influences 
behavior and emotion through its dense connections with other brain regions such as the cortex, 
amygdala, and hypothalamus. Therefore, it is plausible that altered PKCε expression in the 
ventral hippocampus may contribute to FXS-associated symptoms in these areas. 
3.2.1. Immunohistochemical Analysis 
Given our preliminary findings that neonatal administration of the PKCε activator DCP-
LA appears to restore anxiety and social disturbances in the Fmr1 mouse model, we next 
investigated whether ventral hippocampal PKCε expression was altered during the early 
postnatal period. We first examined PKCε expression levels at P6, at which point expression of 
PKCε within the hippocampus begins to steadily increase until P14-P15.248 This was then 
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followed up a second, near-identical study in which we evaluated PKCε expression at P18, 
coinciding with the period shortly after eye-opening, and a subsequent dramatic rise in 
synaptogenesis.305  
To resolve spatial expression patterns of PKCε within the ventral hippocampus and 
within cells, immunohistochemical labeling of the protein was performed. We observed that 
PKCε was highly expressed within the ventral dentate gyrus, (DG), CA3, and CA1 regions at 
both P6 and P18.  High magnification imaging (63x with added zoom) revealed that the kinase 
was primarily localized the soma and dendrites (Figure 23). 
 Although we did not detect a meaningful difference in PKCε levels in the ventral 
hippocampus at P6 (Figure 24) between WT and KO groups, we did observe a significant 
reduction in ventral CA1 PKCε expression in the KO group at P18 (p=1x10-4) (Figure 25), as 
measured by immunofluorescence intensity. This corresponded to a 25% decrease in expression. 
Importantly, the total number of neurons in this region remained unchanged (Figure 26), 
suggesting that the decrease in PKCε expression was not due to a reduced number of neurons.  
Intriguingly, this phenomenon was not observed in the CA3 region, although we did discover a 
possible trend towards significance in the dentate gyrus (DG) (p=0.089).  We speculate this 
discrepancy may be attributed to functional differences between these regions that are only 
beginning to be understood. However, given that CA1 is the major output region of the 
hippocampus, our findings may be particularly relevant to FXS as it is likely that any disruption 
of CA1 activity may product effects on behavior.  
Importantly, the fact that we were unable to detect a difference in PKCε expression at P6, 
combined with our observation that PKCε expression does not appear to be fully ablated in the 
Fmr1 KO pups at P18, suggests that translational regulation by FMRP may be one of many 
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pathways governing PKCε expression. (Such redundancy in signaling pathways regulating gene 
expression may serve a protective function: in the event that one signaling pathway becomes 
compromised, another may take its place.) Different signaling pathways regulating the 
expression of a single protein, such as PKCε, may be active at different developmental time 
points, depending on the protein’s function at that time point. Indeed, PKCε-mediated signaling 
appears to play a role in a variety of cellular processes.243, 306 Here, we report that PKCε 
expression is normal in Fmr1 KO mice at P6, which marks the beginning of postnatal 
hippocampal development, but is impaired by P18. Importantly, the immediate days following 
eye-opening at P15 are marked by a dramatic surge in hippocampal synaptogenesis. Considering 
that PKCε expression significantly rises in the hippocampus from P6 to P15 (Figure 11), it is 
likely that the protein plays a role in mediating these changes. Interestingly, P6 corresponds to 
the third term in humans, whereas P18 corresponds to 3 years of age, the average age of Fragile 
X diagnosis in boys. Given the link between the ventral hippocampus and emotion, we 
questioned whether reduced PKCε expression in the hippocampus during this time frame could 
potentially contribute to emotional symptoms in our Fmr1 KO mouse model. 
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Figure 23. Hippocampal PKCε is localized to the soma and dendrites of neurons. Green 
indicates NeuN labeling of neuronal nuclei; red indicates PKCε labeling. Images acquired at 
63x magnification. Images obtained from P6 WT pups. 
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Figure 24. (A, B) Ventral hippocampal PKCε expression does not differ between WT and 
Fmr1 KO mice at P6, as measured by PKCε	  immunofluorescence (IF) intensity normalized 
to NeuN IF. Red: PKCε, Green: NeuN. Images acquired at 63x magnification. (A,C) The 
number of NeuN+ neurons is also unchanged between the two groups at P6. Group n’s: 5-6 
per group. 
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Figure 25. PKCε expression is suppressed in the ventral CA1 region of Fmr1 KO mice at P18 
compared to WT controls, as measured by PKCε	   immunofluorescence (IF) intensity 
normalized to NeuN IF. Red: PKCε, Green: NeuN. Green: NeuN; red: PKCε. Images acquired 
at 63x magnification. Group n’s: 5-6 per group. 
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Figure 26. The number of NeuN+ ventral hippocampal neurons is unchanged in Fmr1 KO 
mice compared to WT mice at P18. Green: NeuN. Images acquired at 63x magnification. 
Group n’s: 5-6 per group. 
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3.2.2. Western Blot Analysis 
To confirm our immunohistochemical findings, we next performed western blot analysis 
on ventral CA1 lysate obtained from P18 pups. Similar to our observations from the 
immunohistochemical experiments, we observed a roughly 33% decrease in ventral CA1 PKCε 
expression in the P18 KO pups, compared to WT controls (Figure 27). Taken together, these 
findings provide novel evidence that PKCε is altered during the later stages of postnatal 
hippocampal maturation, coinciding with the surge in synaptogenesis following eye-opening, in 
Fmr1 KO pups. 
  
PKCɛ 
β-Actin  
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Figure 27. Ventral hippocampal CA1 PKCε expression is significantly reduced in Fmr1 KO 
mice at P18, when normalized to beta actin (β-actin). Group n’s: 6 per group. 
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3.3. Hippocampal neurogenesis is not altered in Fmr1 KO mice at 
P6. 
 In our earlier studies, we have found evidence that that early postnatal PKCε-mediated 
signaling, downstream of the serotonin 1a receptor (5-HT1A-R), may be required for the 
establishment of normal anxiety levels (Figure 13). Moreover, we have obtained evidence that 
anxiety-like behavior during adulthood appears to be linked to neonatal hippocampal neuroblast 
proliferation, where disruption of this process at P6 is associated with heightened anxiety-like 
behavior during adulthood in female 5-HT1A-R KO mice (Figures 13 and 14). 
 Although we did not observe altered PKCε expression at P6 in our Fmr1 KO mice, we 
nevertheless deemed it important to evaluate whether hippocampal neurogenesis was altered in 
these mice at this age, given that this process is linked to anxiety. In our earlier studies, 
stimulation of PKCε only partially rescued neuroblast proliferation in the female 5-HT1A-R KO 
pups, and male 5-HT1A-R KO pups did not exhibit reductions in neuroblast proliferation despite 
loss of activation of the 5-HT1A-R à PKCε signaling pathway. Thus, while PKCε-mediated 
signaling does seem to influence neuroblast proliferation, it is most likely not the only signaling 
pathway that does so. Other signaling pathways regulated by FMRP may contribute to early 
postnatal hippocampal proliferation, yet remain unknown. Some reports have provided evidence 
that adult hippocampal neurogenesis may be altered in FXS, though the findings have been 
mixed and require further study.315-317 To our knowledge, however, the integrity of early 
postnatal neurogenesis in FXS has not been reported. Therefore, in our next set of studies, we 
investigated hippocampal neuroblast proliferation at P6, the time-point at which this process 
begins to peak postnatally, in our Fmr1 KO mice. 
 In brief, WT and Fmr1 KO pups were injected with BrdU (100 mg/Kg, i.p.) at P6, and 
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then sacrificed 24 hours later to allow incorporation into dividing cells. Since males are more 
severely affected by the FXS mutation, only male pups were used. Immunohistochemical 
experiments were then performed to label BrdU and doublecortin (DCX) double-positive cells 
(newborn neurons) within the subgranular zone of the dentate gyrus. Lastly, the double-positive 
cells were then quantified using stereological methods (Section 2.3.6). Interestingly, we did not 
observe any differences in the number of proliferating neuroblasts under these conditions (Figure 
28). However, this is consistent with our observation that PKCε expression did not appear to be 
altered in our Fmr1 KO pups at this age.   
Nevertheless, we do observe a substantial decrease in ventral CA1 PKCε expression in 
our Fmr1 KO pups by P18. Importantly, at this time, neuroproliferation begins to wane as the 
dominant process driving hippocampal maturation; while synaptogenesis (in response to new 
visual inputs following eye opening) comes into play instead. Therefore, we explored possible 
mechanisms by which PKCε -mediated signaling may contribute to early postnatal hippocampal 
synaptogenesis, and how this process may potentially be disrupted in FXS. This may occur by 
several possible mechanisms. For instance, we have found that PKCε signaling influences gene 
expression via activation of transcription factors such as ERK1/2 (Figure 12). Thus, it is 
conceivable that the expression of genes related to synaptic function may be altered in FXS, not 
as a direct consequence of FMRP deficiency itself, but as a result of impairment in secondary 
pathways that would normally mediate the expression of such genes, such as PKCε signaling. 
Alternatively, PKCε might influence synaptic function in a more direct manner, for instance, by 
modulating receptor dynamics via phosphorylation. Therefore, our next aim was to explore such 
possibilities. 
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Figure 28. Hippocampal neuroblast proliferation is not altered in Fmr1 KO mice at P6. (A) 
Representative images of the dentate gyrus obtained from WT and Fmr1 KO pups at P6. 
Blue: doublecortin (DCX) labeling of immature neurons, red: BrdU labeling of proliferating 
and newly divided cells. Dashed lines demarcate the subgranular zone (SGZ). (B) Same 
images without SGZ demarcation. (C) Zoomed image indicating specificity of staining. (D) 
Stereological analysis detected no differences in the number of newborn neurons (DCX, 
BrdU double-positive cells) between WT and Fmr1 KO pups in the SGZ at P6. Group n’s: 
6. 
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3.4. Surface levels of GluR2-containing AMPA receptors are 
elevated in the Fmr1 KO ventral hippocampal CA1 region at P18. 
To ascertain potential consequences of reduced PKCε expression in the Fmr1 KO 
hippocampus, we first honed in on excitatory synapses, which make up the vast majority of 
neuronal connections within this region. Ionotropic glutamate receptors - namely, the AMPA, 
NMDA, and kainate receptors - are requisite for excitatory post synaptic currents (EPSCs), in 
conjunction with metabotropic glutamate receptors. Most excitatory transmission in the brain is 
mediated by AMPA receptors,252 and dynamic alterations in the number of synapse-localized 
AMPA receptors is an important factor contributing to synaptic plasticity.255 AMPA receptors 
are tetramers consisting of combinations of four individual subunits, named GluR1-4.253 During 
development, the majority of hippocampal AMPA receptors contain the GluR2 subunit, the 
expression of which is gradually up-regulated in the hippocampus from birth until adulthood.255 
Moreover, the GluR2 subunit is not only a suitable marker for hippocampal AMPA receptors, 
but may play a particularly important role in hippocampal synaptogenesis since it has been found 
to be required for both LTP and LTD.259, 260 Since both of these processes are disrupted in FXS,74 
we therefore investigated the expression of GluR2-containing AMPA receptors in the ventral 
hippocampus.  
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3.4.1. Total expression of GluR2 
	  Since expression of PKCε was most significantly reduced in the ventral CA1 region  of 
our Fmr1 KO mice (Figure 25), we honed in on this same region to examine GluR2 expression. 
Interestingly, western blot analysis did not detect any differences between the two groups in total 
GluR2 expression between our WT and Fmr1 KO pups at P18 (Figure 29). This demonstrates 
that GluR2 expression may not rely on PKCε signaling, which is consistent with the finding that 
GluR2 mRNA does not appear to be regulated by FMRP.43 Other studies have reported similar 
findings from hippocampal lysates obtained from WT and Fmr1 KO pups.318 
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Figure 29. Total levels of CA1 GluR2 do not differ between WT and Fmr1 KO mice at P18, 
when normalized to beta actin (β-actin). Group n’s: 6 per group. 
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3.4.2. Surface GluR2 expression 
 Although total GluR2 levels were unchanged between our WT and Fmr1 KO mice at 
P18, total levels of GluR2 may not necessarily reflect levels incorporated into synapses. Subunit 
phosphorylation is a common mechanism by which receptors are tagged for insertion to the 
synaptic membrane from the total internal receptor pool. Similarly, receptors may also be tagged 
for removal from the synapse (surface) via subunit phosphorylation. It has been shown that 
AMPA receptors are internalized via GluR2 phosphorylation at serine 880 in a PKC-dependent 
process.319 Therefore, our next question was whether PKCε was the PKC isoform that mediated 
this process in the ventral hippocampus.  
 In order to most precisely study synaptic levels of GluR2, we performed 
immunohistochemical analysis of ventral hippocampal brain slices, obtained from WT and Fmr1 
KO pups at P18. Our preliminary study revealed, as expected, high GluR2 expression in 
hippocampal excitatory synapses, as indicated by its high degree of co-localization with the 
excitatory synaptic marker PSD-95 (Figure 30).  
 However, since PSD-95 is an internal structure, its immunohistochemical labeling 
requires the use of detergents that puncture the cell membrane, allowing antibodies to freely 
enter the cell. This presents a confound since this method could potentially result in labeling of 
internal GluR2 subunits adjacent to the synapse. In our next set of experiments, therefore, 
immunohistochemical analysis was performed under non-permeabilizing conditions to 
selectively and accurately label surface levels of GluR2 only (Figure 31). Most intriguingly, we 
discovered a 34% increase in surface GluR2 levels in the ventral CA1 region of Fmr1 KO mice, 
compared to their WT counterparts, which was significant. A similar trend was also observed in 
the CA3 region.  Interestingly, we did not observe an increase in surface GluR2 in the dentate 
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gyrus, possibly reflecting differences in function between these regions. The total number of 
cells in the CA1 region was also unchanged in the Fmr1 KO group (Figure 31). 
  
	  
50 µm 
	  
Figure 30. GluR2 co-localizes with PSD-95 in the CA1 region of the hippocampus. 
Representative images of GluR2 labeling in the WT hippocampus at P18 to demonstrate 
specificity of staining. Blue: Hoechst, green: PSD-95, red: GluR2. Yellow punctae indicate 
areas of PSD-95 and GluR2 co-localization. Images acquired at 63x plus zoom. Images 
obtained from P18 WT mice. 
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Figure 31. Surface GluR2 is increased in the hippocampal CA1 region in Fmr1 KO mice at 
P18. (A) Under non-cell permeabilizing conditions, a significantly higher level of GluR2 
fluorescence intensity is detected in the CA1 region of the hippocampus in P18 Fmr1 KO 
mice compared to WT mice. Images represent Z-projections of 30µm thickness acquired at 
63x magnification. Blue: Hoechst, red: GluR2 (extracellular N-19). (B) High-resolution 
image acquired at 63x plus zoom at a single z-position, to demonstrate specificity of staining.  
Group n’s: 5-6 per group. 
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Figure 32. (A, B) The total number of Hoechst+ cells is not changed in the ventral 
hippocampus of Fmr1 KO mice at P18, compared to WT mice. Blue: Hoechst labeling. 
Images acquired at 63x magnification. Group n’s: 5-6 per group. 
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Taken together, these findings may be interpreted as evidence that at this age, the overall 
pool of GluR2-containing AMPA receptors is not increased in the Fmr1 KO ventral 
hippocampus, but mechanisms governing trafficking of the receptor to and/or from the synapse 
may instead be altered, at least in the ventral hippocampus. This would presumably modulate 
synaptic responsiveness to incoming excitatory signals, thereby potentially leading to alterations 
in long-term synaptic modification during postnatal brain wiring. Intriguingly, when we 
performed the same analysis on adult mice (P90), a difference in CA1 surface GluR2 levels was 
no longer apparent (Figure 33). This suggests our observations at P18 may be a transient 
difference specific to early postnatal development, and that different regulatory pathways may 
oversee ventral hippocampal PKCε-mediated signaling and/or AMPA receptor dynamics during 
development versus adulthood. 
What may be the consequences of our observation of heightened basal surface levels of 
GluR2-containing AMPA receptors in the juvenile Fmr1 KO hippocampus? It is possible this 
may lead to an excess of glutamatergic signaling in the hippocampus at this age. If this were the 
case, then these findings may be compatible with evidence that the FXS hippocampus is hyper-
excitable,13, 320 contributing to heightened seizure susceptibility that is common in young FXS 
patients, but often remisses by adulthood. Importantly, excess hippocampal activity at this young 
age may lead to inappropriate signaling to downstream structures, such as the cortex, amygdala, 
and/or hypothalamus, resulting in altered brain wiring that may later manifest as behavioral 
symptoms.  
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Figure 33. Surface GluR2 no longer differ between WT and Fmr1 KO mice in the 
hippocampal CA1 region by adulthood (P90). Red: Surface GluR2 (N-terminus), blue: 
Hoechst. Images acquired at 63x magnification. Group n’s: 5-6 per group.  
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3.5. Phosphorylated serine 880 GluR2 levels are decreased in the 
Fmr1 KO ventral hippocampal CA1 region at P18. 
Given our observations that reduced PKCε expression in the juvenile Fmr1 KO ventral 
hippocampus coincides with heightened synaptic levels of GluR2, it is possible that PKCε 
signaling may be involved in AMPA receptor trafficking. It has been found that synaptic AMPA 
receptors may be internalized via phosphorylation of the GluR2 subunit at serine 880 in a PKC-
dependent manner.262 However, the PKC activator used in this study, the phorbol ester 12-O-
tetradecanoylphorbol-13-acetate (TPA), is largely non-isoform specific. Therefore, we next 
questioned whether this process was potentially mediated specifically by the epsilon isoform of 
PKC.  
To address this question, we first examined whether serine 880 phosphorylation of GluR2 
was altered in Fmr1 KO mice during the juvenile stage. True to our hypothesis, western blot 
analysis revealed a 52% reduction in levels of serine 880 phosphorylated GluR2 subunits in the 
KO mice at P18, when normalized to beta actin (Figure 34). Considering that earlier we observed 
that total levels of the GluR2 subunit were unchanged in the KO group, this finding is highly 
indicative of a specific reduction in phosphorylation of the AMPA receptor at serine 880. 
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Figure 34. Serine 880 phosphorylated GluR2 subunits (P-Ser880 GluR2) are significantly 
reduced in the Fmr1 KO ventral hippocampal CA1 region at P18 compared to WT controls, 
after normalization to beta actin (β-actin). Group n’s: 6 per group. 
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3.6. PKCε interacts with the GluR2 subunit of the AMPA receptor. 
If PKCε directly phosphorylates GluR2 at the serine 880 site, then a protein-protein 
interaction between the two proteins should be detectable. To investigate whether this was 
indeed the case, we performed co-immunoprecipitation studies on hippocampal lysate obtained 
from WT pups at age P18. Lysates were incubated with antibodies targeting PKCε, and then 
PKCε and bound proteins were immunoprecipitated with protein A/G agarose beads. The pulled 
down protein complexes were then resolved via SDS-Page and analyzed via western blotting. As 
expected, GluR2 bands were detectable following this procedure, indicating that GluR2 indeed 
co-immunoprecipitated with PKCε (Figure 35A, B). Similarly, when the experiment was 
performed in the reverse manner, PKCε was pulled down with GluR2 (Figure 35C). To our 
knowledge, this is the first reported evidence of an interaction between the two proteins. Given 
this interaction, we speculated that is likely that PKCε plays a hand in phosphorylation of the 
AMPA receptor at the GluR2 subunit. The GluR2 subunit has two known phosphorylation sites 
sensitive to PKC,321 but as of yet, only phosphorylation of serine 880 has been linked to AMPA 
receptor endocytosis, which we report appears to be disrupted in the Fmr1 KO hippocampus. 
FMRP regulates protein translation in response to synaptic activity, and this presumably includes 
translation of PKCε. Since reduction of PKCε expression in the Fmr1 KO ventral CA1 region 
coincides with increased surface levels of GluR2, it is plausible that PKCε may normally serve to 
phosphorylate the Ser880 site to modify activity-dependent synaptic plasticity, downstream of 
FMRP. 
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Figure 35. PKCε co-immunoprecipitates with GluR2 from P18 hippocampal lysate. (A) Input 
(non-immunoprecipitated samples) reveal that PKCɛ is normally expressed in hippocampus at 
P18. (B) When hippocampal GluR2 is isolated by immunoprecipitation and the isolate is 
subjected to Western blotting, PKCɛ bands (~84 kDa) are detected. Bands corresponding to the 
antibody used during the IP procedure are also present on the blot (IgG, ~50 kDa). WT=wild-
type male. (C) Similarly, when hippocampal PKCɛ is isolated by immunoprecipitation and the 
isolate is subjected to Western blotting, GluR2 bands (~98 kDa) are detected. 
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3.7. Pharmacological PKCε stimulation by selective activator DCP-
LA normalizes surface GluR2 levels in the Fmr1 KO ventral 
hippocampal CA1 region. 
If PKCε normally mediates AMPA receptor endocytosis at synapses, then a reduction in 
PKCε levels would lead to an increase in the number of AMPA receptors at the cell surface, 
which we have observed in our Fmr1 KO mouse model (Figure 31). Similarly, if PKCε signaling 
were to be restored in Fmr1 KO mice, then surface levels of the GluR2 should be returned to WT 
levels. To evaluate this possibility, we next examined surface GluR2 expression in KO mice that 
were treated systemically with the selective PKCε activator DCP-LA on P6, P10, and P14. As 
expected, we observed that our neonatal treatment regimen was sufficient to normalize surface 
levels of GluR2 completely in the ventral CA1 region (Figure 36), as determined by 
immunohistochemical analysis when non-cell permeabilizing conditions were used to label 
GluR2. Importantly, the number of cells in the CA1 region of the DCP-LA treated group did not 
differ significantly from the WT and vehicle-treated KO group, as determined by Hoechst 
labeling (Figure 37).  Interestingly, surface GluR2 levels were also normalized in area CA3 in 
our DCP-LA treated KO mice, although we had been unable to detect a difference in PKCε in 
the CA3 region at this age. However, there still remains the possibility that PKCε levels may 
indeed be reduced in the CA3 region in Fmr1 KO mice at P18, but the difference may be so 
subtle that it would not be easily detectable.  
Based on this finding, it is possible that (1) PKCε-mediated signaling, downstream of 
FMRP, may be involved in AMPA receptor endocytosis in the juvenile ventral hippocampus to 
modify activity-dependent synaptic plasticity; and (2) that this process may go astray in FXS, 
presumably as a result of decreased PKCε expression.  
 
 
 
 
115 
	  
	  
	  
	  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KO+Vehicle WT+Vehicle 
D
G
 
C
A
3 
C
A
1 
KO+DCP-LA 
0 
20 
40 
60 
80 
100 
120 
D
G
: S
ur
fa
ce
 G
lu
R
2/
H
oe
ch
st
 
In
te
ns
ity
 R
at
io
, %
W
T 
0 
25 
50 
75 
100 
125 
150 
C
A
1:
 S
ur
fa
ce
 G
lu
R
2/
H
oe
ch
st
 
In
te
ns
ity
 R
at
io
, %
W
T 
	  
	  
p=1.3x10
-4
 
p=2x10
-4
 
0 
50 
100 
150 
C
A
3:
 S
ur
fa
ce
 G
lu
R
2/
H
oe
ch
st
 
In
te
ns
ity
 R
at
io
, %
W
T 
	  
	  
p=0.14 p=0.05 
Figure 36. Surface GluR2 levels are increased in the hippocampal CA1 region of Fmr1 KO 
mice at P18, but are restored to WT levels by intra-peritoneal injection of 3 mg/kg DCP-LA at 
ages P6, P10, and P14.   Labeling conducted under non-cell permeabilizing conditions. Images 
acquired at 63x magnification. Blue: Hoechst, red: GluR2 (extracellular N-19). Group n’s: 6. 
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B 
Figure 37. Neonatal DCP-LA treatment does not alter the number of Hoechst+ cells in 
the Fmr1 KO hippocampus at P18. Blue: Hoechst labeling. Images acquired at 63x. 
Group n’s: 6. 
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3.8. Oxytocin-positive cells are reduced in the Fmr1 KO 
hypothalamic PVN at P20. 
 Given the many neurobehavioral symptoms associated with FXS, we next questioned the 
contributions of the synaptic aberrations we have observed within the hippocampus during the 
juvenile stage. The neuropeptide oxytocin is widely known to promote social behavior and 
temper anxiety levels (Section 1.5.2). Considering that many behavioral symptoms of FXS, 
including social deficits, can stem from anxiety, it is likely that oxytocinergic signaling may be 
compromised in FXS. To date, however, there has been a surprising dearth of studies 
investigating this possibility. One potential avenue by which oxytocinergic signaling may be 
altered in the FXS brain is as a consequence of upstream hippocampal aberrances. For instance, 
the hippocampus is known to inhibit activity of the paraventricular nucleus (PVN) of the 
hypothalamus, the main supplier of oxytocin in the brain.  
A subset of parvocellular neurons within the PVN have been shown to produce centrally-
distributed oxytocin that has been linked to behavioral effects.174 Moreover, the ventral 
hippocampus tonically inhibits activity of the parvocellular PVN.168, 222, 322 Does this inhibition 
include oxytocin-producing neurons? While the answer to this question remains unclear, it has 
been shown that activation of pyramidal neurons in the CA1 region of the ventral hippocampus 
produces anxiety-like behavior in rodents, possibly by suppressing central oxytocin signaling at 
its root, in the PVN.155, 156 Supporting this hypothesis, studies have suggested that oxytocin 
production in this region may be especially sensitive to early life manipulation.190 
 To address this possibility, we first investigated whether oxytocin production was altered 
in the Fmr1 KO brain relative to WT controls. We first studied oxytocin signaling at P20 
(weaning age), at which point the hypothalamic oxytocinergic system is fully developed. 
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Immunohistochemical analysis was used to quantify oxytocin positive cells within the PVN. We 
found that the number of the oxytocin-positive cells was sharply suppressed in the Fmr1 KO 
PVN compared to the WT group (Figure 38). To determine whether this deficit was due to a loss 
of neurons or loss of oxytocin synthesis within the PVN, we next quantified the total number of 
cells within the PVN. However, no differences between the two groups in PVN cell number 
(Figure 38D) were detectable, indicating that the reduction in oxtytocin-positive cells most likely 
reflected a depression in oxytocin synthesis. Thus, for the first time, we provide evidence that a 
deficit in oxytocinergic signaling appears to be associated with FXS, and moreover, this deficit 
appears to stem from a loss of oxytocin synthesis.  
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Figure 38. (A, C), The number of oxytocin positive cells (OXT+) in the paraventricular 
nucleus (PVN) is significantly reduced in male Fmr1 KO mice at P20, compared to WT 
controls. (B) Zoomed image demonstrating specificity of staining. (D) The total number of 
PVN cells does not differ between WT and Fmr1 KO mice. Images acquired at 20x 
magnification. Blue: Hoechst, red: oxytocin. 
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3.9.  PKCε  is under-expressed in the Fmr1 KO hypothalamic PVN 
at P20. 
 Here, we report a significant reduction of oxytocin synthesis in the PVN in Fmr1 KO 
mice at age P20. Concurrently, we observe increased levels of AMPA receptor surface 
expression in the CA1 region of the ventral hippocampus, which is indicative of increased 
excitation of the hippocampus, which in turn has been linked to anxiety.323 The CA1 region is the 
major output site of the hippocampus, and the ventral hippocampus is known to exert an 
inhibitory effect on PVN neurons.168, 222, 322 Thus, our observations of reduced oxytocin synthesis 
in the PVN could be a result of excessive inhibitory influence from the hippocampus. 
Alternatively, impaired oxytocin synthesis may instead be a direct effect of loss of PKCε 
expression in the PVN. For instance, we have previously found that in the hippocampus, PKCε is 
capable of activating ERK1/2 to influence gene expression (Figure 12). Could PKCε influence 
oxytocin gene expression in the PVN in a similar manner? To address this possibility, we first 
investigated whether PKCε expression was reduced in the hypothalamus of Fmr1 KO mice, as it 
was in the hippocampus.  
 Western blot analysis was performed on PVN lysate obtained from P20 pups. 
Intriguingly, our densitometry analysis revealed a ~20% reduction in PKCε expression in the 
PVN at this time-point (Figure 39), which was significant (p=0.03). This raises the possibility 
that PKCε might normally influence oxytocin expression directly in PVN neurons, but this 
process is disrupted in FXS. We have previously found that PKCε is capable of mediating gene 
expression via ERK1/2, but as of yet no links between PKCε nor ERK1/2 and oxytocin 
expression have been identified. To examine this possibility, we next performed western blot 
analysis to measure activated (Thr202/Tyr204 phosphorylated) ERK1/2 within the same lysate.  
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If PKCε is involved in ERK1/2 activation in the hypothalamus, then the loss of PKCε in 
Fmr1 KO mice would be reflected by a reduction in activated ERK1/2. However, we did not 
detect a significant difference in activated ERK1/2 relative to basal ERK (Figure 40) between the 
WT and KO groups. Therefore, a hypothetical pathway in which PKCε directly stimulates 
oxytocin expression through ERK1/2 may not be the mechanism at play here. This does not 
exclude the possibility that PKCε may influence oxytocin expression in the hypothalamus 
directly; however, no links between PKCε and pathways known to regulate oxytocin expression 
(the primary pathway being activation of estrogen-receptor beta324) have been discovered. On the 
other hand, considering that the hippocampus is a powerful inhibitor of PVN activity (Section 
1.4.3), the suppression of oxytocin expression that we observe in the Fmr1 KO brain may instead 
be due to heightened inhibitory drive exerted by the hippocampus, resulting from elevated levels 
of synaptic GluR2 in the CA1 region. 
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Figure 39. PKCε expression is significantly reduced in the Fmr1 KO hypothalamic PVN at 
P20, compared to WT controls, after normalization to beta actin (β-actin). Group n’s: 6 per 
group. 
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Figure 40.  Phospho (activated) ERK 1/2 (Thr202, Tyr 204 phosphorylated ERK1/2) levels 
are not changed in the hypothalamus of Fmr1 KO mice at P20, after normalization to total 
ERK 1/2 levels. Group n’s: 6 per group. 
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 Since we have shown that stimulation of PKCε appears capable of altering surface 
AMPA levels within the ventral hippocampus at P18 (Figure 36), we must also address the 
possibility that PKCε may influence PVN oxytocin synthesis by performing a similar action 
within the PVN itself. We have demonstrated here that PKCε co-immunoprecipitates with the 
GluR2 subunit of the AMPA receptor (Figure 35), which has been shown to signal for AMPA 
receptor internalization when phosphorylated by PKC at serine 880.319 Moreover, we show that 
PKCε deficiency in the Fmr1 KO ventral hippocampus is linked to reduced serine 880 
phosphorylation of GluR2 (Figure 34), and consequently, surface GluR2 over-expression (Figure 
31), presumably leading to heightened neuronal excitability in this region.  On the other hand, 
neonatal pharmacological stimulation of PKCε in these mice appears to rescue surface GluR2 
expression to normal levels (Figure 36).  
Could this same mechanism be at play in PVN centrally-projecting, oxytocin-
synthesizing cells? Heightened excitation of oxytocin-synthesizing cells in Fmr1 KO mice would 
hypothetically lead to an increase in oxytocin synthesis, the opposite of our observations (Figure 
38). On the other hand, heightened excitation of GABAergic interneurons within the PVN, which 
contact oxytocin-producing cells, could instead lead to a suppression of oxytocin synthesis. 
However, we predict that PKCε-mediated changes to GluR2 phosphorylation within the PVN is 
unlikely to explain oxytocin suppression in our Fmr1 KO mice, due to inherent differences in 
AMPA receptor composition in the PVN: while the GluR2 subunit is found within the majority 
of AMPA receptors in the hippocampus, AMPA receptor composition within the PVN is much 
more heterogeneous. Here, GluR2 is predominantly found in hypophysiotrophic, peripherally-
releasing cells, whereas GluR1 is the major AMPA receptor subunit found in centrally-releasing, 
pre-autonomic cells.325  
 
 
 
 
125 
	  
	  
	  
	  
Importantly, it has been found that AMPA receptor channel conductance can be enhanced  
via phosphorylation of the GluR1 subunit at serine 831 (Ser831).326 Moreover, PKC is capable of 
catalyzing this phosphorylation.327 Could decreased PKCε expression in the Fmr1 KO PVN lead 
to reduced GluR1 serine 831 phosphorylation, and therefore reduced excitability of neurons 
within the PVN? To answer this question, we studied examined both total and phosphorylated 
Ser831 GluR1 levels in the WT versus Fmr1 KO PVN at P20. However, our western blot 
analysis detected no significant differences between the two mouse groups in either measure 
(Figure 41). Although here we were unable to distinguish between oxytocin-synthesizing versus 
inhibitory neurons, these results suggest that PKCε signaling may not be as influential to AMPA 
receptor dynamics within the PVN, as it appears to be within the hippocampus.  On the other 
hand, PKCε may serve different functions within the PVN that are, as of yet, unknown. Based on 
this finding and the supporting literature, we speculate that heightened inhibitory drive exerted 
by the ventral hippocampus is a more likely explanation for the suppressed oxytocin synthesis 
we observe in the neonatal Fmr1 KO PVN, as opposed to altered AMPA receptor dynamics 
within the PVN itself, potentially resulting from PKCε deficiency. 
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Figure 41.  Levels of total (A) and serine 831-phosphorylated (ser-831) (B) GluR1 are not 
significantly different in the WT and Fmr1 KO PVN at P20. Group n’s: 6 per group. 
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3.10. Pharmacological stimulation of PKCε  during the neonatal 
stage rescues oxytocin levels in the juvenile Fmr1 KO hypothalamus 
in a PKCε-dependent manner. 
 We have obtained data indicative of reduced PVN oxytocin expression in the juvenile (P20) 
Fmr1 KO mouse brain. We hypothesize that this reduction may be due to increased inhibitory 
drive exerted on the PVN by the Fmr1 KO hippocampus. This in turn may be traced back to 
reduced PKCε expression in the CA1 area of the ventral hippocampus, which we have found 
may be involved in AMPA receptor trafficking during the juvenile developmental period (P18). 
To confirm whether oxytocin expression is PKCε dependent, we systemically treated Fmr1 KO 
pups at P6, P10, and P14 with either the selective PKCε inhibitor, DCP-LA, or (2) DCP-LA plus 
the selective PKCε inhibitor, Myr-V1/2. Brain slices were then obtained from the pups at P20 
and immunolabeled for oxytocin. 
 As expected, we found that DCP-LA treatment alone was sufficient to fully normalize the 
number of oxytocin-positive cells in the Fmr1 KO PVN to wild-type levels (Figure 42). On the 
other hand, when DCP-LA was administered simultaneously alongside the PKCε inhibitor, Myr-
V1/2, oxytocin expression was further suppressed compared to vehicle-treated KO controls. Both 
these changes occurred without any changes in the total number of PVN neurons, indicating that  
the process of oxytocin synthesis itself was altered. Based on this collective evidence, oxytocin 
synthesis within the PVN at this developmental stage appears to be dependent, in part, on PKCε 
signaling. 
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Figure 42. (A, B) Neonatal DCP-LA treatment fully rescues the number of PVN oxytocin 
positive (OXT+) cells in the Fmr1 KO hypothalamic PVN at P20. On the other hand, co-
administration of the selective PKCε inhibitor εV1-2 abolishes this rescue. Images acquired at 
20x magnification. Red: oxytocin; blue: Hoechst. (C) The total number of PVN cells is 
comparable across groups. Group n’s: 5-6 per group. 
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3.11. Pharmacological stimulation of PKCε during the neonatal 
stage rescues hyper-anxiety and social deficits in adult male Fmr1 
KO mice. 
 We have found evidence that PKCε is involved in AMPA receptor internalization in the 
CA1 region of the ventral hippocampus during the neonatal stage. This is significant because 
neuronal responses to excitatory stimuli are greatly dependent on AMPA receptor localization. 
During the early postnatal stage of brain wiring, synapse formation is largely activity dependent. 
However, this process appears to be impaired in the Fmr1 KO brain, due to a reduction in PKCε 
expression, and as a result, surface levels AMPA receptors become abnormally elevated. 
Subsequently, altered responses to excitatory signals in Fmr1 KO CA1 neurons may lead to 
aberrant synapse formation between the hippocampus and efferent targets, such as the PVN, the 
major source of brain oxytocin. The effect of the hippocampus on the PVN is predominantly 
inhibitory.119, 120 Accordingly, we hypothesize that in the neonatal Fmr1 KO brain, ventral CA1 
neurons are hyper-responsive to incoming excitatory signals, and in turn exert increased 
inhibitory drive upon the PVN, potentially suppressing oxytocin production. These changes 
begin early in development, and may lead to permanent consequences on downstream oxytocin-
dependent circuits involved in behavior, particularly anxiety and social behavior. If this is the 
case, then behavioral aberrances in adult Fmr1 KO mice could theoretically be rescued by 
neonatal PKCε stimulation. To test this hypothesis, we treated Fmr1 KO pups with either vehicle 
or 3 mg/Kg DCP-LA at P6, P10, and P14 and then assessed anxiety and social behavior upon 
adulthood (2 months of age). Unlike the studies previously outlined in this thesis, for these 
behavioral experiments we treated both male and female pups. This was done to determine 
whether DCP-LA would exert a behavioral effect on the generally asymptomatic KO females. 
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3.11.1. Anxiety-like Behavior 
 We first assessed anxiety-like behavior in the elevated plus maze (EPM), the gold 
standard for evaluation of anxiety in rodents. Consistent with reports of heightened anxiety 
disorders in human FXS patients, we observed that vehicle-treated Fmr1 KO males made 
significantly less entries to the open arms (Figure 43A), and demonstrated a trend of spending 
less time in the open arms, compared to vehicle-treated WT males (Figure 43B). On the other 
hand, this phenomenon was not observed in our homozygous Fmr1 KO females, which behaved 
comparably to WT females. In line with our hypothesis, KO males that were treated systemically 
with DCP-LA from P6-P14 were indistinguishable from WT males, and displayed significantly 
higher entries to the open arms, and a trend of higher time spent in the open arms, than vehicle-
treated KO males.  DCP-LA treated KO females were also statistically indistinguishable from 
WT and KO females, indicating that DCP-LA had no effect on EPM performance in the KO 
females. 
 While these data are indicative of reduced anxiety in DCP-LA treated KO males, we 
sought to confirm these findings using a second assay. For this purpose, the light dark test was 
selected based on its high degree of validity. Here, we observed that vehicle-treated Fmr1 KO 
males spent significantly less time in the lit chamber than WT control males, once again 
indicative of heightened anxiety (Figure 44). Consistent with our observations in the EPM, DCP-
LA-treated KO males behaved identically to the WT males, indicating a complete rescue of the 
anxiety phenotype observed in the vehicle-treated KO males in this test. Interestingly, we 
observed that in this more naturalistic test, KO females spent slightly less time in the lit chamber 
than WT females, but this difference was ultimately non-significant (p=0.27). On the other hand, 
DCP-LA treated KO females were indistinguishable from the WT females (p=0.99). 
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Figure 43.  Neonatal DCP-LA treatment rescues male-specific anxiety behavior in visually 
intact, adult Pde6bWT Fmr1 KO mice in the elevated plus maze (EPM). Male Fmr1 KO mice 
(KOM) make significantly less entries to and spend less time in the open arms compared to wild-
type males (WTM), but this is corrected with administration of 3 mg/kg DCP-LA at P6, P10, and 
P14. On the other hand, KO females (KOF) do not differ significantly from WT females (WTF), 
and neonatal DCP-LA treatment has no effect on these behaviors in KO females. Group n’: 12-14 
per group. 
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Figure 44.  Neonatal DCP-LA treatment rescues hyper-anxiety behavior in Fmr1 KO mice in the 
light-dark test (LD). Male Pde6bWT Fmr1 KO mice (KOM) spend less time in the lit chamber of 
the apparatus compared to wild-type males (WTM), but this is corrected with administration of 3 
mg/kg DCP-LA at P6, P10, and P14. In contrast, KO females (KOF) do not differ significantly 
from WT females (WTF), and neonatal DCP-LA treated KO females are indistinguishable from 
WT females. Group n’s: 12-14 per group. 
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3.11.2. Social Interaction  
Taken together, our results from the EPM and light-dark tests demonstrate that neonatal 
DCP-LA administration is capable of rescuing anxiety-like behaviors in adult male Fmr1 KO 
mice in these tests. Moreover, this treatment did not seem to exert any negative effects when 
administered to our asymptomatic Fmr1 KO females. Thus, we next questioned whether the 
same neonatal regimen was capable of rescuing social deficits in our Fmr1 KO mice. To answer 
this question, we performed the three-chambered social interaction test, which is considered the 
gold standard for measuring sociability in mice.  
Consistent with human FXS patients, we observed noticeable social deficits in our 
vehicle-treated Fmr1 KO male mice. Whereas WT control males spent a significantly greater 
amount of time investigating the novel mouse than the novel object, the vehicle-treated KO 
males investigated the novel mouse and novel object roughly equally (Figure 45). However, this 
deficit was fully corrected in DCP-LA-treated KO males, which, similarly to the WT males, 
spent significantly more time investigating the novel mouse than the novel object. Thus, the 
social deficits in our Fmr1 KO mice, as measured by this assay, appeared to be reversed by 
neonatal DCP-LA treatment. 
Using the same assay, we next examined social behavior in female Fmr1 KO mice. 
Interestingly, while the WT control females spent a significantly greater amount of time 
investigating the novel mouse than the novel object, the vehicle-treated KO females displayed a 
trend towards spending more time with the novel mouse that was approaching significance 
(Figure 45). Thus, any social deficits in the vehicle-treated KO females were noticeably milder 
than the vehicle-treated KO males. Curiously, however, we found that neonatal DCP-LA 
treatment caused the Fmr1 KO females to spend equivalent amounts of time investigating the 
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novel mouse and novel object, in a similar manner to our vehicle-treated Fmr1 KO males. One 
explanation for this unexpected discrepancy could possibly be attributable to down-regulation of 
oxytocin receptors or oxytocin-synthesizing neurons. Since KO females did not demonstrate an 
appreciable deficit in social interaction in the first place, the oxytocinergic system in these 
animals was likely, for the most part, intact. As a result, DCP-LA treatment may have potentially 
lead to excess oxytocin synthesis in KO females during the juvenile stage. Interestingly, a recent 
study has shown that oxytocin receptors in the BNST appear to stimulate social avoidance in 
female, but not male, mice in response to social stress, possibly explaining our observations in 
our DCP-LA treated KO females. 328 Supporting this hypothesis, we observed no effect of 
neonatal DCP-LA treatment on social behavior in our wild-type males (Figure 46), indicating 
DCP-LA may have a female-specific detrimental effect on social behavior. However, data from 
DCP-LA treated WT females is still needed at this time. Nevertheless, since our vehicle-treated 
KO females appear to be, for the most part, asymptomatic, there would be no need for DCP-LA 
treatment in the first place, and so the observed effect would not be an issue. On the other hand, 
these results demonstrate that DCP-LA treatment appears sufficient and capable of fully 
reversing hyper-anxiety and social deficits in symptomatic Fmr1 KO males. 
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Figure 45.  Adult Pde6bWT Fmr1 KO males (KOM), but not females (KOF), displayed lack of 
a preference for the novel mouse over a novel object in the three-chambered social interaction 
test (SI). Social preference index = time spent with novel mouse / (time spent with novel 
mouse + time spent with novel object).  This deficit was eliminated in KOM neonatally 
treated with 3 mg/kg DCP-LA. WTM: Wild-type males, WTF: wild-type females. Group n’s: 
12-14 per group. 
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Figure 46. Administration of 3 mg/kg DCP-LA from P6-P14 does not seem to alter 
later-life social behavior in male WT mice. Group n’s: 7-8 per group. 
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3.11.3. Locomotor Behavior   
 To ensure that our results from the EPM, light-dark, and social interaction tests were not 
influenced by differences in locomotor activity, we lastly performed the open field test on these 
mice. However, we were unable to detect statistically significant differences in distance traveled 
or time spent mobile between any of the groups tested (Figure 47). Since the open field did not 
reveal any discernable differences in locomotor activity between groups, we have reasonable 
confidence that our reported effects of neonatal DCP-LA treatment on EPM, light-dark, and 
social interaction test performance were not due to altered locomotor activity, and thus can be 
attributed to anxiolytic effects. Therefore, for the first time, we have demonstrated that a novel, 
early-intervention strategy is capable of rescuing the abnormal anxiety and social behavior 
phenotype of Fmr1 KO mice, by rescuing aberrant PKCε signaling. 
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Figure 47. Adult Pde6bWT Fmr1 KO mice show normal locomotor behavior when compared 
to WT mice in the open field. Neonatal DCP-LA treatment does not alter these behaviors. 
Group n’s: 12-14 per group. 
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. 
IV. Discussion  
 
4.1. Discussion 
Fragile X Syndrome (FXS) is a heritable genetic disorder that is one of the leading causes 
of monogenic autism. However, unlike classical autism, many of the symptoms of FXS are 
attributed to hyper-anxiety, including social interaction deficits. Because FXS is a lifelong 
disorder that significantly affects the quality of life of the patient, the need for effective 
treatments for FXS remains imperative. Despite this, no direct cure for FXS exists, and current 
treatment strategies have significant disadvantages. 
 In this thesis, we have proposed an innovative, early-intervention strategy for the 
treatment of FXS. It has been widely accepted that developmental disorders like autism and FXS 
involve aberrant brain development during early development, which is highly difficult or almost 
impossible to correct in adulthood. However, the majority of translational studies have attempted 
to ameliorate the symptoms of FXS in adult subjects, after most of the neural circuitry has been 
permanently established. On the other hand, we propose that early intervention can redirect brain 
development onto a normal path, mitigating these symptoms before they fully develop.  
Using the well-established Fmr1 KO mouse model of FXS, we have discovered a novel, 
PKCε-dependent pathway by which ventral hippocampal communication with downstream brain 
regions may be altered during the early postnatal brain wiring. In our previous studies, we have 
discovered that PKCε is abundantly expressed during early postnatal hippocampal maturation, 
peaking after eye opening.248 Although it has been reported that PKCε mRNA is a binding 
partner of FMRP, it was unclear how PKCε expression was affected in individuals with FXS. 
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Here, we report that in the juvenile Fmr1 KO ventral hippocampus, PKCε is significantly under-
expressed (Figures 25 and 27). In our attempts to elucidate the consequences of this under-
expression in these mice, we discovered that shortly after eye-opening (P18), PKCε appears to 
interact with the GluR2 subunit of the AMPA receptor (Figure 35), and that PKCε deficiency 
coincides with increased surface incorporation of GluR2-containing AMPA receptors in the 
ventral hippocampus (Figure 31). This is significant because hippocampal responses to sensory 
stimuli are greatly dependent on AMPA receptor localization, and any changes to this process 
can upset the critical balance of excitation and inhibition in the hippocampal circuitry. However, 
we find that this process of AMPA receptor localization appears to be disturbed in the Fmr1 KO 
brain, possibly as a consequence of reduced PKCε expression. As a result, AMPA receptors 
appear to be overexpressed in ventral CA1 pyramidal neuron synapses during the basal state, 
potentially leading to hyper-excitability of these neurons. Interestingly, these findings are 
consistent with an independent study that has reported heightened hippocampal excitability in 
Fmr1 KO mice at this age.85 Taken together, these observations may help explain, at least 
partially, heightened network excitability in FXS,329 and the fact that many children with FXS 
are more susceptible to seizures.108 Moreover, the fact that we no longer observe a difference in 
surface GluR2 levels in our Fmr1 KO mice by adulthood (Figure 33) is consistent with the fact 
that for a significant proportion of these children, seizures remiss by adulthood. 108 On the other 
hand, the changes we observe in surface AMPA receptor levels appear limited to early postnatal 
hippocampal maturation. Importantly to note, the time point at which we observe this difference, 
P18, corresponds to the average age of FXS diagnosis in humans (roughly 3 years old). 
At this point, it is necessary to address the fact that an independent study by Nakamoto 
and colleagues has found evidence of heightened AMPA receptor internalization in FXS, 
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presumably contributing towards the heightened LTD that has been observed in these mice.330 
While at first glance, our observations reported here may appear contradictory to these earlier 
findings, this is not necessarily the case. The results from Nakamoto’s study are postulated to 
result from excess expression and activation of group 1 metabotropic glutamate receptors 
(mGluRs); however, we instead report that basal surface levels of the receptor appear to be 
increased. Moreover, the aforementioned study was conducted on cultured hippocampal neurons 
originating from embryonic rats transfected with siRNA against Fmr1. Given the great 
differences in model systems and developmental stages studied, these results may not necessarily 
contradict our in vivo findings. It should also be mentioned that in these independent studies, 
relatively high concentrations of the mGluR agonist DHPG (dihydroxyphenylglycine) were used 
(50uM), which may not reflect physiological conditions. On the other hand, we report intrinsic, 
baseline differences between Fmr1 KO and WT mice in the juvenile stage.  
In a separate study by Huber examining the phenomenon of heighted group I mGluR-
mediated LTD in the Fmr1 KO model, hippocampal slices were taken from P21-P30 mice from 
the C57 strain.331 However, this corresponds to a later time-frame than the one studied in this 
thesis - a time-frame closer to early puberty. On the other hand, we report differences in surface 
AMPA receptor levels earlier on (P18), during the peak of early postnatal hippocampal 
synaptogenesis. Although further study is required, it is not unreasonable to assume that 
mechanisms governing AMPA receptor dynamics may be largely different between these two 
distinct stages of development. Aside from the age difference between the mice used in this 
study and ours, one must also pay attention to the strains used. Importantly, it has been shown 
that Fmr1 KO mice on the C57 background, as used in Huber's study, have been reported to 
display normal levels of sociability and conditioned fear.295 In this thesis, we have honed in on 
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the social and emotional aspect of FXS, and therefore used Fmr1 KO mice on the FVB strain, 
which do express altered social and emotional behavior.295 Because of this, we have specifically 
targeted the ventral hippocampus, whereas the origin of the hippocampal slices in the 
aforementioned study (dorsal versus ventral) was not specified. Lastly, group I-mGluR inhibitors 
have so far failed to produce meaningful improvements in human FXS patients, compared to 
placebos.87 
 Nevertheless, based on our findings, we next questioned whether pharmacological 
stimulation of PKCε could compensate for its reduced expression in the hippocampus, reversing 
our observed aberrances in surface AMPA receptor levels. To answer this question, we enlisted 
the selective PKCε activator, dicyclopropyl-linoleic acid (DCP-LA), which binds to PKCε’s 
phosphatidylserine binding site. We have previously reported that PKCε expression in the mouse 
hippocampus rises between the ages of P6 and P15.248 We therefore treated Fmr1 KO pups with 
3 mg/Kg DCP-LA at three points during this time-frame: P6, P10, and P14. Being a hydrophobic 
linoleic acid derivative, DCP-LA readily crosses the blood-brain barrier,281 and hence, the 
treatments were administered via intra-peritoneal injection. Confirming our hypothesis, DCP-LA 
treatment fully reversed GluR2-overexpression in the ventral CA1 region at P18 (Figure 36). 
Internalization of the AMPA receptor has been linked to PKC-mediated phosphorylation 
of the GluR2 subunit at serine 880 (Ser880).319 Consistent with our findings that surface GluR2 
is over-expressed in the Fmr1 KO CA1 region, we observe a reduction of phosphorylated Ser880 
GluR2 in these mice (Figure 34). Given our observation that that PKCε co-immunoprecipitates 
with GluR2 (Figure 35), this can be interpreted as evidence that PKCε may phosphorylate GluR2 
at the Ser880 subunit to regulate synaptic AMPA expression. However, it is also possible that 
PKCε may not directly catalyze the Ser880 phosphorylation of GluR2. The precise nature of 
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PKCε regulation of GluR2 Ser880 phosphorylation could be determined via an in vitro kinase 
assay. In such an experiment, purified PKCε and GluR2 protein could be incubated together with 
ATP as a phosphate donor. Phosphorylation of GluR2 at the Ser880 residue could be assessed 
via Western blotting under basal conditions, as well as following treatment with PKCε activators 
and inhibitors. 
What are the potential global consequences of GluR2 over-expression and net hyper-
excitability in the FXS hippocampus? The hippocampus is a hub which receives sensory stimuli, 
and in response, influences the activity of several downstream brain regions relevant to behavior, 
such as the cortex, amygdala, and hypothalamus. Consequently, altered responses to excitatory 
signals in Fmr1 KO CA1 neurons may lead to aberrant synapse formation between the 
hippocampus and its efferent targets during brain wiring.  
 Because a high proportion of patients with FXS suffer from anxiety disorders, especially 
social anxiety, we studied the integrity of the central oxytocinergic system in FXS, as a 
downstream target of ventral hippocampal regulation. The major source of oxytocin in the brain 
is the paraventricular nucleus of the hypothalamus (PVN). Ventral hippocampal neurons are 
known to project to and activate GABA-ergic BNST neurons, which in turn inhibit the PVN.119, 
120 We speculate that in the neonatal Fmr1 KO brain, CA1 neurons may be hyper-responsive to 
incoming excitatory signals, and in turn exert increased inhibitory drive upon the PVN, 
potentially suppressing oxytocin production. Such changes may begin early in postnatal 
development, and may lead to permanent consequences on the development of downstream 
oxytocin-dependent circuits involved in behavior, particularly anxiety and social behavior 
(Figure 48). Supporting our hypothesis, we discovered that at P20, Fmr1 KO mice displayed a 
reduced number  of  oxytocin-positive  cells in the PVN compared to wild-type controls  (Figure  
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Figure 48. Overall hypothesis of the study. The findings reported in this thesis point to 
heightened basal levels of surface AMPA receptors in the Fmr1 KO ventral hippocampal 
CA1 region during the juvenile period (P18). This would presumably lead to heightened 
excitability of the CA1 neurons, and in turn, heightened inhibitory drive upon the PVN 
through recruitment of the BNST. As a result, oxytocin synthesis is suppressed, leading to 
reduced oxytocin input to the brain during critical periods in which circuits relevant to 
emotion and social behavior are being established. In consequence, Fmr1 KO mice exhibit 
deficits in later life social behavior, as well as exaggerated anxiety levels.  BNST: bed 
nucleus of the stria terminalis; PVN: Paraventricular nucleus of the hypothalamus; NA: 
Nucleus accumbens. 
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38).  Although we do not distinguish between centrally-projecting and peripherally-releasing 
cells in this study, given the deficits in social behavior that are characteristic of Fmr1 KO 
mice,287 it is very likely that centrally-projecting cells are affected. 
If our hypothesis that the Fmr1 KO hippocampus exerts increased inhibitory drive on the 
PVN - thus suppressing oxytocin synthesis - is correct, then reversal of synaptic GluR2 over-
expression in the Fmr1 KO hippocampus would relax this inhibitory drive and consequently 
boost oxytocin synthesis. To address this possibility, we examined PVN oxytocin synthesis in 
Fmr1 KO pups treated with 3 mg/Kg DCP-LA at P6, P10, and P14.  Supporting our prediction, 
we observed that the DCP-LA treated KOs displayed normal levels of oxytocin-positive cells in 
the PVN, when compared to WT controls (Figure 42). Thus, DCP-LA treatment during the 
neonatal stage seems capable of not only correcting synaptic GluR2 expression in the Fmr1 KO 
ventral hippocampus, but also rescuing oxytocin synthesis within the PVN. To confirm that this 
rescue was PKCε-dependent, we also treated a separate group of KO pups with DCP-LA and the 
selective PKCε inhibitor, Myr-εV1/2, simultaneously. In this group, we observed a further 
decline in the number of oxytocin-positive cells in the PVN (Figure 42) relative to the vehicle-
treated KO group. Because the inhibitor negated the effects of DCP-LA, it is most likely that our 
observed pro-oxytocin effect of DCP-LA is mediated through PKCε signaling. 
Although we observed a reduction of PKCε expression in the KO hypothalamus, the 
possibility of a role of PKCε in oxytocin synthesis within PVN neurons remains unclear. It is 
unknown whether PKCε influences oxytocin gene expression through the recruitment of 
transcriptional regulators. However, we plan to more comprehensively address this question in 
our upcoming experiments. The most practical way to accomplish this would most likely be 
through in vitro experiments. For instance, primary cultured neurons obtained from the PVN 
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could be treated with PKCε activators and inhibitors, and then oxytocin mRNA levels could be 
measured via real-time PCR. Oxytocin itself could be directly quantified via 
radioimmunoassay.190 Additionally, oxytocin-positive cells could be quantified visually via 
immunocytochemistry, in a similar manner to the experiments outlined in this thesis. In the event 
that we observe that PKCε activators enhance oxytocin levels while inhibitors suppress them, 
similar follow-up experiments could be performed to identify the downstream signaling 
molecules in the pathway, since the role of PKCε in oxytocin synthesis could be indirect 
(through phosphorylation of other, intermediary kinases). However, to our knowledge, no link 
has been found between PKCε and pathways mediating oxytocin synthesis in the PVN (the main 
pathway being estrogen-receptor beta activation).324  
There also exists the possibility that PKCε could be involved in the stimulation of PVN 
oxytocin-synthesizing neurons by altering AMPA receptor dynamics. We have shown that PKCε 
co-immunoprecipitates with the GluR2 subunit of the AMPA receptor (Figure 35), and propose 
that PKCε may serve to internalize surface AMPA receptor levels in the hippocampus through 
phosphorylation of GluR2 at the serine 880 residue. However, we predict this is unlikely to occur 
within centrally-projecting, oxytocin-synthesizing neurons due to the inherent AMPA receptor 
subunit composition in the PVN. Although most hippocampal AMPA receptors contain GluR2 
subunits,252 AMPA receptor composition in the PVN is much more heterogeneous. Here, GluR2 
is more predominantly found in hypophysiotrophic cells, whereas GluR1 is more highly 
expressed in centrally-projecting, pre-autonomic cells.325 Interestingly, it has been found that the 
catalytic unit of PKC is capable of increasing AMPA receptor conductance by phosphorylating 
the serine 831 (Ser831) residue of GluR1.327 However, our western blot analysis determined that 
phosphorylated Ser831 GluR1 levels were comparable in WT versus Fmr1 KO mice at P20 
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(Figure 41). This suggests that PKCε may have a more influential role in AMPA receptor 
dynamics in the hippocampus, as opposed to within the PVN. Thus, we predict it is more likely 
that oxytocin suppression in the Fmr1 KO mouse is due to enhanced hippocampal inhibition of 
the PVN, rather than an autonomous effect within the PVN. While this scenario is strongly 
backed by the existing literature, in order to truly establish whether the hippocampus is the 
source of the oxytocin suppression in our Fmr1 KO mice, future studies must be performed in 
which PKCε activators and inhibitors are delivered directly to the hippocampus (for example, via 
stereotactic injections). Inherent effects of PKCε within the BNST must also be examined. 
Correcting anomalies in the FXS brain is of little use to human patients, unless these 
corrections meaningfully improve the patients’ symptoms. We hypothesize that by correcting 
hippocampal communication with targets such as the PVN during brain wiring, neonatal DCP-
LA treatment may aid in re-directing the development of behaviorally-relevant circuits back onto 
a normal course, before FXS symptoms become permanent. To examine whether this was indeed 
possible, we treated KO pups with either vehicle or 3 mg/Kg DCP-LA at P6, P10, and P14, and 
then tested them behaviorally when they reached adulthood. As expected, we found that unlike 
our vehicle-treated group, our DCP-LA-treated mice were statistically and visually 
indistinguishable from WT controls in the elevated plus maze, light-dark test, and social 
interaction test (Figures 43-45). These data provide compelling evidence that neonatal DCP-LA 
treatment is capable and sufficient of permanently rescuing the exaggerated anxiety and social 
impairments in Fmr1 KO mice.  
Intriguingly, the aforementioned behavioral anomalies were only observed in male KO 
mice. At first glance, this finding seems compatible with the observation that females typically 
display milder symptoms than male patients. This is attributed to the fact that all human females 
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with the full mutation are heterozygous, because the full mutation can only be transmitted 
maternally. Consequently, due to lionization, all full mutation females are mosaics for activity of 
the affected X chromosome. Based on this, it is presumed that tissue-specific skewed X 
inactivation may underlie the variability of FXS in women. However, the female KO mice used 
in this study were homozygous for the Fmr1 KO mutation, and therefore, the sex-specific effect 
of Fmr1 knockout on anxiety and social interaction profiles remains to be explained.  
This study introduces early postnatal PKCε-mediated signaling as an important regulator 
of brain wiring, in regards to social and anxiety behavior. For the first time, we have provided 
evidence that PKCε expression is impaired in the Fmr1 KO hippocampus and hypothalamus. We 
hypothesized that during the early postnatal period, this loss of normal PKCε expression may 
produce long-lasting changes in the formation of circuits involved these behaviors. Supporting 
this idea, we report that early-life pharmacological stimulation of PKCε is sufficient to fully 
rescue male-specific hyper-anxiety and social deficits in our Fmr1 KO mice, in three well-
validated behavioral assays: the elevated plus maze, light-dark box, and social interaction test.  
While these results are an encouraging start towards a viable early-intervention treatment 
for FXS, they also raise several important questions. To begin, further work needs to be done to 
elucidate the finer mechanisms by which DCP-LA exerts its therapeutic effect, as such studies 
would provide valuable insights into potential new avenues of treatment for FXS. First, the 
manner in which PKCε expression in the Fmr1 KO brain affects the basal excitability of CA1 
neurons at this young age still remains to be fully confirmed. This can be most directly addressed 
through electrophysiological studies. For instance, measurement of field excitatory synaptic 
potentials and population spike amplitudes in CA1 neurons, following paired-pulse stimulation 
of the Schaffer collaterals, could greatly illuminate the relationship between CA1 inputs and cell 
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outputs.131  Moreover, the question of whether PKCε directly phosphorylates GluR2 must also be 
confirmed. This can be accomplished via a combination of in vitro kinase assays including 
recombinant PKCε and GluR2 proteins. In addition, cryo-electron microscopy could be used to 
further analyze the molecular architecture of the PKCε:GluR2 complex. Given our co-
immunoprecipitation data (Figure 35), these studies would likely be fruitful in illuminating the 
nature of this novel interaction.  
The safety of DCP-LA itself as a potential treatment for FXS is another significant 
concern, especially considering the treatment regimen outlined in this thesis takes place during 
early postnatal brain development. While we have not detected any adverse side effects of DCP-
LA in our male KO mice, rigorous screening will be required to ensure it is suitable for human 
use. Beginning with the first treatment through adulthood, DCP-LA-treated mice should be 
closely monitored in the home cage for the presence of any external symptoms, such as aberrant 
behaviors, twitching, seizures, or abnormal eating or sleeping patterns. In order to assess 
abnormal effects on liver, blood collected from the 24-hour time point should be used to assess 
the levels of the enzymes alanine aminotransferase (ALT) and alkaline phosphatase (ALP), 
which rise sharply in the blood during liver damage.  The fact that DCP-LA treatment appeared 
to modify social behavior in our originally asymptomatic female KO mice (Figure 45) should 
also be addressed. It is possible that DCP-LA treatment may prove effective in severe cases of 
FXS, but should be avoided in mild cases. Moreover, this effect may be sex-specific, since we 
did not observe any effect of DCP-LA on social behavior in our WT males (Figure 46).  
If no other adverse side effects of DCP-LA are observed, then the best regimen for 
neonatal treatment will also need to be determined. Besides the dose used in this thesis (3 
mg/Kg), both lower and higher doses should be tested to identify the safest effective dose. Such 
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preclinical testing will be necessary to predict human responses to DCP-LA as a drug candidate 
and to screen for unwanted CNS and peripheral side effects. Moreover, the most effective time-
course of DCP-LA treatment must still be clarified. Although in this thesis, we have treated our 
Fmr1 KO mice at P6, P10, and P14, a single treatment at one of these time-points may be 
sufficient to produce the therapeutic effects reported here. Since P6 is considered pre-term in 
humans, our future studies will evaluate whether a single treatment at P10 or P14 will be 
sufficient. The ideal regimen would be a single treatment at P14, which corresponds to ~2 years 
of age, at which point symptoms are beginning to emerge in the patients. Given the fact that we 
observe a negative effect of DCP-LA on social behavior in asymptomatic females, we would 
caution against preventative DCP-LA administration in humans, until more studies are 
performed to determine which populations of patients would respond best to the treatment. 
Lastly, the extent to which DCP-LA exerts its therapeutic effect must be more thoroughly 
evaluated. While in this thesis we have only examined anxiety and social behavior, DCP-LA 
may prove beneficial in treating other symptoms of FXS, such as learning delays and hyper-
sensitivity to sensory stimuli. Rescue of the former could very well be likely, since it has already 
been discovered that DCP-LA improves age-related cognitive impairments in senescence-
accelerated mice. In a similar vein, Alkon and colleagues have demonstrated that bryostatin, a 
non-specific PKCε inhibitor, is capable of rescuing spatial learning and memory in adult Fmr1 
KO mice, by correcting structural abnormalities in hippocampal dendritic spines. Thus, DCP-LA 
may be of use in combating cognitive impairments in FXS patients, by normalizing hippocampal 
synapses. The efficacy of DCP-LA in treating cognitive impairment can be tested in Fmr1 KO 
mice using well-validated assays such as the Morris water maze or Barnes maze, which provides 
insight into spatial and reversal learning similarly to the Morris water maze, but without the 
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anxiety provoked by being forced to swim. Similarly, hippocampal-dependent declarative 
memory can be studied using a simple object recognition assay. 
As mentioned, DCP-LA may also be effective in rescuing FXS-associated hyper-
sensitivity to sensory stimuli. It is believed that in FXS, hippocampal neurons are hyper-
excitable,332-334 leading to over-activity of circuits involved in processing visual, auditory and 
tactile stimuli. In the patient, this may result in feelings of being overwhelmed by sensory stimuli 
in their environment, in turn causing difficulty focusing, distress, or even seizures. However, by 
normalizing basal levels of synaptic AMPA receptors in CA1 neurons, DCP-LA may counteract 
these defects, normalizing sensory processing in the FXS brain. The hyper-arousal state can be 
gauged in vehicle versus DCP-LA treated Fmr1 KO mice in several ways. For instance, 
exaggerated responses of the auditory cortex in response to tones have been well-described in 
both FXS patients335, 336 and mice,337 and can be measured through in vivo electrophysiological 
recording. Additionally, serum cortisol can be measured in response to various environmental 
stressors, for instance, during exploration of novel environments. 	  	  
4.2. Concluding Remarks 
In our efforts toward a therapeutic strategy for FXS, we have adopted a unique approach 
of focusing on the early stages of postnatal brain development. In the process, we have 
discovered an FXS-associated defect in an FMRP target (PKCε) that is likely to be linked to 
multiple behavioral deficits. We demonstrate that early intervention, using a highly selective 
stimulator of PKCε, is able to correct later-life social behavior deficits and hyper anxiety in the 
leading FXS model; and attempt to identify possible mechanisms by which this rescue takes 
place. The work described in this thesis introduces the possibility that early intervention using 
PKCε activators may serve as a promising new avenue of treatment for FXS during a time where 
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existing treatments are still desperately lacking. Consequently, it is my hope that this work and 
our described future experiments will, in some way, ultimately contribute to our understanding 
of FXS and pave the way for better treatments for human patients. 
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